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SUMMARY 
Diabetes has become the next most widespread epidemic after cancer, the 
pathogenesis of type 2 diabetes mellitus (T2DM) is complex and involves the 
interaction of genetic and environmental factors. A number of environmental factors 
have been shown to play a role in the development of the disease, particularly 
excessive caloric intake leading to- obesity-and a sedentary lifestyle. Patients with 
T2DM consistently demonstrate. three cardinal abnormalities: defective insulin 
secretion, particularly in |r^'konse to a glucose stimulus (p-cell dysfunction); 
resistance to action of insulin-in the peripheral tissues, particularly muscle and fat but 
also liver (insulin resistance>,.^J|Ad,, increased glucose production by the liver 
(hyperglycemia).The common forms of f ^ M are polygenic in nature and are due to 
a combination of insulin resistance and abnormal insulin secretion. Therefore 
extensive research is being carried out to develop drugs for its therapeutics; however 
the drugs being used are not only expensive but also pose a treat of severe side 
effects. Therefore, probable use of vitamins as anti-diabetic agents is being largely 
worked upon as this will not do any harm to the patients concerned. 
Recent studies have found that deficiency of Vitamin D results in reduction in insulin 
secretion and thus in hyperglycemia. Both insulin secretion and sensitivity depencs 
upon intracellular calcium concentration also Vitamin D is one of the hormone which 
has been found to regulate calcium flux within the cells. In both observational and 
case control studies, an inverse relationship has been reported with level of 
25(OH)Vit D and degree of glycemic control. Therefore, in the first chapter of the 
present study, an attempt is made to present scientific evidence of linkage of Type 2 
Diabetes with Vitamin D levels in order to explore the possibility of Vit D as an ada-
on therapy to the existing treatment to strive near normo-glycemia. However, in the 
second and third chapter of the thesis, effect of combination of vitamin D along with 
vitamin C and vitamin A has been explored. 
Since, hyperglycemia, from a pathophysiological standpoint, serves as a root cause c f 
all the underlying complications by mediating its effects in more than one way.s, 
namely: l.p-cell glucotoxicity; 2. increased polyol pathway flux; 3. increased 
advanced glycation end product formation and 4. PKC activation, converging to 
ultimately give rise to the major player: oxidative stress. Once generated, the free 
radicals cause pancreatic p cell damage, thus adding to increased insulin resistiince, 
mitochondrial dysfunction, lipid peroxidation, glucose oxidation, DNA damage and 
last but not the least, manifesting changes in the histology of diabetic tissues. 
Therefore, in order to stop the progression of the disease or to slow down the 
occurrence of diabetic complications, these reactive oxygen species (ROS) should 
either be quenched or their production must be stopped. To carry out these functions, 
antioxidants like vitamin C might be used however, it would be of double benefit if 
the cause as well as the effect of type 2 diabetes mellitus complications i.e. 
hyperglycemia as well as oxidative stress, are targeted simultaneously. To work out 
this strategy we used 1, 25 (0H)2 vitamin D3 against hyperglycemia and vitamin C to 
act against the oxidative stress in the second chapter. 
In the last chapter of the study, we tried to see the combined effect of vitamin A and 
vitamin D on several diabetes related parameters as both these vitamins belong to the 
steroid family and have been found to share signalling pathways. 
The results foimd in all the three cases i.e. in case of vitamin D alone and Vitamin D 
along with vitamin C and vitamin A, we observed that the most effective results ;ind 
values closest to control levels were observed in case of vitamin D alone however the 
results of combination vitamin C with vitamin D proved to be better than vitamin C 
alone. Although the mode of action, the targets acted upon and the mechanism of 
action of both these vitamins is totally different from each other but given together, 
they have the potential to act upon the two biggest and most basic abnormalities of 
type 2 diabetes mellitus i.e. hyperglycemia and oxidative stress. This combination 
approach therefore, brings together the anti-hyperglycemic effect of vitamin D and the 
anti-oxidant effect of vitamin C, thus targeting both, the cause and the effect leading 
to type 2 diabetes mellitus and following complications. 
In case of vitamin A with vitamin D, the results did not follow any pattern. In case of 
some parameters like the activity of glucose metabolic enzymes hexokinase, FBPase 
and G6Pase, vitamin A alone proved to be better in terms of the recovery of enzyme 
activities while dealing with the anti-oxidant parameters, the combination (vitamin 
A+vitamin D) was more effective. Vitamin A supplementation has already t)een 
found to induce the expression of GLUT-2 in insulinoma cell line INS-1. All trans-
retinoic acid induced GLUT-2 m-RNA expression was observed after 48 lus of 
incubation. Another mechanism by which vitamin A increased glucose uptake may 
involve PKC and thus effecting insulin sensitivity positively. It has been found that all 
trans retinoic acid modulates the activity of PKC by directly binding to its isoz>mes. 
These PKC isoforms might play a role in ser/thr phosphorylation of insulin receptor 
substrate (IRS-1, IRS-2) and also inactivate NADH oxidase. This may inactivatt- and 
block the dovmstream signalling pathway of insulin action and free radical 
production. This effect of all trans-retinoic acid may prove helpful in insulin 
signalling pathway ultimately improving insulin sensitivity and reducing oxidative 
stress. However, the changes were not that significant in the group given the 
combination treatment i.e. vitamin A+ vitamin D, this could be due to the fact that 
both vitamin D and vitamin A involve RAR for their cellular action, the presence of 
both these vitamins together can lead to the decrease in the available RAR in the cell. 
As the number of available RAR decreases, neither of the vitamins (vitamin D or 
vitamin A) are probably able to carry out their molecular functions, thereby leading to 
poor results. This is the reason that combination of vitamin D and vitamin A shewed 
mixed results depending upon the parameter analysed and the pathway used by the 
vitamins. The oxidative stress parameters showed better results in case of combination 
group when compared to vitamin A alone. This could be because vitamin A probably 
uses the PKC pathway to lower down the free radical production that inhibhs N^DH 
oxidase and thus lowers oxidative stress parameters. However in case of glucose 
metabolic enzymes both vitamin A and vitamin D probably mediate their effecis via 
molecular mechanism involving RAR. Thus insufficiency of RAR in the cell 
decreases the effect of combination when compared to individual vitamins (A or D) 
results than in case of either of the vitamins alone. 
In the end , we suggest that, these vitamins could be given as an add-on therapy to 
diabetic patients as they not only help in bringing down hyperglycemia and diabetes 
related complications but also are less costly, easily available, free from side effects 
and pose no threat of further complications. 
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Literature Review 
1 Epidemology 
Type 2 diabetes mellitus is the predominant form of diabetes worldwide, accounting 
for 90% of cases globally. This deadly disease has taken the form of an epidemic in 
both developing and developed countries with increasing number of people suffering 
from diabetes. From 366 million in 2011, the number of diabetics is expected to reach 
a level of 552 million in 2030, at an average annual growth of 1.7 times the growth of 
total adult world population, making diabetes one of the most serious public health 
problems worldwide. Ninety percent of the diabetic patients are either 3bese or 
overweight with maximum number of patients falling in the age ranging from 40-60 
years, also most of the diabetes deaths occur in low and middle income countries 
including India. In the present scenario India has 160 million diabetics and is expected 
to have the largest number of diabetic patients by 2025. In the last two decadt;s. type 2 
diabetes, once thought to be a metabolic disorder exclusively of adulthood, has 
become increasingly frequent in obese adolescents. For example, in Japan 
(H.Sekikawa et al, 2000) 80% of all new cases of type 2 diabetes diagnosed are in 
children and adolescents. Likewise, in Taiwan (P. Chou et al, 1994) 54.2°/'o of new 
cases were diagnosed with type 2 diabetes, with an incidence of 6.5% per 100.000. In 
contrast, in U.K. the minimum incidence of type 2 diabetes in children (<17 years of 
age) was 0.53 % 100,000"' year"' (N.G. Forouhi et al, 2006). According to Diabetes 
Atlas 2010, India has 40.9 million diabetics and this number is likely to become 87 
million by 2030, making India the "diabetes capital of the world" (J.E. Shaw et al, 
2010). 
Since, the number of diabetics are increasing at an alarming rate in our country and 
worldwide, it is of due importance to understand the underlying factors helping in the 
progression of this disease and to develop a mechanistic approach towards finding a 
solution of this growing epidemic. By developing clinical methods to lower the 
incidence and to increase the recovery of individuals diagnosed with type 2 diabetes 
mellitus, it will soon be possible to control the incidence, progression and clinical 
manifestation of this rapidly rising syndrome. 
Type 2 diabetes is thought to occur in genetically predisposed individuals who are 
exposed to a series of environmental influences that finally precipitates the onset of 
this clinical disease. However, there are various other factors responsibli for the 
development of type 2 diabetes mellitus: 
Genetic Factors 
Demographic Characteristics 
Genetic Maricers 
Family History 
Thrifty Genes 
Sex 
Age 
Ethnicity 
Behavioral And Lifestyle Related Risk Factors 
Obesity (including distribution and duration) 
Physical inactivity 
Diet 
Stress 
Metabolic Determinants And Intermediate-Risk Categories Of Type 2 Diabetes 
Impaired glucose tolerance 
Insulin Resistance 
Pregnancy related determinants 
• Parity 
• Gestational diabetes 
• Diabetes in offspring of women with diabetes in pregnancy 
• Intrauterine malnutrition or ovemutrition 
Table 1. Factors responsible for type 2 diabetes mellitus. 
2 Pathogenesis 
The pathogenesis of type 2 diabetes mellitus (T2DM) is complex and involves the 
interaction of genetic and environmental factors. A number of environmental factors 
have been shown to play a role in the development of the disease, paiticularly 
excessive caloric intake leading to obesity and a sedentary lifestyle. Patients with 
T2DM consistently demonstrate three cardinal abnormalities: defective insulin 
secretion, particularly in response to a glucose stimulus (P-cell dysfanction); 
resistance to action of insulin in the peripheral tissues, particularly muscle ard fat but 
also liver (insulin resistance); and increased glucose production by ihe liver 
(hyperglycemia).The common forms of T2DM are polygenic in nature and are due to 
a combination of insulin resistance and abnormal insulin secretion. From a 
pathophysiological standpoint, it is actually the inability of the pancreatic beta cell to 
adapt to the reductions in insulin sensitivity that occurs over the lifetime c f human 
subjects, that precipitates the onset of T2DM (S. Fajam et al, 2001).Ihe most 
common factors that place an increased secretory burden on the beta cell are puberty, 
pregnancy, a sedentary lifestyle, and an over-eating leading to weight gain. 
In Type 2 diabetes mellitus, insulin is present at normal levels but the tissutjs do not 
respond to the hormone. This is caused by decreased sensitivity of target tissues to the 
metabolic effect of insulin. In type 2 or non-insulin-dependent diabetes mellitus, 
muscle and fat cells become 'resistant' to the actions of insulin and compensatory 
mechanisms that are activated in the P-cell to secrete more insulin are not sufficient to 
maintain blood glucose levels within a normal physiological range (E.A. Davis et al, 
1999).The. precise way these factors interact, finally lead to the onset of T2DM. 
2.1 Obesity 
Obesity is one of the major risk factors and an underlying cause of type 2 diabetes 
mellitus. Therefore most of the diabetic individuals have a problem of central 
adiposity. In case of obesity there occurs P cell compensation such that there is 
increased insulin secretion even in response to normal glucose levtls This 
abnormality can only be possible if there is increased p-cell sensitivity in response to 
glucose. The root cause of this defect can be: (a) an increase in P cell mass and thus 
presence of more GLUT2 receptors, as found in obese individuals or (b) increased 
expression of hexokinase as compared to glucokinase leading to increased insulin 
secretion in response to wide range of glucose concentrations, thus resulting in 
hyperinsulinemia. Central obesity can also alter the levels of secretion of adipokines 
which regulate and mediate processes like lipid metabolism, lipolysis, and insulin 
mediated glucose uptake and utilization. The abnormal decrease in the levels of these 
hormones adds to the already existing conditions for T2DM. In obesity, the levels of 
adipocyte hormones like leptin and adiponectin are decreased while the levels of 
TNF-a and resistin are found to be increased thus making obesity a cause for 
T2DM.f?.^. Kern et al,2001) 
Adiponectin is a secreted protein of 247 amino acids, produced specifically from 
adipocytes. (P.E. Scherer et al, 1995) In circulation, adiponectin is found in two 
forms: a full length protein and a globular form (due to proteolytic cleavage). Both 
these forms have different modes and sites of action. The globular form acts mainly 
on skeletal muscles and increases the P-oxidation of fatty acids via activating PPARa, 
along with AMPK mediated increase in GLUT4 translocation. Whereas, the full 
length protein functions only to decrease the hepatic glucose output by activation of 
AMPK (adenosine monophosphate kinase) in liver. Since the increase in triglyceride 
content as in cases of obesity, interferes with the insulin mediated phosphorylation of 
PI-3 kinase, thereby affecting insulin action, both, full length protein and globular 
form of adiponectin mediate their insulin sensitizing actions by decreasing the 
triglyceride content. (T. Yamauchi et al, 2003) 
Another probable mechanism by which adiponectin helps in reducing diabetes related 
complications, is by reducing the levels of inflammatory cytokines like TNF-a and 
IL-6.Adiponectin and these cytokines especially TNF-a antagonize each other and 
are negatively correlated. Adiponectin suppresses TNFa-induced inflammatory 
changes in endothelial cells by blocking inhibitory nuclear factor-KB phosphorylation 
and nuclear factor-kB activation without affecting TNFa-mediated activation of c-Jun 
N-terminal kinase, p38, and Akt. 
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Fig. 1 Adiponectin can activate AMPK and PPARa in the liver and skeletal muscle. In skeletal 
muscle, both globular and full-length adiponectin activate AMPK, thereby stimulating 
phosphorylation of ACC, fatty-acid oxidation, and glucose uptake. Adiponectin activates 
PPARa thereby also stimulating fatty-acid oxidation and decreasing tissue TG content in 
muscle. In the liver, only full-length adiponectin activates AMPK, thereby reducing molecules 
involved in gluconeogenesis and increasing phosphorylation of ACC and fatty-acid oxidation. 
Adiponectin activates PPARa, thereby stimulating fatty-acid oxidation and decreasing tissue 
TG content in the liver. These alterations increase insulin sensitivity in vivo. WAT, White 
adipose tissue; PEPCK, phosphoenolpyruvate carhoxykinase; GdPase, gliicose-6-
phosphatase. (Adaptedfrom Kadowaki and Yamauchi /Endocrine Reviews; 2005) 
The signaling pathway by which adiposity is linked to insulin resistance is however, 
complex. It is mediated by more than one factors, like non-esterified fatty acids 
(NEFA), tumor necrosis factor a (TNF-a) and hormones like leptin and adiponectin. 
These modulate insulin action in the peripheral tissues contributing to insulin 
resistance. (M. Stumvoll, 2002; Steven Kahn et al, 2006) 
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Fig 1.2 Genes responsible for obesity and insulin resistance interact with environmental 
factors (increased fat/caloric intake and decreased physical activity), resulting in the 
development of obesity and insulin resistance, (adaptedfrom Steven Kahn/nature 444; 2006) 
2.2 Insulin resistance 
Insulin resistance indicates the presence of an impaired biologic response to either 
exogenously administered or endogenously secreted insulin. It is manifested by 
decreased insulin stimulated glucose transport and metabolism in adipocytes and 
skeletal muscles and by impaired suppression of hepatic glucose output. (K. Hida et 
al, 2005) 
Understanding of the mechanism and signaling of insulin action allows to divide the 
insulin resistance into three types: prereceptor, receptor and postreceptor insulin 
resistance. Type A insulin resistance is due to a decrease in the number of insulin 
receptors, whereas patients with type B insulin resistance have circulating auto-
antibodies against some portion of their insulin receptors, and this results in impaired 
binding of insulin to target cells (Vandana Saini, 20I0).Thc majority of insulin 
resistance is of the postreceptor type due to the extraordinary complexity of the 
intracellular pathways of insulin action. 
Table 1.2 Various types of Insulin Resistance in type 2 diabetes mellitus. 
Table 1.2 Type of Insulin Resistance in T2DM. 
Insulin Resistance 
i. Pre-Receptor Resistance 
• Antibodies against insulin. 
• Mutant insulin structures. 
• Defect in primary structure of insulin p chain at one or more positions. 
• Familial hyperproinsulinemia. 
• B-C proinsulin: mutation at the cleavage site between die B chain and the 
connecting (C) peptide. 
• A-C proinsulin: mutation at the cleavage site between the A chain and connecting 
(C) peptide. 
ii. Receptor Resistance 
• Type A. Decrease in insulin receptor number and/or affinity for the hormone. 
• Impaired ex{n-ession of receptor tyrosine kinase activity 
• Point mutation blocks insertion of mature receptor into plasma membrane. 
• Type B. Receptor blocked by cmiulatory antibodies to the receptor 
• Leprechaunism: An autosomal recessively inherited disorder of insulin fiiiclion 
that leads to severe intrauterine growth retardation, characteristic dismorphic 
features and a disturbed glucose homeostasis. The defect underlying this disease 
is in structure of insulin receptor. 
iii. Post- Receptor Resistance 
• 
• 
Decreased capacity of pancreatic P cells to compensate for the underlying 
insulin resistance by increased insulin secretion 
Possible under expression (down regulation) of ^-cells glucose transptMlers 
(therefore &ilure to recognize and respond to hyperglycemia) 
Auto-antibodies to GLUT-2 transporter in P cells 
2.3 Peripheral insulin resistance: 
2.3.1 Skeletal muscle insulin resistance 
1) Non Esterified Fatty Acids 
NEFA's being the most critical of all; compete with glucose for substrate oxidation in 
isolated muscle. (Barry Goldstein, 2002) The increase in fatty acid metabolism leads 
to an increase in intramitochondrial acetyl coenzyme A (COA)/COA and reduced 
adenine dinucleotide (NADH)/NAD+ ratios, with subsequent inhibition of pyruvate 
dehydrogenase. This results in increased intracellular mitrochondrial and cytosolic 
citrate concentrations result in allosteric inhibition of phosphofrucktokinase, the key 
regulating enzyme of glycolysis. Subsequent accumulation of glucose 6 phosphate 
would then inhibit hexokinase II activity, resulting in an increased intracellular 
glucose concentration and decreased glucose uptake finally leading to insulin 
resistance. (G. Boden, I. Gerald Shulman, 2003) Increased NEFA concentration inside 
the cells can also trigger a serine/threonine signaling cascade via fatty acid 
metabolites like diacylglycerol (DAG) and fatty acyl coenzyme A(fatty acyl 
COA).This pathway once activated causes phosphorylation of insulin receptor 
substrate l(IRSl) and insulin receptor substrate 2(IRS2) thereby decreasing their 
ability to bind phosphatidylinositol-3-OH kinase (PI(3)K), this interaction is 
necessary for glucose transporter 4(GLUT4) translocation and insulin mediated 
glucose uptake. (P.J. Randle et al, 1963) 
2) Triglyceride content 
Glucose uptake and intramuscular triglyceride content has been found to follow an 
inverse relationship. The increase in the triglyceride content occurs due to 
imbalance of free fatty acid uptake and oxidation, as in case of obese individuals. 
The major reason for this can be the presence abdominal adiposity, since 
abdominal fat is lipolytically more active leading to increased circulating levels of 
NEFAs. This follows the muscular uptake of free fatty acids which is more than it 
can oxidize. The mechanism involved in this mismatch of uptake and oxidation is 
mediated by malonyl Co A. (J.D. McGarry, 1995) The increased insulin levels in 
circulation due to p cell dysfunctions mediate initial increase in glucose uptake by 
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skeletal muscles. This glucose entering the glycolytic pathway causes an increase 
in citrate levels by activating tricarboxylic acid(TCA) cycle and providing an 
alternate substrate for acetyl CoA carboxylase (ACC).ACC after acti\ation 
generates malonyl CoA thus inhibiting carnitine palmitoyltransferase-! (Cl'7-1) 
and blocking the transfer of fatty acyl CoA into mitochondria for oxidation (7 D. 
McGarry, 1995; S.T. Swanson,1998; KB. Ruderman, 1999) This accumulation of 
triglycerides like long chain fatty acyl CoA and diacyglycerol after activation sets 
several protein kinases into action, leading to serine/threonine phosphorylation of 
insulin receptor and resulting in decreased IR kinase activity finally causing insulin 
resistance. (Iria Nieto-Vazquez et al, 2008) 
2.4 Hepatic glucose production: it's role in insulin resistance. 
Liver is the main site for glucose synthesis and storage in the form of glycogen 
which can later be utilized for giving energy to carry out various cellular processes. 
The process of conversion of glycogen into glucose and glucose synthesis from 
other precursors is strictly controlled by the pancreatic hormone, insulin, (E. 
Stephen Borst, 2004; R. Gasa, 2000) Insulin can inhibit both glycogenolysit and 
gluconeogenesis by activating and de-activating enzymes involved in hese 
pathways. Insulin suppresses glycogenolysis by increasing phosphodiesterase 
activity and by changing the assembly of protein phosphatase complexes. <V.B. 
Newgard, 2000; D. Yeagley, 2001) Gluconeogenesis however is controlled by 
insulin mediated inhibition of phosphoenolpyruvate carboxykinase transcriptional 
activation via phosphorylation of foxhead transcription factor (Foxol and 
FoxoA2). (J.G. Jackson et al, 2000; R.K. Hall et al, 2000) 
An alternate pathway of insulin mediated inhibition of glucose synthesis in li\ er is 
mediated via glucagon and free fatty acids. Insulin causes a decrease in glue igon 
secretion from pancreatic a cells thereby inactivating and downregulating both 
glycogenolysis and gluconeogenesis. (C. Wolfrum et al, 2004) Insulin also exhibits 
its anti-lipolytic effect by decreasing the activity of triacylglycerol lipase and other 
enzymes in adipocytes. This leads to decreased amount of fatty acids in circulation 
and decreased uptake by liver eventually resulting in reduction in gluconeogenesis 
and hence glucose production. 
In case of obese individuals, insulin mediated inhibition of glucose production is 
impaired due to the presence of abdominal fat deposits. These deposits are resistant to 
the anti-lipolytic actions of insulin so insulin in unable to inhibit lipoprotein lipase 
activity resulting in increased levels of free fatty acids in circulation, thus more FFA 
are available to act as precursors for glucose synthesis in hepatocytes. (I. Magnusson 
et al, 1992; M. W. Schwartz et al, 2000) 
2.5 P-cell dysfunction 
The endocrine pancreas contains P-cells that secrete insulin in response to elevated 
glucose levels. Once secreted, insulin performs the function of maintaining normal 
glucose levels in the body by interacting with the plasma lemma receptors of a 
number of different cell types. It is the inability of the P cells to secrete required 
amounts of insulin in response to circulating levels of glucose, that paves the way for 
T2DM.The exact mechanism by which glucose stimulates insulin release from p cells 
is mediated by facilitated diffusion of glucose inside pancreatic P cells via glucose 
transporter GLUT2. This is present on the surface of pancreatic P cells. The numbers 
of these transporters are however found to be reduced on the cells of T2DM patients. 
Glucose after entering P cells is converted to glucose-6-phosphate, by one of the 
glycolytic , rate determining enzyme, glucokinase or hexokinase IV. (J.C. Bruning et 
al, 2000) Glucokinase acts as a glucose sensor of the p cells and leads to increased 
insulin secretion. (F.M. Matschinsky et al, 1998) The entry of glucose to p cells 
follows insulin release. The dose-response relationship leads to more insulin secretion 
as more and more glucose enters the pancreatic P-cell. The pathway by which 
glycolysis mediates insulin secretion depends upon the opening and closing of ATP 
dependent K"^  channels present inside the cell. The step involving the oxidation of 
glyceraldehyde-3-phosphate generates NADH which eventually generates ATP. 
Increase in ATP concentration in P cells leads to blockade of ATP-dependent K^ 
channel causing membrane depolarization followed by increased cytosolic Ca^* 
concentration. This causes fusion of preformed insulin granules with the plasma 
membrane and thus insulin secretion. (ID. Dukes et al, 1994) 
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3 Insulin signaling abnormalities in insulin resistance 
3.1 Insulin signaling 
Insulin signaling is initiated through binding to and activation of its cell 
surface receptor that initiates a cascade of phosphorylation events, second 
messenger generation, and protein-protein interactions. This results in the 
diverse metabolic events in nearly every tissue. The insulin receptor consists 
of two insulin binding a subunits and two catalytic p subunits that are disulfide 
linked into an a2p2 heterotetrameric complex. (A.Pick et al, 1998) Insulin binds 
to the extracellular a subunits, activating the intracellular tyrosine k nase 
domain of P subunit. Once receptor P subunit phosphorylates its partner on 
specific tyrosine residues, it causes stimulation and intramolecular associ ition 
of signaling molecules such as She and Grb, members of the insulin receptor 
substrate family (IRS 1,2,3,4), She adaptor protein isoforms, and SIRP (s gnal 
regulatory protein) family members. (S. Obici, 2002) 
The insulin receptor P subunit has also been shown to uncergo 
serine/threonine phosphorylation, which might decrease the ability of receptor 
to autophosphorylate, as in case of obesity. The NEFA's that entei the 
peripheral tissues change into lipid metabolites like fatty acyl CoA's and 
diacylglycerol (DAG). DAG once formed activates novel PKC isoforms that 
catalyze the serine/threonine phosphorylation of the P subunit and thus 
attenuates insulin signaling , making way for insulin resistance. The acti\ ities 
of a number of protein kinase C (PKC) isoforms that catalyze the serine or 
threonine phosphorylation of the insulin receptor are found to be elevated in 
animal models of insulin resistance as well as in human subjects having insulin 
resistance. (J.K. Elmquist, 2003) 
4 Role of central nervous system in Type 2 Diabetes Mellitus 
Central nervous system plays an important role in insulin secretion and glucose 
homeostasis. Insulin has its receptors not only on peripheral tissues but also on the 
surface of brain cells where it maintains energy balance. (W. Fan, 2000) Deletic n of 
these receptors from neurons has been found to induce obesity, (J.R. Zierath, 2000) 
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thereby highlighting their probable importance in pathogenesis of T2DM.Any 
alteration in the number of brain insulin receptors causes an imbalance in the glucose 
homeostasis, not leaving behind the liver glucose production. (J.Avruch et al, 1998) 
These findings, clearly suggest that T2DM can also result due to underlying defects in 
central nervous system. 
5 Oxidative stress 
The term oxidative stress can be defined as a cellular condition when the production 
of reactive oxygen species (ROS) like superoxide anions, hydrogen peroxides etc. is 
greater than the quenching capacity of the cellular antioxidant enzymes and cellular 
reductants. (A.G. Danielsen, 1995) In this condition the cell is under stress due to 
overproduction of ROS which react and cause oxidation of cellular biomolecules, 
resulting in peroxidation of the membrane lipids, affecting the cellular integrity, 
oxidation of all the cellular proteins including enzymes involved in metabolism as 
well as DNA oxidation leading to strand breaks and degradation, eventually resulting 
in cellular and tissue damage. (Peter Proctor, 1989) In normal cells there exists a 
mechanism for controlling oxidative stress involving enzymes and other molecules. 
These enzymes include superoxide dismutase, catalase and glutathione peroxidase 
with GSH (L-y-glutamyl-L- cysteinyl-glycine) as the major reducing molecule in the 
cell. 
5.1 Superoxide dismutase (SOD) 
Superoxide dismutase belongs to a class of enzymes that converts superoxide anions 
to molecular oxygen and hydrogen peroxide, quenching the harmful reactive oxygen 
species (superoxide O2") and rendering it ineffective. SOD can be classified into two 
groups based on their reactive centres; Cu-Zn SOD and Mn SOD. MnSOD is found in 
mitochondria whereas Cu-Zn SOD is present in the cytosol. The mechanism by which 
SOD performs dismutation of superoxide ions can be summarized in two equations: 
. M("+'^ -^SOD + 02~ -^ M"^-SOD + O2 
. M"''-SOD + O2" + 2H^ ^ M *"+') ^ -SOD + H2O2. 
Where M is the metal ion at the reaction center or active site of the enzyme. 
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If M = Cu (n=l); Mn (n=2); Fe (n=2); Ni (n=2). 
5.2 Catalase 
Catalase enzyme is majorly located in peroxisomes but is also found in mitochondria 
though at lower levels. The main function of this enzyme is to convert of hydiogen 
peroxide (H2O2) to oxygen and water. This scavenging reaction is carried out in a 
two-step process: 
H2O2 + Fe (III)-E -^ H2O + 0=Fe (IV)-E (. +) 
H2O2 + 0=Fe (IV)-E (. +) -^ H2O + Fe (III)-E + O2 
Here Fe (III/IV)-E represents the iron center of the heme group attached to the 
enzyme. Fe (IV)-E (. +) is a mesomeric form of Fe (V)-E, meaning the iron is not 
completely oxidized to +V, but receives some "supporting electron" from the lieme 
ligand. This heme has to be drawn then as a radical cation (. +) 
Hydrogen peroxide once generated as a result of several metabolic processes can 
severely damage cells and tissues thus, catalase converts these H2O2 to stable 
molecules (O2 and H2O) protecting the cell from free radical induced damage. 
5.3 Glutathione Peroxidase 
Glutathione peroxidase is the major hydrogen peroxide scavenger enzyme founc both 
in cytosol and mitochondria. It reduces the lipid peroxides to their correspoiding 
alcohols and hydrogen peroxide to water. This enzyme plays its anti-oxidant role in a 
single step process, in which reduced glutathione (GSH) is converted to oxidized 
glutathione (GSSG). 
2GSH + H2O2 -^ GS-SG + 2H2O 
After the oxidation, GSSG is converted back to its reduced form by the enzyme 
glutathione reductase, thus completing the cycle and regenerating the substrate f )r the 
action of glutathione peroxidase. 
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5.4 GSH (L-y-glutamyl-L-cysteinyl-glycine) 
GSH is the most abundant non protein thiol source and antioxidant in the cell. Apart 
from playing its antioxidant role, it also performs many other functions: 
• GSH provides a substrate for GSH peroxidase. 
• GSH conjugates with harmful exogenous and endogenous toxic 
compounds 
• It reduces disulfide linkage of proteins and enzymes thus maintaining 
them in reduced state for their proper physiological action. 
• This thiol source helps in maintaining the redox status of the cell. 
• GSH also plays an important role in reduction of ribonucleotides to 
deoxyribonucleotides. 
6 Hyperglycemia induced oxidative stress 
In normal cells, when glucose is metabolized via tricarboxylic acid cycle (TCA), it 
produces two reducing powers; NADH and FADHa.These electron donors transfer 
their electrons to complex I and complex III of the mitochondrial electron transfer 
chain (ETC) respectively. During this whole process, protons are driven out of the cell 
membrane through complex I, III and IV generating a potential gradient inside the cell 
for the synthesis of ATP via ATP synthase. However, in diabetic cells, the condition 
is almost reversed. Due to hyperglycemia, more glucose enters the TCA cycle 
generating an increased concentration of reducing equivalents (NADH and 
FADH2).This increase pushes these electron donors more and more into the ETC, 
increasing the transfer of protons outside thereby leading to enhanced voltage gradient 
across the mitochondrial membrane. This rise in voltage gradient when reaches the 
critical threshold, blocks further transfer of electrons to complex III. The electrons 
thereby return to coenzyme Q, which transfers one electron at time to water, thus 
generating superoxide radicals. (M.D Evans, M.S. Cooke, 2004) These radicals 
increase the production of lipid peroxides by reacting with membrane lipids and also 
cause increase in the levels of H2O2, finally increase the total concentration of ROS 
inside the cell. (Michael Brownlee, 2005) 
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6.1 Activation of major damaging pathways 
Hyperglycemia induced superoxide radical generation activates four major pathways 
of cellular damage. The exact mechanism is mediated via the inhibition of enzyme 
glyceraldehyde 3 phosphate dehydrogenase (GAPDH) of the glycolytic pathway. (S.S. 
Korshunov, 1991) Superoxide radicals cause DNA damage and thus activate the 
enzyme poly ADP-ribose polymerase (PARP), which on sensing the damage done, 
breaks NAD* to nicotinic acid and ADP-ribose. PARP then polymerizes ADP-ribose 
units which get attached to several nuclear proteins including GAPDH (GAPDH is 
found in cytosol but it actually shunts in and out of nucleus where it helps in DNA 
repair) thereby reducing its activity. (X. Du et al, 2003; A. Sawa et al, 1997) This 
decrease in activity causes accumulation of glycolytic metabolites upstream of 
GAPDH activating four major pathways: 
• Glyceraldehyde-3-phosphate accumulation activates advanced glycation end 
product (AGE) formation via major intercellular precursor methylglyoxal and 
also activates protein kinase C (PKC) pathway by forming diacylglycerol. 
PKC stimulation has been found to activate NAD(P)H oxidase in diabetes. 
Once activated NAD(P)H transfers electron from NAD(P)H to molecular 
oxygen, generating superoxide and thus adding to oxidative stress. 
Fructose-6-phosphate upon accumulation increases the flux through 
hexosamine pathway leading to the formation of UDP-N-acetylglucosamine 
(UDP-GlcNAc) via glucosamine-6-phosphate.Glucosamine-6-phosphate once 
formed can inhibit the activity of enzyme glucose-6-phosphate dehydrogenase, 
which is also involved in reduction of NADP"^  to NADPH. This decreases the 
cellular ratios of NADP^/NADPH and thus causing oxidative stress either by 
decreasing the regeneration of GSH from GSSG or by decreasing the activity 
of antioxidant enzyme. 
Finally, increased amount of glucose gets directed into the polyol pathway 
converting glucose into sorbitol and finally fructose, utilizing NADPH and 
reducing its concentration inside the cell. Since NADPH is a substrate for 
glutathione reductase (GR), the depletion in NADPH levels decreases the 
activity of GR and an increase in free radicals thereby causing oxidative stress. 
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Mitochondria -> 
Fig 1.3 Various pathways of hyperglycemia induced oxidative stress in diabetic tissues 
(adaptedfrom Diabetes /2005; American Diabetes Association). 
7 Vitamins as potential anti-diabetic agents 
Vitamins are natural substances found in plants and animals and are known as 
essential nutrients for human beings. These are the components of a balanced diet 
which the human body cannot synthesize on its own (except vitamin D and vitamin 
K) and thus have to be consumed through diet either in the form of food or as 
supplements. The term vitamin is derived from words "vital" and "amine" because 
vitamins are required for life and were originally thought to be amines, however not 
all vitamins are amines. Vitamins are organic compounds required by humans in 
small amounts. An organic compound is considered vitamin if a lack of that 
compound in diet results in overt symptoms of deficiency. Since people suffering 
from T2DM are also found to be deficient in many vitamins this deficiency can add to 
many other causes of developing type 2 diabetes. Diabetes as a disease does not cause 
severe health problems, but the complications associated with diabetes can lead to 
problems. Since vitamins play an important role in glucose metabolism, 
understanding the impact of vitamin deficiencies and the potential utility of 
supplementation is relevant to the prevention and management of type 2 diabetes 
mellitus (T2DM). 
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7.1 Vitamin D 
Vitamin D is an assemblage of fat-soluble secosteroids, i.e., steroids in which one of 
the bonds in the steroid rings is broken. (H.D. Schmidtz, 2001) The two major 
physiologically pertinent forms are vitamin D2 (ergocalciferol) and vitamin D3 
(cholecalciferol).The structural dissimilarity between vitamin D2 and vitamin D3 is in 
their side chains. The side chain of D2 contains a double bond between carbons 22 and 
23, and a methyl group on carbon 24. These are collectively known as calciferol. 
Vitamin D2 (made from ergosterol) is produced by invertebrates, fungus and plants in 
presence to UV light and is not produced by vertebrates. Vitamin D3, on the other 
hand, is produced photo-chemically in the skin from 7-dehydrocholesterol.7-
dehydrocholesterol is produced in relatively large quantities in the skin of most 
vertebrate animals, including humans. 
Vitamin D3 is synthesized in the skin of vertebrates after exposure to UV-B light and 
also by intake of wide variety of foods. 
Foods containing Vitamin D include catfish - 85gm provides 425 lU , mackerel-
lOOgm provides 325 lU, Eel - lOOgm provides 200 lU, Salmon - lOOgm provides 
345 lU, Sardines - 50 gm. provides 250 lU, Beef liver - lOOgm provides 15 lU, 
Whole eggs - provide 20 lU, fish oil - 15ml provides 1360 lU. 
7.1.1 Vitamin D Metabolism 
Vitamin D has been identified as a prohormone synthesized in the skin and regulates 
calcium metabolism after undergoing metabolic conversion to its hormonally active 
form, 1,25 dihydroxyvitamin D [l,25(OH)2 D] in liver and kidney. In skeletal muscles 
the action of vitamin D is mediated by binding to its receptor. When l,25(OH)2 D 
interacts with the vitamin D receptor (VDR) it induces heterodimerization of VDR 
with the retinoid X receptor (RXR).This heterodimer then binds to the Vitamin D 
response elements in DNA and recruits various coactivators. This leads to the 
enhanced transcription of genes whose protein products control calcium homeostasis. 
(J. Bar Sony, S.J. Marx, 1988) The presence of rapid, transcription-independent events 
have also been observed in response to physiologic levels of vitamin D and the 
existence of l,25(OH)2D-inducible signal transduction pathways are located within 
17 
various tissues including adipocytes. (J.C. Fleet, 2004) l,25(OH)2D rapidly (within 
seconds and minutes) stimulates events, normally associated with the activation of 
membrane receptors for growth factors and peptide hormones. (H.L. Gulseth et al, 
2010) These include: 
• Phospholipase C (PLC) and Phospholipase D activation. 
• Phosphoinositide turnover leading to the generation of the second messengers, 
inositol 1,3, 4-triphosphate (IP3) andl, 2-diacylglycerol (DAG). 
• Increase in intracellular calcium by increasing calcium uptake and the release 
of intracellular calcium stores. 
• Adenylate cyclase activation to increase cAMP levels and stimulation of 
protein kinase A (PKA) activity. 
• Calcium-dependent protein kinase C (PKC) activation and cellular 
redistribution. 
7.1.2 Probable Mechanisms of Action of Vitamin D on Glucose Metabolism 
Impaired pancreatic P-cell function, insulin resistance and systemic inflammation are 
the major causes of the pathogenesis of NIDDM, and vitamin D has been shown to 
have influence on them as summarized below: 
7.1.2.1 Vitamin D and Pancreatic Beta cell function/ Insulin Secretion 
Various studies have shown the presence of specific vitamin D receptors (VDRs) on 
pancreatic P-cells, the expression of 1 -a-hydroxylase enzyme in pancreatic P-cells (R. 
Bland et al, 2004) which catalyzes the conversion of 25(OH)D to 1,25-
dihydroxyvitamin D(l,25(OH)2D3), (B. Maestro et al, 2003) and the presence of a 
vitamin D response element in the human insulin gene promoter. All these findings 
indicate the influence of Vitamin D on glucose homeostasis. The mechanism by 
which 1, 25(OH)2D3 might act on insulin secretion is suggested by the significant rise 
in cytosolic Ca^ "^  levels. This is observed following l,25(OH)2D3-sfimulated secretion 
of insulin by islet cells. Pancreatic p-cells depend on an acute intracellular calcium 
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increase for insulin secretion (Enju Liu et al, 2009), which may also be attenuated 
with elevated cytosolic calcium. (C. B.Wollheim and G.W. Sharp, 1981) The 
controversy remains as to whether an influx of external Ca^^ via voltage-dependent 
Ca^^ channels is solely responsible for this rise or whether the mobilization of Ca^^ 
occurs from intracellular organelles via the activation of release of potentiating 
systems via protein kinase C and protein kinase A pathways. 
la Hydroxylase 
25 0HD > 1,25 0HD Insulin 
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' Ca +2 
Fatty acid metabolism 
Fig 1.4 Mechanism of action of vitamin D in increasing insulin sensitivity in peripheral 
tissues of Type 2 diabetic individual (adaptedfrom springer images). 
7.1.2.2 Vitamin D and Insulin sensitivity 
VDR is also expressed by human skeletal muscle and adipose tissue, (J. C. Fleet, 
2004; H. L. Gulseth, et al 2010) the main determinants of peripheral insulin 
sensitivity. These tissues were, shown to express the 1 a-hydroxylase gene in male 
Wistar rats. (A.L.Sutton, 2003) Notably, skeletal muscle expression of VDR declines 
with age, and so does the insulin sensitivity. (C. Cade, 1983) Vitamin D deficiency 
may influence insulin sensitivity via its effects on intracellular calcium. Elevated 
intracellular calcium impairs post-receptor insulin binding action, such as-
dephosphorylation of glycogen synthase and of the insulin regulatable glucose 
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transporter (GLUT-4). (H. A. Bischoff-Ferrari et al, 2004) Vitamin D deficiency 
results in elevated parathyroid hormone (PTH), which in turn is known to elevate 
intracellular calcium. Sustained elevations of intracellular calcium may inhibit 
insulin-target cells from sensing the brisk intracellular calcium fluxes necessary for 
insulin action, such as glucose transport. (J. E.-B. Reusch, 1991) Therefore vitamin D 
may improve insulin action by its ability to reduce PTH levels (K. Hida et al, 2005). 
There is evidence that increased blood PTH is associated with insulin resistance or 
glucose intolerance. (J.L Evans et al, 2003; A.C. Maritim et al, 2003) It is well 
established that there is an increased prevalence of type 2 diabetes mellitus (8 %) and 
glucose intolerance (40 %) in patients with primary hyperparathyroidism. In addition, 
fasting PTH levels were shown to be inversely correlated with insulin sensitivity 
index in fifty-two normotensive, healthy subjects, even after adjustment for 
potentially confounding factors, supporting the hypothesis that higher fasting serum 
PTH may mediate a reduction in glucose tolerance. These results support a role of 
physiological levels of PTH and 1,25 (0H)2D hormones in insulin action. Another 
possible mechanism is mediated via intracellular calcium, which enhances calmodulin 
binding to insulin receptor substrate-1 (IRS-1), therefore interfering with insulin-
stimulated tyrosine phosphorylation and PI3-kinase activation. (D. S. Worrall and J. 
M. Olefsky, 2002; M. B. Zemel, 1998) In addition, 1, 25(OH)2D3 directly activates 
transcription of the human insulin receptor gene that activates peroxisome 
proliferators activator receptor-y (H. G. Munshi, 1996) , that stimulates the expression 
of insulin receptor, and enhances insulin-mediated glucose transport in vitro. 
It has also been found that 1,25 dihydroxyvitamin D3 modulates the rennin-
angiotensin system. Although the exact mechanism is not known but studies have 
reported that vitamin D deficiency leads to an increase in the levels of rermin and 
angiotensin II synthesis, angiotensin II once synthesized increases the production of 
reactive oxygen species (ROS) through membrane bound NADPH oxidase and 
activates small molecular weight G-proteins like Rho A. Rho A inhibits insulin 
receptor substrate (IRS) phosphorylation thus blocking PKC (Akt) mediated 
translocation of glucose transporter (GLUT-4) in case of skeletal muscles and 
adipocytes, and limiting the amount of glucose entering the cell thereby decreasing 
insulin sensitivity and causing insulin resistance. 
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The genotypic links of vitamin D to insulin resistance are one the major reasons that 
help it in maintaining glucose homeostasis. The presence of vitamin D response 
elements in the promoter region of insulin receptor gene can be one of the reason 
paving way to improved insulin sensitivity in response to vitamin D supplementation. 
Therefore, increase in vitamin D concentration in circulation can directly increase the 
concentration of insulin receptors on the surface of target tissues. In addition to this, it 
has been found that the individuals having BsmI (VDR/BB) genotypes have higher 
levels of fasting glucose as compared to those having genotype (Bb), though some 
studies have found this association to be conflicting. This finding supports the very 
idea that not only vitamin D as a molecule but also its receptors and response 
elements are involved in its insulin sensitizing effects. 
7.1.2.3 Vitamin D and Systemic Inflammation 
Inflammatory factors have often been associated with insulin resistance and P-cell 
failure, both of which are the key features of NIDDM. An increase in acute-phase 
proteins, cytokines and mediators associated with endothelial dysfunction has been 
reported in NIDDM. In NIDDM, abnormalities in many systemic inflammatory 
markers have been found, such as tumour necrosis factor (TNF)-a and TNF-P, 
interleukin-6 (IL-6) and its receptor, C-reactive protein and plasminogen activator 
inhibitor-1. (B.S. Chertow et al, 1983) Some of these immune mediators, such as 
TNF-a and IL-6 may directly interfere with insulin signaling, leading to insulin 
resistance by several mechanisms. Interestingly, vitamin D has been reported to 
down-regulate the production of several cytokines: IL-2, IL-6 and IL-12, interferon y, 
TNF-a and TNF-p. Since a variety of studies have reported that these inflammatory 
changes may occur many years before diabetes onset, therefore they are regarded as 
contributors rather than a consequence of the disease. 
The reported existence of VDRs in activated T lymphocytes, macrophages and 
thymus tissue supports the idea that vitamin D may also function as an immune-
modulator. Some of the non-classical actions of vitamin D therefore point to the role 
of this molecule in the pathogenesis of NIDDM. 
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1.2 Vitamin C 
Ascorbic acid is a weak sugar acid structurally related to glucose and is synthesized 
de novo from glucose in most adult mammals, however some primates and humans 
cannot synthesize it due to the absence of enzyme L-glucono-5-lactone oxidase 
(GULO), which is required in the last step of vitamin C synthesis and thus depend on 
diet for proper intake of this vitamin. (G. Pittas et al, 2008) The normal levels of 
vitamin C found in the body of healthy individuals varies between 900-1500 mg. 
Foods rich in vitamin C include strawberries, papayas, kiwi, bell peppers, guava, 
melons, dark leafy vegetables which may contain up to 130 mg vitamin C in a single 
serving, broccoli, cauliflower, tomatoes, 100 gm. of which contain over 100 mg of 
vitamin C and some herbs like thyme contain 160 mg of vitamin C in one cup. 
Vitamin C has many physiological functions including the biosynthesis of collagen, 
carnitine and neurotransmitters like dopamine. As an antioxidant , it scavenges free 
radicals and acts as a reducing agent donating electrons and preventing oxidation to 
keep iron and copper atoms in their reduced states. Apart from these functions vitamin 
C also acts as a cofactor for eight different enzymes (R. Jenness,1980): Three of these 
enzymes participate in collagen hydroxylation (M. Levine, 2000), adding hydroxyl 
groups to the amino acids proline or lysine in the collagen molecule via prolyl 
hydroxylase and lysyl hydroxylase. Hydroxylation allows the collagen molecule to 
assume its triple helix structure, and thus vitamin C is essential to the development 
and maintenance of scar tissue, blood vessels, and cartilage. 
The other two enzymes are necessary for synthesis of carnitine (D.J. Prockop and K.I. 
Kivirikko, 1995) which is essential for the transport of fatty acids into mitochondria 
for p-oxidation. The remaining three enzymes have some functions in common in 
addition to their individual specific actions like dopamine beta hydroxylase 
participates in the biosynthesis of norepinephrine from dopamine (C.J. Kivirikko, 
1991), another enzyme adds amide groups to peptide hormones, greatly increasing 
their stability (M. Levine et al, 1992) and the last one modulates tyrosine metabolism. 
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7.2.1 Vitamin C metabolism 
Ascorbic acid (AA) after ingestion is absorbed by the gastrointestinal tract. After 
coming in contact with the oxidants in lumen of gastrointestinal tract, some of the 
ascorbic acid is converted into its oxidized form dehydroascorbic acid (DHA). (B.A. 
Eipper et al, 1993) Both A A and DHA are then transported across the cell membrane 
of enterocytes via specific transporters. The Na^- ascorbate cotransporter takes up the 
AA with high affinity while DHA is transported by facilitated diffusion in a Na^ 
independent low affinity process mediated by glucose transporter family (GLUT). 
(S.A. Kyrtopoulos, et al, 1991) GLUT 1 and GLUT 3 are the major transporters of 
DHA located predominantly in osteoblasts, (C. Malo et al, 2000) muscles (S. Qutob et 
al, 1998) and retinal cells (J. Korcok et al, 2003) however GLUT 4, found in skeletal 
muscles and adipocytes is also involved in DHA uptake but at a lower level. (K. 
Hosoya et al, 2004) Once inside enterocyte, DHA is converted back to AA by DHA 
reductases (S.C. Rumsey et al, 2000), thus maintaining the gradient for continuous 
uptake DHA, lowering the chances of its escape in the blood stream. Since DHA 
shares the transporters with glucose, its uptake is competitively inhibited by this 
monosaccharide. (G.D. Buffmton and W.F. Doe, 1995) Changes in the circulating 
levels of glucose inhibit the uptake of DHA inside the cell and thus attenuate the 
bioavailability of vitamin C. 
Antioxidant role of Vitamin C 
There are two major properties of vitamin C that makes it an ideal antioxidant. First is 
the low one-electron reduction potentials of both ascorbate (282 mV) and ascorbyl 
radical (217 mV), which is derived from the ene-diol fiinctional group of the molecule 
(Halliwell, 1996). These low reduction potentials enable ascorbate and ascorbyl 
radical to react with and reduce almost all physiologically relevant radicals and 
oxidants. The second major property that makes vitamin C an effective antioxidant is 
the stability and low reactivity of the ascorbyl radical formed when ascorbate 
scavenges a reactive oxygen or nitrogen species. The ascorbyl radical readily 
dismutates to form ascorbate and dihydroascorbic acid or is reduced back to ascorbate 
by an NADH-dependent semidehydroascorbate reductase (Wells and Jung, 1997). In 
this conversion, DHA takes up electrons from the mitochondrial electron transport 
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chain specifically from complex III thereby decreasing the reduced state of electron 
transport chain and the subsequent electron leakage finally leading to decreased 
reactive oxygen species (ROS) formation. (J. Korcok et al, 2003) Another pathway 
involved in the inter-conversion of DHA to AA is mediated by reduced glutathione 
(GSH). In this process GSH is converted to its oxidized form (GSSG), which at the 
expense of NADPH can again be brought back to its reduced form. (X.Li et al, 2002) 
Thus, DHA conversion to AA indirectly can stimulate pentose phosphate pathway to 
produce more cellular reductants, decreasing the chances of oxidative stress. Once 
generated AA can scavenge the ROS directly at the site of generation. Therefore 
vitamin C shows anti-oxidant effect both during and after conversion. 
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Fig 1.5 Vitamin C uptake and recycling in mitochondria. Vitamin C in its oxidized form 
dehydroascorbic acid (DHA) is transported into mitochondria of the isolated kidney cells via 
GLUT-1.The transported DHA is reduced in the mitochondria. The respiratory chain can 
donate electrons for the reduction and the site of the reduction is complex III (Li et al, 
2002).DHA is also reduced back to ascorbate by DHA reductase and glutathione. The 
oxidized glutathione is reduced back at the expense of NADPH (Li et al, 2001).DHA 
reduction can also be mediated by lipoic acid containing complexes (Xu and Wells.,1996). 
Ascorbic acid (AA) can leave the mitochondria, mediated by a presently unknown 
transporter. AA quenches ROS protecting the mitochondrial genome and preventing 
mitochondrial membrane depolarization. (Adapted from J Mandl et al/ British Journal Of 
Pharmacology; 2009). 
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7.3 Vitamin C and Diabetes 
The excess amount of glucose in circulation (hyperglycemia) as in case of diabetes 
competitively inhibits the uptake of DHA via GLUT transporters inside the cells due 
to the structural similarity between glucose and vitamin C. This creates an imbalance 
in the levels of vitamin C which can also become detrimental for the cell. 
Administration of DHA has been found to protect the neural cells from ischemic 
stroke by increasing antioxidant levels through GLUT mediated vitamin C 
accumulation. This may also protect against ROS generated from mitochondrial 
respiration as mitochondria is the major site for generation of ROS. (X. Li et al,2001) 
In normal tissues, insulin increases the facilitated transport of DHA inside the cell but 
in case of diabetes (S.Qutob et al, 1998), when the cells become insulin resistant, the 
cellular DHA uptake is impaired leading to decreased regeneration of AA and reduced 
antioxidant levels thereby increasing the susceptibility of ROS mediated damage of 
biomolecules. The decrease in cellular reductants provides an ideal niche for reactive 
oxygen species to oxidize proteins, lipids and DNA, causing diabetes related 
complications like cardiovascular diseases (CVD) and atherosclerosis. 
DHA 
Glucose 
Insulin 
Glucose 
DHA 
Insulin ^ A 
0 
AA 
Normal cell Insulin resistant cell 
Fig 1.6 In type 2 diabetes, insulin resistance and hyperglycemia together blocks the transport 
of DHA inside the cell and thus its conversion to ascorbic acid thereby decreasing cellular 
reductants and increasing oxidative stress (adaptedfrom J.X Wilson/FEBS Letters; 2002). 
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7.4 Vitamin A 
Vitamin A is a name given to fat soluble, related compounds including retinol, 
retinaldehyde, retinoic acid etc. Both mammals and other animals depend upon their 
diet for the intake of this vitamin due to their inability to synthesize it. The two major 
forms of vitamin A present in foods are: 
• Retinol, a yellow colored fat soluble substance is obtained from foods of 
animal origin like fish, meat (especially liver) and dairy products. Since retinol 
(a pure alcohol form) is an unstable form of vitamin A, it is generally found in 
the form of retinyl esters mostly retinyl palmitate or retinyl acetate. 
• Carotenes are the form of vitamin A obtained from foods of plant origin like 
carrots. However, carotenes lacking beta-ionone rings cannot be converted 
into vitamin A by herbivorous and omnivorous animals, while humans possess 
the enzyme beta carotene 15-15' monoxygenase and thus convert alpha-
carotene, beta-carotene, gamma-carotene; and the xanthophyll beta-
cryptoxanthin (all of which contain beta-ionone rings) to vitamin A. 
7.4.1 Vitamin A biosynthesis 
The first committed step in plant carotenoid synthesis is the condensation of two 
molecules of GGDP (geranylgeranyl diphosphate) to produce phytoene (Figure 1.7) 
by the enzyme phytoene synthase (PSY). (P. Beyer, 1989) Phytoene is produced as a 
15-cis isomer, which is subsequently converted to all-trans isomer derivatives. Two 
plant desaturases, phytoene desaturase (PDS) and ^-carotene desaturase (ZDS), 
catalyze similar dehydrogenation reactions by introducing four double bonds to form 
lycopene. (P. Carol et al, 1999) Desaturation requires a plastid terminal oxidase and 
plastoquinone in photosynthetic tissues. (E. Collakova, et al, 2003) Lycopene once 
formed is then acted upon by lycopene cyclase generating a-carotene and (3- carotene. 
Both these carotenes act like vitamin A precursors or provitamin A and are a substrate 
for enzyme beta carotene 15-15' monoxygenase, found in animals and humans which 
convert them to vitamin A (Retinol). (Dean Delia Penna and Barry J. Pogson, 2006) 
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Fig 1.7 Biosynthetic pathway of Vitamin A precursors in plants and their final conversion to 
vitamin A in humans. 
7.5 Vitamin A metabolism 
Vitamin A metabolism begins with the physical release of retinol, retinyl esters or 
carotenoids from the diet. All these three forms of vitamin A imdergo different stages 
before they are released in circulation. Retinol after entering the lumen undergoes 
emulsification by fatty acids and bile acids in order to enter enterocytes, however 
retinyl esters in the lumen are acted upon by two enzymes; pancreatic triglyceride 
lipase (PTL) and pancreatic lipase related protein 2(PLRP2), which covert them into 
retinol which can enter directly into the enterocytes whereas the conversion of 
carotenoids to retinol taken place in the enterocytes itself (H. Earl Harrison, 2005) 
Carotenoids in the enterocytes undergo both symmetrical and asymmetrical cleavage 
by P carotene 15-15'monoxygenase and P carotene 9'-10'monoxygenase respectively 
yielding retinol and P apo-carotenoids. (JA Olson, 1989) Finally, retinol in the 
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enterocytes xindergoes esterification by the action of two enzymes; 1. Lecithin: retinol 
acyltransferase (LRAT) which performs the trans-esterification of retinol by 
employing the fatty acyl group present at the Al position of a membrane phosphotidyl 
choline molecule for its packaging into chylomicrons. 2. Acyl-CoA: retinol 
transferase (ARAT) which carries out the fatty acyl CoA dependent esterification of 
retinol. (R.K. Randolph, et al, 1991) After being esterified, retinol is released in the 
circulation in the form of retinol bound chylomicrons, which are taken up by liver for 
storage and release depending upon the level of vitamin A in circulation. (S. Vogel et 
al, 1999) 
t^mnmUKHHw tyutm 
Fig 1.8 The metabolic pathway of Vitamin A (adaptedfrom Theo 
J. C. van Berkel/journal of lipid research; 2009). 
7.6 Vitamin A and Diabetes 
Vitamin A is required for normal growth, vision, and resistance to infection. 
According to studies, vitamin A also plays a role of cardinal importance in processes 
like(i) stimulating glucose transporter expression in L6 muscle cells, (R. Blomhoffand 
H.K. Blomhoff, 2006) (ii) restoring insulin secretion in vitamin A deficient mice, 
(M. W. Sleeman et al, 1995) (ii) inducing both first and second phase insulin secretory 
responses to glucose in explants of human fetal pancreas, ("5. S. Cher tow et al, 1987) 
(iv) increasing insulin production in RINmSF cells and human islets and last but not 
the least (B.E. Tuch and K.J. Osgerby, 1990) (v) stimulating glucokinase gene 
expression and enzyme activity in pancreatic islets and improving glucose sensing 
system. Therefore, its deficiency can affect the physiological functions required for 
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proper functioning of the body. Several studies have found a deficiency in the status 
of vitamin A (especially in levels of all-trans retinoic acid and 9 cis-retinoic acid) in 
type 2 diabetic patients, thereby increasing their oxidative stress and also enhancing 
their probability of developing other complications related to insulin secretion and 
sensitivity. 
After having an understanding of the mechanisms and risk factors underlying the 
incidence, development and progression of type 2 diabetes mellitus and possible 
related complications, extensive research should be extended to fight this deadly 
disease. From a pathophysiological standpoint, the two major players of T2DM are 
hyperglycemia and oxidative stress. Hyperglycemia serves as a root cause ol all the 
underlying complications by mediating its effects in more than one ways. (P. Anabela 
Rolo, M. Carlos Palmeiro, 2006; L. George King, R- Mary Loeken, 2004) All the 
pathways however, converge to ultimately give rise to the major player: oxidative 
stress in the pathogenesis of T2DM. Once generated, the free radicals cause 
pancreatic |3 cell damage, thus increasing hyperglycemia, mitochondrial dysfunction, 
lipid peroxidation, glucose oxidation, DNA damage and lastly, manifesting changes in 
the histology of diabetic tissues. (A. Ceriello, 2003) In order to stop the progression of 
the disease or to slow down the occurrence of diabetic complications, these reactive 
oxygen species (ROS) should either be quenched or their production nust be 
downregulated. (J.L. Evans et al, 2003; A.C. Maritim et al, 2003) However, it will be 
of double benefit if T2DM complications like hyperglycemia as well as oxidative 
stress, are targeted simultaneously. With this approach we studied the effect of several 
vitamins (Vitamin D, Vitamin C and vitamin A) alone and in combination of each 
other in type 2 diabetic swiss albino mice. The sole purpose of taking different 
vitamins was to see their individual effect since all three vitamins have different 
modes, sites and targets of action. 
Therefore, in this study conducted, we not only observed the parameters related to 
glucose metabolism but also those involved in oxidative stress, since both are inter-
related and equally important in order to come up with a vitamin or a combination 
with highest anti-diabetic potential. 
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1.1 In Vivo Studies 
1.2 Animal Husbandry 
50 adult Swiss albino female mice were bought from animal house facility of Central 
Drug Research Institute, Lucknow. All of them were kept in sufficiently large cages 
with uninterrupted supply of standard pellet mice diet (Ashirwad Industries, 
Chandigarh, India) and clean drinking water ad libitum. They were acclimatized and 
treated under humane and hygenic conditions with maintained 25±2 °C and 12 hours 
day: night cycle according to 'University Guidelines for Experimentation on 
Animals'. 
The mice were randomly divided into various groups of 6 mice each according to 
demand of the study mentioned in the below. They were given alloxan monohydrate 
dissolved in water in order to be made diabetic as required in the study. After 
induction of diabetes, different groups were given different treatments of 1, 25 
dihydroxyvitamin D3, vitamin A and vitamin C dissolved in propylene glycol and 
water respectively both separately and in combination with each other. 
1.3 Dosing and Treatment Strategy 
The drug for inducing diabetes, alloxan monohydrate (2,4,5,6-tetraoxypyrimidine; 
5,6-dioxyuracil) 150mg/kg body weight, was administered intraperitonealy and its 
effect was observed via fasting blood glucose level estimation after a period of 15 
days. Once the establishment of diabetic state was confirmed (FBG< 160 mg/dl), 
different groups were given 250^1 of different vitamins alone and in combination in 
respective groups. Group I was considered as the control to compare with all other 
groups for all calculations and evaluations purposes. All the mice were healthy during 
the treatment. The animals showing the signs of distress were removed fi-om the 
treatment. The treatment was scheduled in such a way that all the animals were 
sacrificed on the same day. 
1.3.1 Mechanism of action of Alloxan 
Alloxan is hydrophilic and unstable substance with a half life of 1.5 minutes at pH 7.4 
and 3 7°C .Alloxan reacts with the sulphydryl groups present in various biomolecules 
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like those present in glukokinase, glutathione, cysteine and protein-bound sulfhydryl 
groups (including SH containing enzymes) etc. and thus gets reduced to dialuric acid. 
Once formed, it is then re-oxidized back to alloxan establishing a redox cycle for the 
generation of superoxide radicals. Superoxide radicals and other reactive oxygen 
species damage pancreatic DNA thus causing pancreatic damage. Alloxan shows its 
diabetogenic action in more than one ways oxidation of essential sulphydryl (-SH) 
groups, generation of free radicals and DNA damage. 
-SH-SH 
GKa! 
Alloxan Dialuric acid 
H202-K)2 
OH-
The mechanism of alloxan-induced reactive oxygen species generation in P-cells of 
mice pancreas. GKa, GKi - glucokinase active and inactive, respectively. 
In vivo study conducted can be divided into 3 chapters as mentioned in the below: 
1.4 Chapter 1: Effect ofl, 25 dihydroxyvitamin Dj alone. 
Two groups of 6 mice each were made diabetic, to one of these groups 1, 25 
dihydroxyvitamin D3 was administered for a regular period of 15 days in order to 
observe its effect on glucose homeostasis, oxidative stress, DNA damage, 
histopathological changes and GLUT-4 expression. Group III was housed in closed 
room with no sunlight to make sure that the treatment given was the only source of 
vitamin D. 
Group 
Group I 
Group II 
Group III 
Name 
Control 
Diabetic 
Diabetic+ Vitamin D3 
Treatment 
No treatment 
Alloxan monohydrate (150gm/kg. body wt.) 
1,25 dihydroxyvitamin D3 (7ng/gm body wt.) 
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L5 Chapter II: Effect of vitamin A alone and in combination of vitamin D 3 
Mice made diabetic were divided into three groups of 6 mice each. To one of these 
groups, vitamin A alone was administered and to the other group, vitamin A along 
with vitamin D 3 was given in order to observe the differential anti-diabetic effects (if 
any) of these vitamins alone and in combination with each other. Group III and IV 
were housed in closed room with no sunlight to make sure that the treatment given 
was the only source of vitamin D 
Group 
Group I 
Group II 
Group in 
Group IV 
Name 
Control 
Diabetic 
Diabetic+ Vitamin A 
Diabetic+ Vitamin A+ 
Vitamin D3 
Treatment 
No treatment 
Alloxan monohydrate (150gm/kg 
body wt.) 
Retinyl Palmitate (86[ig/gm body 
wt.) 
Retinyl Palmitate (86|xg/gm body 
wt.) +1,25 dihydroxyvitamin D3 
(7ng/gm body wt.) 
1.6 Chapter III: Effect of vitamin C alone and in combination of vitamin Ds 
Three groups of 6 diabetic mice each were taken and to two of them vitamin C alone 
and in combination with vitamin D3 was administered respectively. Group III 
(diabetic+vitamin C) and IV (diabetic+vitamin C+vitamin D) were housed in closed 
room with no sunlight to make sure that the treatment given was the only source of 
vitamin D This was done to observe and enquire the effects of these vitamins when 
acting alone and together, and if they enhance or inhibit the action of each other when 
given in combination. 
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Group 
Group I 
Group II 
Group III 
Group IV 
Name 
Control 
Diabetic 
Diabetic+ Vitamin C 
Diabetic+ Vitamin C+ Vitamin 
Da 
Treatment 
No treatment 
Alloxan monohydrate (150gm/kg 
body wt.) 
Ascorbic acid (14mg/kg body wt.) 
Ascorbic acid (14mg/kg body wt.) 
+1,25 dihydroxyvitamin D3 < 7ng/gm 
body wt.) 
1.7 Animal sacrifice and sample collection 
The animals under treatment were sacrificed on the next day to the final dose (15"^  
dose) in each study. The animals were sacrificed by cervical dislocation method 
according to standards of animal handling. After the sacrifice, their blood was 
collected by cardiac puncture in separate centrifuge tubes. Besides, their kidney, liver 
and pancreas were washed in chilled saline and their weights were noted. 
1.8 Sample preparation for biochemical estimations and assays 
First of all, blood of each mouse was allowed to stand undisturbed for one hour, in 
order to collect their serum which was stored in separate vials at -ICC. 
After weighing, the organs were placed into ice cold potassium phosphate buffer (0.1 
M, pH 7.36) separately as 10% (w/v) basis. They were minced with sterile scissors in 
petridish in followed by centrifiigation at 5000 rpm (3000xg) by glass Teflon 
homogenizer for 10 minutes. Their supematants were kept in separate glass vials at 
-20 °C till fiirther analysis. 1 ml of pellet fi-om each organ centrifiigation was also 
stored for GSH and MDA estimation. 
2 Biochemical assays and estimations 
2.1 Protein estimation 
The protein content in all the samples was estimated by the method of (Lowry et al. 
1951) in which BSA (30mg %) was taken as standard for calculation. Aliquot of the 
samples were taken in separate tubes and the final volume was made up to 1 mi. To 
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this, 5 ml of alkaline copper reagent (98ml of 2% sodium carbonate in 0.1 M sodium 
hydroxide+ 1ml of 1% copper sulphate + 1ml of 2% sodium potassium tartrate) was 
added. This solution was kept as such at room temperature for 10 minutes followed by 
addition of Folin's Ciocaheau reagent. The test tubes were vortexed followed by 
incubation for 30 minutes at room temperature. The resulting blue color intensity was 
read at 660 nm using spectrophotometer. The concentration of protein was reported in 
mg protein per gram of the tissue (for liver, kidney and brain samples) and in mg 
protein per ml serum (for serum). 
2.2 Fasting blood glucose estimation 
Glucose levels were estimated in collected serum samples by glucose oxidase-
peroxidase method of (Trinder P.1969) using Ranbaxy Diagnostic kit. Briefly lOul of 
the fasting blood samples were mixed with 1ml of working solution (containing 
6.7U/ml of glucose oxidase, 6.2U/ml of horseradish peroxidase, 0.2Mm of 4-
aminoantipyrene, 8M of phosphate buffer and 86mM of phenol).The blank and 
standard solutions were also prepared simultaneously by adding lOjil of distilled 
water and \0\x\ of standard glucose (lOOmg/dl) to 1ml of working solution. All the 
tubes were mixed well and incubated at room temperature for 30 minutes. Blank 
solution was used to set the spectrophotometer and absorbance was read at 505rmi. 
2.3 Serum calcium estimation 
Serum calcium levels were estimated by using alkaline murexide reagent {Peter D. 
Spare 1964) .To 1.5 ml of color reagent (containing 50ml of stock color reagent and 
1.5ml of 3.75N KOH) 2.5 ml of distilled water and 0.05 ml of serum sample was 
added. The stock color reagent was prepared by dissolving 40mg of ammonium 
purpurate in 5ml of distilled water and then diluting it with 500ml of propylene 
glycol. The blank and the standard solutions were also prepared simultaneously by 
adding 2.55ml and 2.5ml of distilled water respectively to 1.5ml of color reagent. To 
make up the volume 0.05ml of standard calcium (O.lmg/ml) was added to standard 
solution. The tubes were capped with parafilm and mixed thoroughly. The tubes were 
then allowed to stand for next 5 minutes and were finally read at 490|im. 
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3 Assay of glucose metabolic enzymes 
3.1 Hexokinase 
The hexokinase activity was measured by the method of (Crane and Sols 1953). The 
Uver tissues were collected and homogenized in sodium phosphate buffer using table 
top homogenizer (REMI, U.S.A).The reaction was carried out at 37°C by adding 1 ml 
reaction mixture containing Tris-HCl (50 |im), MgCb (lO^m), ATP (S^moles), 
glucose {2[im) is added to l-1.5mg of sample protein. The reaction was stopped after 
1 hour by adding 0.5ml each of 10% Ba (0H)2 and ZnS04 solutions. The samples 
were centrifiiged at 2000xg for 10 minutes and glucose was estimated in supernatant 
(free from phosphorylated derivatives).The glucose estimation was then done by the 
method of (Nelson N.A. 1994) with standard glucose solution ranging between 5-
45|igm. 
3.2 Fructose 1, 6 bisphosphatase (FBPase) activity 
The liver FBPase activity was measured by the method of (Freedland and Harper 
1959). The reaction was carried out by adding 1.5ml of reaction mixture containing 
Tris HCl (50^m), MgCl2(10^m), Cysteine HCl (12^m), Fructose 1,6 diphosphate 
(10|xm) to sample containing 0.6-0.8 mg protein. The reaction was stopped by adding 
1ml of 10% TCA after 60 minutes and the samples are centriftiged at 2000xg for 10 
minutes. The phosphate released was estimated by the method of (Tausky and Shorr 
1953) in the supernatant. 
3.3 Glucose 6 Phosphatase (G6Pase) activity 
It was assayed according to the method of (Shull et al 1956).The reaction mixture in a 
total volume of 1.5 ml contained Tris- HCl buffer (50|j,m); MgCb (10|jm); g)ucose-6-
Phosphate(lO^m) and 2-3 mg sample protein. The reaction was carried out at 37°C 
and stopped with 1ml of 10%TCA after 60 minutes. The samples were centriftiged at 
2000xg and phosphorous was estimated in the protein free supernatant by the method 
of (Tausky and Shorr 1953). 
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4 Assay of antioxidant enzymes 
4.1 Superoxide dismutase (MnZn SOD) 
The assay of SOD was conducted according to the method of (Marklund and 
Marklund 1974) on the basis of autoxidation of pyrogallol. In this procedure, 2.85 ml 
of tris-succinate buffer (0.05M, pH 8.2) was added to 50\i\ of sample, followed by 
addition of 100 |il of pyrogallol (8mM) under dark condition. The change in 
absorbance was read at 412nm on Centra-5 spectrophotometer for 3 minutes. 
References were also taken for every 10 samples. The specific activity was reported in 
units per mg of protein. One enzyme unit is defined as the amount of enzyme 
required to cause 50% inhibition to auto-oxidation of pyrogallol per 3 ml of assay 
mixture. 
4.2 Catalase (CAT) 
The activity of CAT was measured by the protocol of (H. Aebi 1984). Tol.95ml of 
potassium phosphate buffer (50mM, pH 7) was added, 50 |xl of the sample to which 1 
ml of hydrogen peroxide (30mM) was pipetted under dark condition. The solution 
was immediately read at 240run for 3 minutes on Centra-5 spectrophotometer. 
Catalase activity was calculated as nmoles of H2O2 consumed per mg of protein per 
minute. 
4.3 Glutathione-S-transferase (GST) 
The assay of this detoxifying enzyme was conducted by the protocol of (Habig et al. 
1974). For this, 0.1ml of the sample was mixed with 2.7ml of GSH (ImM) and 0.2ml 
of CDNB (ImM) in the sequence. After mixing well, it was read at 340 run in the 
time span of 3 minutes against the blank containing all the reagents except the enzyme 
source (the sample). Its specific activity was calculated taking millimolar extinction 
co-efficient value of 9.6 mM"' cm'' of CDNB and was expressed in nmoles of CDNB 
conjugates formed per mg of the protein per minute in the sample. 
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4.4 Glutathione reductase (GR) 
The assay of this enzyme was carried out by the method of (Carlberg and Mannervik 
1985) that is based on the NADPH dependent reduction of glutathione disulfide 
(GSSG) into glutathione (GSH). The reaction mixture in 2 ml contained 1.65ml of 
sodium phosphate buffer (O.IM, pH 7.4), 100^1 of EDTA (0.5mM), 50 i^l of (rSSG 
and 100 ^1 of the sample. The reaction was initiated by adding 100 [i\ of NADPH and 
absorbance was recorded at 340nm for 3 minutes on UV-visible spectrophotometer. 
The specific activity was reported in nmoles of NADPH oxidized per mg of protein 
per minute. 
5 Estimation of cellular reductants 
5.1 Glutathione reduced (GSH) 
For the estimation of total GSH level in the samples, (Jollow et al. 1974) method was 
implemented. According to this protocol, 0.5 ml of sample homogenate was mixed 
with equal volume of 4% (w/v) sulphosalicylic acid and it was incubated at 4 C for 1 
hour followed by centrifugation at 1200g for 15 minutes. The supernatant (0.2ml) was 
carefully taken out and was mixed with 1.1 ml of potassium phosphate (O.IM, pH 
7.4). The reaction was initiated by addition of 0.2ml of DTNB which was read at 
412nm within 30 seconds. The GSH level was reported in nmoles per gram of the 
tissue. 
5.2 Sulfhydryl groups (-SH) 
The estimation of-SH level was conducted by method of (Sedalk and Lindsay J 968). 
For this, 100 \i\ of the sample was added to 2.5 ml of Tris- HCl (O.IM, pH 8), 0.3ml 
of EDTA and 0.1 ml of DTNB. The reaction mixture was vortexed well followed by 
incubation at room temperature for 30 minutes which was later read at 412nm. Its 
level was expressed in nmoles per gram of tissues. 
6 Estimation of renal function markers (RFT) in serum 
6.1 Urea 
The level of urea in the serum samples was estimated by commercially available kit 
(Span Diagnostics Limited, India.) and was reported in mg per 100ml of the sample. 
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6.2 Creatinine 
The level of creatinine in the serum samples was estimated by commercially available 
kit (Span Diagnostics Limited, India.) and was reported in mg perl00ml of the 
sample. 
7 Estimation of liver function markers (LFT) in serum 
7.1 Glutamate pyruvate transaminase (GPT) or Alanine transaminase (ALT) 
GPT activity was assayed by commercial kit (Span Diagnostics Limited, India.) that 
was based on the protocol of (Reitman and Frankel 1957). The enzyme catalyses the 
following reaction 
a- ketoglutarate +L- alanine "^ ^^  ^ L-glutamate + Pyruvate 
The method involves the reaction with pyruvate formed with DNPH to produce brown 
colored hydrazones which is read at 505rmi taking distilled water as blank. The 
activity was reported in units per ml of the sample by the standard plot provided with 
kit. 
7.2 Glutamate Oxaloacetate transaminase (GOT) or Aspartate transaminase (AST) 
The assay of GOT was also carried out by commercially available kit (Span 
Diagnostics Limited, India) based on (Reitman and Frankel method 1957). The 
enzyme catalyses the reaction given in the below-
a- ketoglutarate +L- aspartate ^^^^ L-glutamate + Oxaloacetate 
The product Oxaloacetate reacts with DNPH to give brownish hydrazones that are 
read at 505nm. The activity was calculated with the help of the standard curve 
provided with kit and was expressed in units per ml. 
7.3 Alkaline phosphatase (ALP) 
The assay of ALP was carried out using commercially available kit (span Diagnostics 
Limited, India) based on Kind and King's method (1954).The principle of the kit is 
that alkaline phosphatase converts phenyl phosphate to inorganic phosphate and 
phenol at pH lO.O.Phenol so formed reacts in alkaline pH with 4-aminoantipyrine in 
presence of the oxidising agent potassium ferricyanide and forms an orange-red 
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coloured complex, which can be measured colorimetrically. The colour intensity is 
proportional to the enzyme activity. The reaction can be represented as: 
Phenyl phosphate Alkaline phosphatase (pH 10.0) ^ p|,^„„i + Phosphate 
P h e n o l + 4 - A m i n o a n t i p y r i n e Potassium ferricyanlde ^ O r a n g e - r e d c o m p l e x 
8 Estimation of melondialdehyde (MDA) level 
MDA estimation is one of the most reliable products to assess the extent af lipid 
peroxidation. Its level was determined by the procedure of (Beuge and Ausi 1978). 
The reaction mixture was made up to 0.5ml homogenate with equal volume of TBA 
(0.67%) and TCA (30%) in centrifuge tubes that were incubated at boiling water bath 
for 20 minutes. The tubes were later centrifuged at 4000rpm (5000xg) for 15 minutes. 
The absorbance of the pink supernatant was taken at 530nm. The level was expressed 
in nmoles of MDA formed per mg of the protein by using molar extinction co-
efficient of 1.56x lO'^ M"' cm"' for MDA-TBA coloured complex. 
9 Preparation of samples for histopathological study 
For histopathology, liver, kidney and brain of the treated animals were kept m 10% 
formalin in separate glass vials for immersion fixation after washing with chilled 
saline. 10x5x3 mm sized tissue blocks of the organs were processed for paraffin 
embedding. Their sections of 10 micrometer thickness were cut with rotary 
microtome and stained with Hematoxylin and Eosin stain. The sections were observed 
under trinocular light microscope (Olympus BX40, Japan) and their 
photomicrographs depicting important features were snapped at final magnification of 
400 X. 
10 Comet Assay (Single Cell Alkaline Gel Electrophoresis) 
10.1 Preparation cellular suspension for comet assay 
Freshly dissected organs (liver and kidney) were washed in PBS and kept in separate 
petri dishes. All the organs in petri dishes were submerged in chilled solution of 
HBSS and RPMI 1640 (1:1) and were minced with scissors or scalpel blade. Their 
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suspensions were filtered with muslin cloth and their filtrates were kept in separate 
vials as cell suspension of each organ. 
10.2 Viability assessment of the cells for comet assay 
The viability of the cells in the suspensions was checked by standard trypan blue 
exclusion method (Pool-Zobel et al., 1993). For this, 100|ul of the cell suspension was 
mixed with same volimie of 0.4% trypan blue solution. The percentage of stained 
cells to the total number of the cells was calculated. The method is based on the 
principle that the non-viable cells have degenerated membrane and hence, they take-
up the dye while viable cells do not show any staining. 
10.3 Comet assay procedure 
The assay was performed in alkaline condition in accordance with protocol of Singh 
et al. (1988) with few modifications. First of all, fully frosted slides pre-coated with 
1% NMA (normal melting agarose) as base layer at 60° C were prepared on a day 
before sacrifice. About 10,000 cells isolated fi-om organ cell suspensions were mixed 
with 80 1^1 1% of LMPA to form the working cell suspensions separately. Such 
suspension was pipetted over the base layer at 37°C followed by covering with cover 
slips immediately. After solidification of second layer on ice packs, the cover slips 
were removed and a third layer of 0.5% LMPA (80 |il) was pipetted over followed by 
placing of cover slips on it. This layer was also kept on ice packs for solidification. 
Then, the cover slips were removed and the slides were immersed in cold lysing 
solution (2.5 M NaCl + lOOmM EDTA + lOmM tris-base + 1% triton X-100 with pH 
10). The lysis was allowed to proceed for 3 hours followed by unwinding for 30 
minutes in alkaline electrophoretic running buffer (300mM NaOH + ImM EDTA at 
pH 13) in electrophoretic tank. Then electrophoresis was performed for 35 minutes at 
4°C with constant field strength of 0.74 volts/cm and variable current strength under 
the range of 295-310 mA. The slides were washed with cold saline and were 
subjected to neutralization by 0.4 M tris-buffer of pH 7.5 followed by washing with 
cold saline and this process was repeated twice. After that, they were stained with 75 
1^1 EtBr (20 (xg/ml) for 5 minutes. Finally, the slides were washed with chilled saline 
again and cover slips were placed on them and were kept in humidified slide box in 
refrigerator followed by analysis on the next day. The slides were scored with the help 
of CX41 fluorescent microscope (Olympus, Japan) coupled with an image analysis 
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system (Komet 5.5, Kinetic imaging, Liverpool, U.K.) attached with integrated CC 
camera COHU 4910 (equipped with 510-560nm excitation and 590nm barrier filters). 
The comets were scored at the magnification of lOOX and images fi"om 50 cells (25 
from each replicate slide) were scored. Comet tail-length (migration of DNA from its 
nucleus in ^m) was chosen as the parameter to assess the cellular DNA damage that 
was automatically generated by Komet 5.5 image analyzing system. 
11 Quantitative determination of glucose transporter 4 (GLUT-4) 
Quantitative determination of GLUT-4 was done in serum, plasma and tissue 
homogenates (adipocytes and skeletal muscles) using ELISA kit. The microtiter plate 
was pre-coated with an anti body specific to GLUT4. Samples were then added to the 
appropriate microtiter plate wells with a biotin-conjugated antibody preparation 
specific for GLUT4 and Avidin conjugated to horseradish peroxidise (HR}') was 
added to each microplate well and incubated. Then a TMB substrate solution was 
added to each well. Only those wells that contain GLUT4, a biotin-conjugated 
antibody and enzyme-conjugated Avidin exhibited a change in colour. The enzyme-
substrate reaction was terminated by the addition of sulphuric acid solution and the 
colour change was measured spectrophotometrically at a wavelength of 450mn ± 2 
nm. The concentration of GLUT4 in the samples is then determined by comparing the 
O.D. of the samples to the standard curve. 
In Vitro study 
Spectroscopic study 
1. Vitamin Ds, Vitamin Ay Vitamin C alone and their combinations (Vitamin C+D, 
vitamin A+D) in aqueous medium 
In order to find out the possible interaction between the vitamins given and if the 
interaction resulted in the formation of a new group or a new absorption peak, 
spectroscopic methods like UV-vis, and fourier transform infi-a red spectroscopy was 
done. These methods offer usefiil tools to understand the interaction between two 
different or similar compoimds. 
Fourier transform infrared spectroscopy is a technique whereby spectra are collected 
based on measurement of the coherence of a radiative source, using time domain or 
space domain measurements of the electromagnetic radiation or other type of 
43 
radiation to study the interaction of different molecules naturally or upon exposure to 
different physical or chemical treatment. Therefore, in order to determine the 
possibility of interaction between different vitamins under study, FTIR of vitamins 
alone and in combination i.e. vitamin (C+D) and vitamin (A+D) conducted. One set 
each of the vitamins alone and in combination was prepared. In every set a 
concentration of 50|iM of each vitamin was taken. The samples were loaded between 
two potassium bromide discs by hydraulic pressing and thus their infrared spectra 
were recorded by Shimadzu-8300 FTIR spectrophotometer (Tokyo, Japan). 
12 Statistical Analysis 
All the data was statistically analyzed in accordance of (Tice et al. 2000) procedure. 
To check the reproducibility, in vitro experiments were repeated thrice while in vivo 
experiments were repeated twice. Minor fluctuations but similar patterns of results 
were observed in both cases. All the data of in vivo studies have been expressed as 
mean ± SEM. A student's t-test was conducted to examine their statistical 
significance. Their analysis of variance was performed by ANOVA. P value < 0.05 
was selected as statistically significant throughout the course of study. 
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Effect ofh 25 Dihydroxy 
Vitamin D3 On Type 2 
Diabetes Mellitus 
1 Glucose Homeostasis 
1.1 Fasting blood glucose levels 
Hyperglycemia or increased circulating levels of fasting blood glucose, is one of the 
cardinal abnormalities of individuals suffering from type 2 diabetes mellitus (7 2DM), 
however hyperglycemia itself can cause insulin resistance. Since elevated glucose 
levels precedes the onset of this syndrome, FBG levels, is generally used as a 
diagnostic feature for classifying people who have impaired glucose toleranct (IGT) 
or diabetes. 
Normoglycemia 
Impaired fasting glucose (IFG) 
Impaired glucose tolerance (IGT) 
Diabetes 
<100mg/dl 
100-125 mg/dl 
140-199 mg/dl 
>126 mg/dl 
Table 2. Criteria for the diagnosis of diabetes 
In this study, the effect of 1, 25 dihydroxyvitamin D3 was observed on the increased 
fasting blood glucose levels of mice made diabetic by alloxan administration. I igure 2 
shows the FBG to be increased in the group with diabetes (250±0.41 mg/dl) narking 
the proper establishment of diabetic state as compared to the control group 
160.97±0.21 mg/dl. The group with diabetes, given 1, 25 dihydroxy vitamin D3 
supplementation shows a significant decrease in the FBG levels 190±0.37mg/dl. thus 
suggesting its role in pathogenesis of hyperglycemia. 
1.2 Serum calcium concentration 
Phyiological levels of calcium is essential for proper insulin secretion and sensitivity 
(Bjorklund, A. Lansner, and V. E. Grill 2000), sustained elevations of intracellular 
calcium may inhibit insulin secretion and the ability of insulin-target eel s from 
sensing the brisk intracellular calcium fluxes necessary for insulin action, such as 
glucose transport (D. S. Worrall and J. M. Olefsky 2002) resulting in peripheral 
insulin resistance and thus increased plasma blood glucose levels. Therefore, 
maintaining the required intracellular calcium levels is of prime importance for proper 
insulin secretion and sensitivity. 
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Fig 2.1 depicts the difference in the serum calcium levels in control, diabetic and 
diabetic+ vitamin D treated groups of mice. The increase in the serum calcium level 
in the vitamin D treated group 9.5±0.40 mg/ml, in comparison to the decreased levels 
in diabetic group 7±0.43 mg/ml, is symptomatic of function of 1,25 dihydroxy 
vitamin D3 in maintaining calcixim homeostasis. 
1.3 Activity of glucokinase or hexokinase IV 
Glucokinase is expressed at highest level in pancreatic P cells and liver. This enzyme 
catalyzes the transfer of phosphate group from adenosine tri-phosphate (ATP) to 
glucose, generating glucose-6-phosphate.This step is the first rate-limiting step of 
glycolysis and thus this enzyme is of prime importance. In liver, this enzyme plays a 
key role in storing glucose in the form of glycogen and thus controlling the level of 
glucose in circulation. Therefore, the increase in blood glucose concentration in 
individuals suffering from T2DM is due to reduced glucose induced insulin secretion 
from pancreas and reduced glycogen storage into liver. 
In this study, it v^as found that in liver, the activity levels of glucokinase (fig 2.2) 
decreased in the group with diabetes 0.241 ±0.014 |ig/mg/ml as compared to control 
group 0.75±0.02 )Lig/mg/ml which was almost restored 0.717±0.003ng/mg/ml on 1,25 
dihydroxy vitamin D3 supplementation. 
1.4 Activity of glucose 6 phosphatase (G6Pase) and fructose 1,6 bisphosphatase 
(FBPase) 
G6Pase is an enzyme specifically found in liver and kidney that catalyzes the 
conversion of glucose-6-phosphate to glucose depending upon the concentration of 
glucose in circulation especially in between meals and extended fasts. Therefore, 
activity levels of G6Pase can be indirectly related to the presence of sufficient glucose 
in circulation. The activity of this enzyme can also provide an idea about the rate of 
gluconeogenesis. 
Glucose 6-phosphate + H2O • glucose + Pi ^G°=-13.8kJ/mol 
In this study, the activity level of enzyme (fig 2.3) in control group was found to be 
0.533±0.02ug/mg/ml however, in diabetic group the level was increased to 
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0.918±0.008ug/mg/ml, showing a rapid enhancement of gluconeogenesis. On vitamin 
D supplementation G6Pase activity was found to be significantly decreased to 
0.71±0.01ug/mg/ml. 
FBPase-1 is an Mg^^ dependent enzyme involved in gluconeogenesis which promotes 
the essentially irreversible hydrolysis of the C-1 phosphate {not phosphoryl group 
transfer to ADP) thus converting fructose 1, 6 phosphate to fructose-6-phosphat{;: 
Fructose 1,6-bisphosphate + H2O • fructose 6-phosphate + Pi A G^ =^ - ' 6.3 
kJ/mol 
By determining the activity of this enzyme (fig 2.4) we can also indirectly understand 
the rate of gluconeogenesis and thus know the effectiveness of the treatment gi\en. In 
our study, the FBPase levels in the control group and diabetic group are found to be 
0.10707±0.002ug/mg/ml and 0.433±0.004ug/mg/ml respectively, whereas on 1. 25 
dihydroxy vitamin D3 supplementation the activity levels were decreased to 0.;!733± 
0.008ug/mg/ml as compared to the diabetic group without supplementation. 
2 Effect on oxidative stress 
Oxidative stress is a major player in all the chronic illnesses including type 2 diabetes 
mellitus. Once generated, the free radicals cause pancreatic p cell damage, adding to 
increased insulin resistance. In addition ROS causes mitochondrial dysfunction lipid 
peroxidation, glucose oxidation and DNA damage thereby manifesting changes in the 
histology of diabetic tissues. Oxidative stress thus indirectly cause glucose ele^'ation 
in circulation, causing hyperglycemia, the main cause of T2DM.There are st^ veral 
parameters analyzed (activity of catalase, superoxide dismutase etc.) in order to 
demonstrate the effect of 1,25 dihydroxyvitamin D3 on oxidative stress but no 
significant changes were observed after the treatment. However, a reduction in MDA 
(malondialdehyde) levels, post treatment was observed. This could be due to the fact 
that 1,25 dihydroxyvitamin D3 reduces oxidative stress indirectly by normalizing 
hyperglycemia, which can cause oxidative stress if kept unchecked. 
Due to hyperglycemia, more glucose enters the TCA cycle generating an increased 
concentration of reducing equivalents (NADH and FADH2).This increase pushes 
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these electron donors more and more into the ETC, increasing the transfer of protons 
outside thereby leading to enhanced voltage gradient across the mitochondrial 
membrane. This rise in voltage gradient when reaches the critical threshold, blocks 
the further transfer of electrons to complex III. The electrons thereby return to 
coenzyme Q, which transfers one electron at a time to water, thereby generating 
superoxide radicals (Peter Proctor, 1989). These radicals once formed increase the 
production of lipid peroxides by reacting with membrane lipids. Therefore by 
reducing hyperglycemia, 1,25 dihydroxyvitamin D3 reduces the extent of lipid 
peroxidation and hence lower MDA levels. 
2. / MDA (malondialdehyde) level estimation 
In case of lipid peroxidation, MDA levels were found to be much higher in diabetic 
mice 0.76±.003 nmol/mg protein as compared to control group 0.55 rmiol/mg protein, 
although 1, 25 dihydroxyvitamin D3 supplementation decreased the MDA levels 
0.644±0.0189 nmol/mg protein significantly (fig 2.5). 
3 Estimation of liver function markers (LFT) in serum 
In case of type 2 diabetes, there occurs a cardinal abnormality of insulin resistance in 
peripheral tissues including muscles and adipocytes. This defect in insulin sensitivity 
leads to increased lipolysis and thus higher levels of circulating non-esterified free 
fatty acids (NEFA's). Once in circulation these products compete with glucose for 
oxidation in liver causing a sequential inhibition of pyruvate dehydrogenase, 
phosphofhicktokinase and hexokinase II activity besides causing accumulation of 
diacylglycerol, ceramides and lipids. 
These metabolites once accumulated activate phosphorylation of insulin receptor 
substrate 1 and 2 (IRS-1 and IRS-2) via ser/threo kinase cascade, finally bringing 
down the downstream events of insulin signalling pathway and contributing further to 
insulin resistance. 
Another mechanism by which type 2 diabetes leads to liver damage is mediated by 
increased oxidative stress. There occurs an increase in mitochondrial oxidative stress 
due to excess intracellular fatty acid deposition thereby leading to increased free 
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radical production which ultimately induces inflammation, cellular necrosis and also 
fibrosis, all contributing to non alcoholic steohepatitis (NASH). 
3.1 Glutamatepyruvate transaminase (GPT) or alanine transaminase (ALT) 
The increased level of this enzyme in serum is a marker of liver disease. The 
estimation of the levels of GPT can be related to the extent of diabetes induced liver 
damage and also to the effectiveness of the treatment given. In control group (fig 2.6) 
the level of the en2yme was 67± 0.34 U/L however, in case of diabetes the levels were 
increased significantly to 171.40± 0.42 U/L. In 1, 25 dihydroxyvitamin D3 
supplemented group there was a marked reduction 80±0.254 U/L in the enzyme level, 
thus supporting the role of 1, 25 dihydroxyvitamin D3 in decreasing diabetic 
complications. 
3.2 Glutamate oxaloacetate transaminase (GOT) or aspartate transaminase (/-ST) 
GOT (AST) catalyses the transfer of amino group fi-om aspartic acid to 2-oxoglutarate 
to form and L-glutamate. The oxaloacetate thus forms reacts with 2, 4 
dinitrophenylhydrazine to be converted to the corresponding hydrazone which is 
coloured and thus can be estimated. Serum aspartate transaminase is another disease 
marker enzyme of liver and its levels were found to be increased in case of diabetic 
group 167.39± 0.45 U/L, as compared to control group 86.521±0.39 U/L however, in 
1, 25 dihydroxyvitamin D3 supplemented group the level was estimated to be 
95.64±0.28 U/L, which were much lower than the diabetic group (fig 2.6). 
3.3 Alkaline phosphatase (ALP) 
Alkaline phosphatase is a hydrolase enzyme responsible for removing phos])hate 
groups from many molecules including nucleotides, proteins and alkaloids. High 
serum levels of ALP are found in diseased conditions. ALP levels were found 10 be 
12.124±0.25 U/L Units in diabetics, 10.694 ±0.37 U/L in control group and 
11.12±0.28 U/L in 1,25 dihydroxyvitamin D3 supplemented group (fig 2.6). 
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4 Estimation of renal function markers (RFT) in serum 
4.1 Creatinine 
The serum creatinine levels in control group was found to be 0.0361± 0.024 
mg/lOOml which was increased in case of diabetic group to 0.043±0.026 mg/lOOml, 
however on vitamin D supplementation the creatinine levels were reduced to 
0.038±0.033 mg/lOOmI and became closer to the control group (fig 2.7). 
4.2 Blood \urea and B UN (Blood urea nitrogen) 
The levels of blood urea and BUN (fig 2.8) in control group were estimated to be 
18.71± 0.41 mg/dl and 35.759±0.29 mg/dl whereas in case of diabetic group it was 
22.8±0.17 mg/dl and 48.652±0.36 mg/dl both these parameters depicted a significant 
increase, however on supplementation with vitamin D the levels were almost 
normalised to 20.8±0.32 mg/dl and 31.654±0.44 mg/dl. Increase in urea is indicative 
of negative nitrogen balance which is an index of chronic illness and muscle wasting. 
5 Effect on DNA damage 
The DNA damage in the tissues of control and treated groups was estimated (fig 2.8, 
2.9) using alkaline comet assay. Diabetes caused major DNA damage in liver and 
pancreas as evidenced by elongated tail length in diabetic group 30.41 ± 2.50)am and 
32.45± 2.87 |xm respectively when compared to liver and pancreatic cells of control 
group 7.65 ± 2.20 |xm and 6.66 ± 1.20 i^ m. However, vitamin D supplemented group 
showed a significant decrease in liver and pancreatic cells DNA tail length with 
values of 21.80 ± 2.40 ^m and 19.25 ± 1.90 ^m respectively, indicating a role of 
VitDs in controlling the damage caused by persistent hyperglycemia (table 2.1). 
6 Histopathological analysis 
The histopathological examination of different organs (fig 2.10, 2.11, 2.12) revealed 
the accumulation of lipid droplets, increased fibrous content, destruction of bile duct 
and hepatocytic degeneration in liver samples in diabetic group, while in case of 
kidneys, there was a significant thickening of the glomerular basement membrane, 
oedema of proximal convulated tubule, hyaline deposition, degeneration of distal 
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convulated tubule and tubule-interstitial inflammation. We also observed an increase 
in islet cell population and presence of insulitis in the pancreas of the diabetic group 
whereas in Vit.Da supplemented group, there was a significant decrease in all these 
pathological conditions in liver, kidney and pancreatic tissues (table 2.1). 
7 GLUT-4 expression study 
The GLUT-4 expression levels were assayed by sandwich elisa in adipocytes and 
skeletal muscles. It has demonstrated the levels to be 5.65±0.02 ng/ml in adipocytes; 
5.122±0.033 ng/ml in skeletal muscles in diabetic group as compared to adip(>c>tes 
7.643±0.036 ng/ml; skeletal muscles 9.02±0.039 ng/ml in control group. Hov/e\er, 
the GLUT-4 levels were significantly improved in Vit.Da supplemented group; 
adipocytes 6.9±0.021 ng/ml; skeletal muscles 9.0±0.034 ng/ml. Thus suggesting a 
role of Vit.D3 in normalizing the GLUT4 expression on the cells, (fig 2.13). 
Fasting blood glucose levels in control, diabetic and vitamin D treatment groups 
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Fig.2 The increase in fasting blood glucose level in diabetic group which decreases on 
1, 25 dihydroxy vitamin D3 supplementation 
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Serum calcium levels in control, diabetic and vitamin D treatment groups 
Fig 2.1 The increase in the serum calcium concentration in the diabetic mice with no 
supplementation; however it became close to the control value in the diabetic group 
given 1,25 dihydroxy vitamin D3. 
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Hexokinase activity levels in control, diabetic and vitamin D treatment groups 
"^> 0.6 
6- 0.3 
• Hexokinase 
Control Diabetic Diabetic+Vit.D 
Fig 2.2 The decrease in hexokinase level in diabetic group which increases on 1, 25 
dihydroxy vitamin D3 supplementation. 
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G6Pase and FBPase activity levels in control, diabetic and vitamin D treatment 
groups 
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Fig 2.3 The changes in G6Pase and FBPase levels in control, diabetic and 1, 25 
dihydroxy vitamin D3 supplemented group. 
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MDA levels in control, diabetic and vitamin D treatment groups 
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Fig 2.4 The extent of lipid peroxidation (MDA levels) in control, diabetic and 1,2;5 
dihydroxyvitamin D3 supplemented group. 
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SGOT, SGOTandALP levels in control, diabetic and vitamin D treatment groups 
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Fig 2.5 The extent enzyme activities of SGOT,SGPT and alkaline phosphatase in 
control, diabetic and 1,25 dihydroxyvitamin D3 supplemented group. 
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Serum creatinine levels in control, diabetic and vitamin D treatment groups 
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Fig 2.6 The increase in serum creatinine level in diabetic group which decreases on 1, 
25 dihydroxy vitamin D3 supplementation. 
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Blood urea and BUN levels in control, diabetic and vitamin D treatment groups 
0£ 
E 
60 
50 
40 
I 30 
c 
fij 
^ 20 o u 
10 
Control 
•J 
V I 
• Blood Urea 
ilBUN 
Diabetic Diabetic+Vit.D 
Fig 2.7 The increase in blood urea and blood urea nitrogen levels in diabetic group 
which decreases on 1, 25 dihydroxy vitamin D3 supplementation. 
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COMET assay 
a. (Control) b. (Diabetic) c. (Diabetic + vitamin D) 
Fig 2.8 Liver hepatocytes showing DNA damage in diabetic state and recovery after 
treatment of 1, 25 dihydoxy Vitamin D3. 
a. (Control) b. (Diabetic) c. (Diabetic + vitamin D) 
Fig 2.9 Pancreatic cells showing DNA damage in diabetic state and recovery after 
treatment with 1, 25 dihydroxy vitamin D3. 
~ ^../^ 
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Tail lengths 
Same of the 
group 
Control 
Diabetic 
Diabetic + 
vitamin D 
Treatment 
Saline 
Alloxan 
l,25(OH)2 vitamin D3 
A verage tail length 
of liver cells (in 
urn) 
7.65 ± 2.20 
30.41 ±2.50 
21.80 ±2.40 
Average tail length 
in pancreatic cells 
(in pm) 
6.66 ±1.20 
32.45± 2.87 
19.25 ±1.90 
1 
Table 2.1: DNA tail length of liver and pancreatic tissue observed by alkaline comet 
assay 
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Histopathological changes in liver, kidney and pancreas of different treatment groups 
Tissue Changes 
(Liver) 
Accumulation of lipid 
droplets 
Increased fibrous 
content 
Destruction of bile duct 
Hepatocytic 
degeneration 
a. Centrilobular 
Tissue Changes 
(Kidney) 
Thickening of 
glomerular basement 
membrane 
Edema in Proximal 
, onvoluted tubule 
L 
Tubulointerstitial 
inflammation 
Tissue Changes 
(Pancreas) 
Islet cell population 
InsulUis 
Control Group 
— 
— 
-
-
— 
-
normal 
— 
Diabetic Group 
+++ 
++ 
+++ 
+++ 
-H-+ 
-f-H-
+++ 
-I-H-+ 
++++ 
Dibetic+ 
vitamin D 
Group 
+ 1 
+ 
+ 
+ 
1 
+++ 
-H-
-H-
i 
-f-H-
+++ 
Table 2.2: The histopathological changes in the liver, kidney and pancreas of diabetic 
and 1,25 dihydroxy vitamin Ds treated mice 
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Histopathological changes in hepatocytes of different treatment groups 
kvXuM l«**i¥i>' l 
a. Control b. Diabetic c. Diabetic + Vit. D 
Fig 2.10 Shows the histopathological changes in the hepatocytes of control, diabetic 
and vitamin D3 supplemented groups. 
Histopathological changes in kidney tissues of different treatment groups 
a. Control b. Diabetic c. Diabetic+Vit.D 
Fig 2.11 Shows the histopathological changes in the kidney tissues of control, diabetic 
and vitamin D3 supplemented group. 
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Histopathological changes in pancreatic tissues of different treatment groups 
a. Control b.Diabetic c.Diabetic+Vit.D 
Fig 2.12 Shows the histopathological changes in the pancreatic tissues of control, 
diabetic and vitamin D supplemented group. 
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GLUT-4 expression levels in different treatment groups 
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Fig 2.13 shows GLUT-4 transporter expression determined by sandwich ELISA in 
different treatment groups (control, diabetic and vitamin D supplemented ones) 
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Effect ofl, 25 dihydroxy vitamin Ds 
in combination with ascorbic acid 
on type 2 diabetes mellitus. 
/ Glucose Homeostasis 
1.1 Fasting blood glucose 
Fig.l shows the fasting blood glucose levels and serum calcium levels in all four 
groups (Control, Diabetic, Diabetes +Vitamin C, Diabetes +Vitamin C+ vitamin 
D).The FBG is seen to be increased in the group with diabetes 250±0.41 mg/dl as 
compared to the control group 160.97±0.21mg/dl, marking the proper establishment 
of diabetic state. The group with diabetes, when given vitamin C supplementation 
shows a decrease in the FBG levels 210±0.37mg/dl, and when only vitamin D was 
administrated the level reached was 190±0.37mg/dl however, the group given the 
combination of vitamin C+D was found to reduce the FBG to levels similar to group 
given vitamin D alone thus demonstrating that the reduction is majorly due to the 
presence of vitamin D in the combination 190±.40mg/dl and vitamin C seems to have 
little effect on hyperglycemia. 
Fig.3 also depicts the serum calcium level of all four groups. In control group the 
level was found to be (12.64±0.001 mg/ml). However, a marked decrease is seen in 
the combination group (vit. C+D) (9.5±0.40 mg/ml) in comparison to the decreased 
levels in diabetic group (7±0.43mg/ml) which is symptomatic of function of vitamin 
D present in the combination (vit. C+D). However, vitamin C supplemented group did 
not show any change in the serum calcium levels. 
1.2 Activities of glucokinase or hexokinase IV, glucose-6-phosphatase and fructose 
1,6 bisphosphatase 
The hexokinase activity (fig 3.1) was 0.744+0.002 ng/mg/ml and 0.523+0.004 
|ig/mg/ml in control liver and kidney which was reduced to 0.241+0.014 |ig/mg/ml 
andO. 175+0.032 ng/mg/ml in the diabetes group. Vitamin C supplementation resulted 
in a very small recovery of 0.2842+0.003 fig/mg/ml and 0.274+0.024 |ag/mg/ml while 
on combination treatment with vitamin C+ vitamin D, the activity recovered 
significantly 0.701+0.003ug/mg/ml and 0.465+0.004 ^g/mg/ml which was 
comparable to vitamin D alone 0.717+0.003ug/mg/ml and 0.47+0.002 |ig/mg/ml 
(Fig.2). Further the activities of G6Pase and FBPase (fig 3.2, 3.3) were analyzed in 
the liver and kidney of the control group and were found to be 1.153+0.02 ^ig/mg/ml; 
0.69+0.032 ^g/mg/ml and 0.1071 + 0.002 |ag/mg/ml; 0.596+0.012 |ag/mg/ml 
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respectively. However, there was a significant increase in their activities in the group 
with diabetes, the FBPase activity was estimated to be 0.2693±0.004|ig 
/mg/ml;0.938±0.023 |ag/mg/ml and G6Pase activity was found to be 2.918±0.008)ag/ 
mg/ml;1.05±0.0035 ng/mg/ml, showing a rapid enhancement of glycogen breakdown, 
indirectly demonstrating an impairment in the amount of glucose reaching the cell. 
Their activity levels recovered to 0.13733±0.008|ug/mg/ml;0.365±0.019 |jg/mg/ml in 
case of FBPase and 1.0546±0.01ng/mg/ml;0.77±0.035 ^g/mg/ml in G6Pase 
respectively on vitamin C + vitamin D supplementation. In case of vitamin C 
supplementation, the recovery of both the enzymes was not significant. However, in 
the group treated with vitamin D alone there was a significant change with activity 
levels of FBPase 0.2733±0.008 ^g/mg/ml;0.0126±0.003 ng/mg/ml and G6Pase 
0.71 ±0.01 ^g/mg/ml;0.75±0.04 |xg/mg/ml. 
2 Oxidative stress 
2.1 Activities of superoxide dismutase, catalase, glutathione-S-transferase 
Fig.3.4, 3.5, 3.6 represents the antioxidant enzyme parameters with the activities of 
SOD, catalase (CAT) and GST in liver and kidney. In control group the activities of 
SOD, catalase and GST were 96.58±0.043 ^lg/mg/ml;75.8±0.021 ng/mg/ml, 3.9±0.4 
Hg/mg/ml in liver and 1.7±0.0019 ^g/mg/ml;80.37±0.46, 37.66±0.001 ^xg/mg/ml in 
kidney respectively. However, in case of diabetes all the enzyme activities exhibited a 
decline. Vitamin C supplementation group exhibited a marked increase SOD 
85.65±0.4 ^g/mg/ml; 68.5±0.003ug/mg/ml, CAT 3.8±0.25 ng/mg/ml;0.88±0.0023 
^g/mg/ml, GST 54.53±0.35 |jg/mg/ml;31.29±0.007 |ig/mg/ml, in liver and kidney 
respectively. In case of combination treatment group the increase in enzyme activities 
was comparable to vitamin C supplemented group SOD 65.54±0.2 ng/mg/ml 
;59.37±0.028 ^g/mg/ml, CAT 3.059± 0.33 ^g/mg/ml;0.81±0.0022 ^g/mg/ml and 
GST 43±0.27 ^g/mg/ml;28.75±0.0019 ^ig/mg/ml suggesting that vitamin D has 
almost no role in directly controlling oxidative stress. 
2.2 Levels of glutathione, sulphydryl group and malondialdehyde 
In case of type 2 diabetic mice the levels of both these cellular reductants were found 
to be greatly reduced in liver (fig 3.7) GSH 0.1121 ± 0.03 nmol/gm tissue and SH 
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0.1015±0.015 nmol/gm tissue as compared to normal mice GSH 0.1845 ±0.0105 
mnol/gm tissue and SH 0.2451±0.0345 nmol/gm tissue. These levels were though 
raised with vitamin C supplemented group GSH 0.1645±0.03 nmol/gm tissue; SH 
0.2348±0.0144 nmol/gm tissue but the increase was more pronounced with 
combination of vitamin C and vitamin D suggesting the effectiveness of the treatment. 
In case of lipid peroxidation, MDA levels were much higher in diabetic group 
0.8940±0.0153nmol/mg protein, as compared to control group 0.3940±0 0180 
nmol/mg protein. Vitamin C supplementation helped in decreasing the MDA levels 
0.44±0.0189 nmol/mg protein, yet the results were found to be better with 
combination theatment 0.394±0.0208 nmol/mg protein. 
3 Estimation of Uver function markers (LFT) in serum 
3.1 Glutamate pyruvate transaminase (GPT) or alanine transaminase (ALT) 
The glutamate pyruvate transaminase (GPT) or alanine transaminase (ALT) and glutamate 
oxaloacetate transaminase (GOT)/ aspartate transaminase (AST) levels were increased in 
diabetes 171.40± 0.42 U/L and 167.39±0.45U/L while alkaline phosphatase (ALP)was not 
affected throughout. The recovery of GPT and GOT was better with vitamin C 
supplementation with 109.5 ± 0.28 U/L,GPT and 120.96±0.48 ng/mg/ml, GOT 
respectively as compared to vitamin D alone with 80±.254 U/L,GPT and 95.64±0.28 
U/L, GOT. However, in case of combination supplemented group with both ascorbic acid 
and 1, 25 dihydroxyvitamin D3 the levels of enzymes reached to GPT; 123.25±0.33 U/L and 
GOT; 154±0.25 U/L. 
4 Estimation of renal function markers (RFT) in serum 
4.1 Creatinine 
The serum creatinine levels in control group was found to be (0.0361± 0.034 
mg/lOOml) which was increased in case of diabetic group to (0.04317±0.022 
mg/lOOml), however on vitamin D supplementation the creatinine levels were 
reduced to (0.038±0.033 mg/lOOmI) compared to groups given vitamm C 
(0.3917±0.046 mg/lOOmI) and Vit.D+Vit.C (0.03916±0.021 mg/100ml).The 
combination thus is most effective in bringing down serum creatinine levels closer to 
the control group (fig 3.9). 
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4.2 Blood urea and BUN (Blood urea nitrogen) 
The levels of blood urea and BUN (fig 3.10) in control group were estimated to be 
16.71± 0.41 mg/dl, 35.759±0.29 mg/dl whereas in case of diabetic group it was 
21.8±0.17 mg/dl, 46.652±0.36 mg/dl both these parameters depicted a significant 
increase, however on supplementation with vitamin D the levels were almost 
normalised to (21.8±0.32 mg/dl and 46.654±0.44 mg/dl) as compared to group given 
vitamin C (17.4485±0.38 mg/dl, 37.339±0.25 mg/dl) and Vit.C+Vit.D (16.9755±0.44 
mg/dl,36.82957±0.37 mg/dl) supplementation. Increase in xirea is indicative of 
negative nitrogen balance which is an index of chronic illness and muscle wasting. 
5 DNA damage 
Diabetes affected the major organs (liver, kidney and pancreas) adversely. The tissue 
damage was monitored using the COMET assay of the major tissues. In this assay the 
migration of DNA fi"om nucleus is expressed in terms of tail length or formation of 
comet which is a direct measure of DNA damage. The DNA tail length of diabetic 
liver and pancreatic cells was 30.41 ± 2.50|am and 32.45± 2.87 |im respectively while 
in control group the tail length was 7.65 ± 2.20 \\xa and 6.66 ± 1.20 |j,m. Vitamin C 
supplemented group showed a partial recovery exhibited by decrease in liver and 
pancreatic DNA tail length with values of 21.80 ± 2.40 jim and 19.25 ± 1.90 i^m 
respectively while in case of vitamin C+ vitamin D supplemented group the change in 
the DNA damage was more evident as seen by the shortening of DNA tail length in 
liver to 18±2.1 |im and pancreas 16±2.34 |im whereas in vitamin D alone treated 
group, it was 21.80 ± 2.40 t^m and 19.25 ± 1.90 i^m (Table 3).Therefore, the effect of 
vitamin C and vitamin D appears synergistic. 
6 Histopathological analysis 
The histopathological analysis revealed increased accumulation of lipid droplets, 
characteristic of non-alcoholic fatty liver disease in hepocytes of diabetic group along 
with increased destruction of bile duct, a marker of cirrhosis, a significant increase in 
fibrous content (fibrosis) and centrilobular hepatocytic degeneration (suggestive of 
parenchymal tissue cell death) while in case of kidneys, there was a significant 
thickening of the glomerular basement membrane, oedema of proximal convulated 
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tubule, hyaline deposition, degeneration of distal convulated tubule and tubule-
interstitial inflammation. We also observed an increase in islet cell population and 
presence of insulitis in the pancreas of the diabetic group. 
The groups supplemented with vitamin C alone, vitamin D alone and vitamin C+ 
vitamin D all the markers of NASH, kidney degeneration and pancreatic tissue 
damage were found to be decreased, showing similarity with the control group (Table 
3.1). 
7 Spectroscopic study 
Since fluorescence technique is considered more sensitive in order to identify inter 
and intra molecular interaction, we observed the emission spectra of the vitamins 
alone and their combination. We observed in fig 3.17a, b that the emission peaks of 
both vitamin C and vitamin D lies in the range of 350-400nm, and the combination 
shows maximum emission in this range. Thus indicating no strong interaction 
between vitamin C and vitamin D. 
The FT-IR studies of vitamin C and vitamin D were recorded in ATR mode at room 
temperature at different time intervals in order to understand the interaction, if any. 
The charecteristics IR bands of free vitamin C at at 1158, 1396, 1690 and 1761 
cm"' were assigned to the stretching and bending vibrations of C=0 and C-0 
hydroxyl groups, respectively. The strong band at 1238 cm~* was originated due to 
C-O-C stretching. The peaks present in the region 821-1015 cm"' were linked with 
the five membered lactone ring deformation. However, various vibrational observ ed 
in the range 3000-3380 cm"' in the IR spectrum was attributed due to stretches of OH 
groups. On immediate addition of vitamin C with D, there was no major spectral 
shifting observed for OH band observed at 3352 cm"'. After 1 h, the positions of OH 
band shifted towards lower frequencies to 3459 cm"' (K.Nakamoto, 1997). This shift 
in the spectra indicates that there was some chemical interaction between vitamin C 
andD. 
8 GLUT-4 expression study 
The Glut-4 expression levels were assayed by sandwhich elisa in adipocytes and 
skeletal muscles, ft was demonstrated the levels to be 5.65±0.02 ng/ml in adipocytes; 
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5.122±0.033 ng/ml in skeletal muscles in diabetic group as compared to adipocytes 
7.643±0.036 ng/ml; skeletal muscles 9.02±0.039 ng/ml in control group. However, 
the levels were found to be slightly improved in vitamin C supplemented group 
adipocytes ; 6.5±0.04ng/ml, skeletal muscles ; 5.257±0.28 ng/ml but the change in 
level was more significant in the group treated with both vitamin C + vitamin D i.e. 
adipocytes ; 7.07±0.044ng/ml, skeletal muscles ; 8.72±0.036ng/ml as well as with 
vitamin D alone, thus depicting the efficiency of the combination in normalizing the 
GLUT4 levels on the cells (fig 3.11). 
Fasting blood glucose level and serum calcium levels in control, diabetic, vitamin C 
and vitamin C+vitamin D treated mice. 
• Fasting Blood 
Glucose 
Serum Calcium 
Control Diabetic Diabetic+Vit.D DIabetic+vit. Diabetic+vit. 
C C+vit. D 
Fig. 3 Shows the changes in fasting blood glucose and calcium levels in different 
treatment groups.Treatment detail given in methods. 
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Hexokinase activity levels in control, diabetic, vitamin C and vitamin C+vitamin D 
treated mice. 
0.9 
0.8 
0.7 
0.6 
c 
• 5 
^ 0.5 
a. 
0.3 
0.2 
0.1 
0.>44 
• liver 
m kidney 
Control Diabetic Diabetic+Vit.O Diabetic+VitC Diabetic+Vit.C+VitD 
Fig 3.1 Shows the the activity levels of Hexokinase in in different treatment groups. 
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FBPase activity levels in control, diabetic, vitamin C and vitamin C+vitamin D 
treated mice. 
1.2 
0^76 0.665 
O.Q-16 • liver 
m kidney 
0 .22»H 
^ i 1 
Control Diabetic Diabetic+Vit.DDiabetic+vit.C Diabetic+vit. 
C+vit.D 
Fig 3.2 The the activity levels of FBPase in in different treatment groups. 
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G6Pase activity levels in control, diabetic, vitamin C and vitamin C+vitamin D treated 
mice. 
I liver 
(kidney 
Control Diabetic Diabetic+Vit.D Diabetic* vit.C Diabetic* vit. 
C+vit.D 
Fig 3.3 The activity levels of G6Pase in C in different treatment groups. 
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Superoxide dismutase activity levels in control, diabetic, vitamin C and vitamin 
C+vitamin D treated mice. 
120 
9658 
Control Diabetic Diabetic +vit. Diabetic+vit. 
C C+vit. D 
I liver 
i kidney 
Fig 3.4 The the activity levels of SOD in different treatment groups. 
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Catalase activity levels in control, diabetic, vitamin C and vitamin C+vitamin D 
treated mice. 
5 
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Control Diabetic Diabetica Diabetic+vit. 
vit.C C+vit.D 
Fig 3.5 The activity levels of catalase in in different treatment groups. 
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Glutathione-s-tranferase activity in control, diabetic, vitamin C and vitamin C+vitamin 
D treated mice. 
• liver 
• kidney 
Control Diabetic Di3betic+ Diabetic+vit. 
vit.C C+vit.D 
Fig 3.6 The activity levels of GST in different treatment groups. 
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GSH, SH and MDA levels in control, diabetic, vitamin C and vitamin C+vitamin D 
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Fig 3.7 The levels of GSH,-SH and MDA in different treatment d groups. 
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SCOT, SGPT and ALP activity levels in control, diabetic, vitamin C and vitamin 
C+vitamin D treated mice. 
• SGOT 
125 •SGPT 
Alkaline 
phosphatase 
Control Diabetic Oiabetic+VitD Diabetic+Vit. C Oiabetic+VitC+VitD 
Fig 3.8 The levels of SGOT, SGPT and alkaline phosphatase in different treatment 
groups. 
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Serum creatinine levels in control, diabetic, vitamin C and vitamin C+vitamin D 
treated mice. 
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Fig 3.9 The levels serum creatinine in different treatment groups. 
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Blood urea and BUN levels in control, diabetic, vitamin C and vitamin C+vitamin D 
treated mice. 
6 0 7 
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Fig 3.10 The levels of blood urea and BUN in in different treatment groups. 
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GLUT-4 expression levels in control, diabetic, vitamin C and vitamin C+vitamin D 
treated mice. 
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Fig 3.11 The levels GLUT-4 expression levels in different treatment groups. 
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COMET assay 
Control Diabetic 
Diabetic+Vit.D 
^ 
Diabetic + Vit. C Diabetic+ Vit. C+ Vit. D 
Fig 3.12 Liver hepatocytes showing DNA damage in diabetic state and recovery after 
treatment of 1, 25 dihydoxy vitamin D3,vitamin C alone and vitamin C along with 1, 
25 dihydoxy vitamin D3 
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COMET assay 
Control Diabetic 
Diabetic+Vit.D 
Diabetic + Vit.C Diabetic+ Vit. C+ Vit. D 
Fig 3.13 Pancreatic DNA damage in diabetic state and recovery after treatment of 1, 25 
dihydoxy vitamin D3,vitamin C alone and vitamin C along with I, 25 dihydoxy Vitamin D3. 
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Tail lengths 
Table 3: DNA tail length of liver and pancreatic tissue observed by alkaline comet assay 
Name of the group 
Control 
Diabetic 
Diabetic + vitamin D 
Diabetic + 
vitamin C 
Diabetic + 
Vitamin C+ 
Vitamin D 
Treatment 
saline 
alloxan 
l,25(OH)2 vitamin 
D3 
Ascorbic acid 
1,2 5 (OH) 2 vitamin 
D3+ Ascorbic acid 
Average tail length 
of liver cells (in jtim) 
7.65 ±2.20 
30.41 ±2.50 
21.80±2.40 
21.80 ±2.40 
18±2.1 
Average tail length in 
pancreatic cells 
(in fini) 
6.66 ±1.20 
32.45±2.87 
19.25± 1.90 
19.25 ±1.90 
16±2.34 
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Histopathological changes in control, diabetic, vitmin C and vitamin C+vitamin D 
treated mice. 
Table 3.1: The histopathological changes in the liver, kidney pancreas of control, diabetic and 
treated mice. 
Accumulation of lipid 
' droplets 
Increased fibrous content 
: Destruction of bile duct 
Hepatocytic degeneration 
a.Centrilobular 
Thickening of glomerular 
basement membrane 
Edema in proximal 
convoluted tubule 
Tubulointerstitial 
inflammation 
Islet cell population 
Insulitis 
Control Diabetic 
Group Group 
Tissue Changes (Liver) 
+++ 
++ 
+++ 
+++ 
Tissue Changes (Kidney) 
+++ 
+++ 
++ 
Tissue Changes (Pancreas) 
normal +++ + 
+++ + 
Dibetic+ 
vitamin C 
Group 
+ 
+ 
+ 
+ 
+ + + 
+ + 
+ + + 
+++ 
+++ 
Diabetic+ 
vitamin C+ 
vitamin D 
Group 
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
++ 
++ 
85 
Histopathological changes in hepatocytes of in control, diabetic, vitmin C and vitamin 
C+vitamin D treated mice. 
Control liver Diabetic liver 
1,25 dihydroxyvitamin D3 treated liver 
Vitamin C treated liver Vitamin C+Vitamin D treated liver 
Fig 3.14 Histopathological changes in the hepatocytes of control, diabetic and 
vitamins supplemented groups. 
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Histopathological changes in kidney tissues of in control, diabetic, vitmin C and 
vitamin C+vitamin D treated mice. 
Control Diabetic 
Diabetic+ 1,25 dihydroxy vitamin D3 
Diabetic+ Vit.C Diabetic+Vit.C+Vit.D 
Fig 3.15 The histopathological changes in the kidneys of control, diabetic and 
vitamins supplemented groups 
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Histopathological changes in pancreatic cells of in control, diabetic, vitmin C and 
vitamin C+vitamin D treated mice. 
, W'.'.i-'-^'.v i.Yfr*!;'-'"' ^.') 
Control Diabetic 
Diabetic+ 1,25 dihydroxy vitamin D3 
Diabetic+ Vit.C 
•*a'il!AjV« 
Diabetic+Vit.C+Vit.D 
Fig 3.16 The histopathological changes in the pancreas of control, diabetic, 1,25 
dihydroxy vitamin D3, vitamin C alone and vitamin C+ vitamin D supplemented 
groups. 
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Fluorescence spectra of vitamin C, vitamin D and vitamin C+vitamin D 
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(b) 
Fig 3.17 Fluorescence spectra of 50jim vitamin D, vitamin C and their combination at 
Ohr.jlhr. respectively. 
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FTIR analysis of vitamin C, vitamin D and vitamin C+vitamin DatO hours. 
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Fig 3.18 (a ) 1,25 dihydroxyvitamin Dj alone; (b) vitamin C alone; (c) 1,25 
dihydroxyvitatnin D3 and vitamin C combination 50|xM each at 0 hr, where X axis 
denotes wave number (cm"') and y axis denotes % transmittance. 
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FTIR analysis of vitamin C, vitamin D and vitamin C+vitamin D after 1 hours. 
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Fig 3.19 (a ) 1,25 dihydroxyvitamin D3 alone; (b) vitamin C alone; (c) 1,25 
dihydroxyvitamin D3 and vitamin C combination 50nM each at 1 hr, where X axis 
denotes wave number (cm'') and y axis denotes % transmittance. 
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Effect of 1, 25 Dihvdroxv Vitamin D? 
in Combination with Retinyl Palmitate 
on Type 2 Diabetes Mellitus 
1 Glucose homeostasis 
1.1 Fasting blood glucose 
Fig.4 shows the fasting blood glucose levels in the experimental groups (control, 
diabetic, diabetes +vitamin A, diabetes +vitamin A+ vitamin D). There is a marked 
increase in the FBG levels of the diabetic group 250.85+0.42 mg/dl as compared to 
the control 100.65+0.19 mg/dl indicative of the establishment of diabetes, A 
heightened decrease in the FBG levels can be seen in the diabetic group treated with 
vitamin A 200.19+0.41 mg/dl; whereas the treatment group provided with an 
Vit.A+Vit.D combination therapy shows the FBG levels 198.0+0.21 mg/dl close to 
control however the most significant decrease was observed in group given vitamin D 
alone 190+0.37 mg/dl thus elucidating the role of 1,25 dihydroxyvitamin D3 in 
diabetic treatment. 
1.2 Serum calcium estimation 
Fig 4.1 depicts the serum calcium level of all four groups. In control group the level 
was found to be 11.464+0.39 mg/ml. However, the decrease seen in the combination 
group (Vit.A+Vit.D) 10.01+0.11 mg/ml is comparable to 15.531+0.25 mg/dl in 
vitamin D treated group 9.5+0.34 mg/ml supporting the role of vitamin D in 
controlling serum Ca*^  levels. However, vitamin A supplemented group did not 
exhibit any change. 
2 Activities of Glucokinase or Hexokinase IV, Glucose-6-phosphatase and 
Fructose 1,6 bisphosphatase 
Fig 4.2, 4.3 and 4.4 shows the changes in the activities of hexokinase, FBPase and 
G6Pase in the experimental groups. The hexokinase activity was severely affected in 
the diabetic group in both liver 0.0294+0.023 |xg/mg/ml and kidney 0.0149+0.021 
Hg/mg/ml, with liver showing a greater decrease in the series. Supplementation of 
Vit.A to the dose tested lead to a recovery L=0.099±0.029 ng/mg/ml, K=0.0131^0.29 
fig/mg/ml while supplementation with Vit.A+Vit.D L=0.09±0.046 |ig/mg/ml, 
K=0.01435±0.043 i^g/mg/ml resulted in activity levels not as good as vitamin A aione, 
however, the levels were best recovered with the treatment of vitamin D alone 
L=0.1033+0.224 Mg/mg/ml, K=0.0153+0.003 ^g/mg/ml. 
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FBPase activity follows an inverse pattern. It is elevated in the diabetic group 
L=0.4911 ±0.001 ^ig/mg/ml, K=0.1373±0.0647 ^ig/mg/ml as compared to the control 
L=0.10321+0.008 ng/mg/ml, K=0.0893+0.00096 ng/mg/ml but supplementation with 
both in vitamin A L=0.3907±0.023 (ig/mg/ml, K=0.1087±0.1044 ^g/mg/ml and 
Vit.A+Vit.D L=0.4279±0.329 ^ig/mg/ml, K=0.1151+0.0066 ^tg/mg/ml resulted in a 
significant decrease in its activity, with maximum change witnessed in vitamin D 
treated group L=0.2733±0.008 ng/mg/ml, K=0.1039±0.29 ng/mg/ml. 
The activity of G6Pase enzyme in control group was found to be; L=0.533±0.02 
}xg/mg/ml, K=.1156±0.032 ^ig/mg/ml however, in diabetic group the level was 
increased to 0.918±0.008 ng/mg/ml, K=0.18±0.041 ng/mg/ml showing a rapid 
enhancement of gluconeogenesis. On vitamin D supplementation, the activity was 
found to be significantly decreased; L=0.71±0.01 ^ig/mg/ml, K=0.129±0.033 
Hg/mg/ml while in groups given vitamin A supplementation and combination therapy 
(Vit.A+Vit.D), the enzyme levels were L=0.806±0.034 |xg/mg/ml, K=0.15±0.29 
pg/mg/ml and L=0.8941±0.044 ^ig/mg/ml, K=0.17±0.43 ng/mg/ml. The results 
therefore clearly points towards Vit.D as the most effective strategy for controlling the 
activity of G6Pase. 
3 Oxidative stress 
3.1 Activities of superoxide dismutase (SOD), catalase, glutathiones-transferase 
(GST) 
Fig 4.5 and 4.6 represents the changes in the activities of the antioxidant enzymes in 
control, diabetic, vitamin D, vitamin A and Vit.A+Vit.D supplemented groups 
(measured in imits/mg/protein). There is increase in catalase activity; Liver = 59.286 
+_0.026, Kidney = 47.93 +_0.542 in the diabetic group as compared to the control 
group Liver = 30.532 ± 0.033, Kidney = 27.7415 ± 0.053, which upon 
supplementation with vitamin A decreased, catalase ; Liver = 44.373 ± 0.039, Kidney 
= 38.049 ± 0.495 however, the decrease was more significant and pronounced in case 
of group given combination of Vit. A + Vit. D; Liver = 1 6.85 4^0.0583, Kidney = 
39.247 +_0.495.Thereby showing that the combination has a better effect on enzyme 
activity than individual vitamin. 
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A similar pattern is followed by SOD and GST in kidney, there is an increase in the 
activity (SOD; 21.504±0.024 and glutathione-s-transferase; 12.658+0.0557) while in 
diabetic condition (SOD; kidney=66.057±0.035 GST; kidney=82.203±0.085) which 
is partially recovered by treatment with vitamin A; (kidney=41.589±0.042, GST; 
kidney=39.749+0.0668) while in case of Vit.A+Vit.D combination it is (SOD; 
kidney=20.314±0.0189,GST; kidney=36.427±0.03824), the values obtained were 
closer to the control in comparison Vit.A alone, suggesting that the combination of 
Vit.A+Vit.D works more efficiently than Vit.A or Vit.D alone in controlling oxidative 
stress induced by diabetes. 
However, a different pattern was observed in case of liver SOD and GST levels. 
There was a marked decrease in the enzyme activities of the diabetic group, 'SOD; 
liver=l83.272+0.0332 GST; liver=66.144+0.0245) as compared to the control values 
(SOD; liver=203.426+0.0367, GST; liver=110.009+0.041).Treatment with vitamin A 
alone and in combination Vit.A+Vit.D resulted in an increase in the SOD \'alues, 
(vitamin A; liver=190.86±0.0459, vitamin A+D; liver=198.75+0.045). In case of GST 
however for unknown reason, vitamin A supplementation further reduced the GST 
levels to 35.53+0.027 while combination of Vit.A+Vit.D elevated the levels closer to 
the control that is 94.495±0.032.Therefore, all the results of the antioxidant enzymes 
suggest that supplementation of Vit.A+Vit.D is more effective in controlling 
oxidative stress as compared to Vit.A or Vit.D alone. (Fig.6,7) 
3.2 Activity of glutathione reductase (GR) along with sulphydry (-SH) and 
glutathione (GSH) level estimation 
There was an increase in glutathione reductase activity (fig 4.7) 
(Liver=0.01362±0.0109, Kidney=0.0108±0.00672) in the diabetic group compared to 
the control (liver=0.00506+0.00113,kidney-0.00723+0.00341) which upon 
supplementation wdth Vitamin A ;GR was liver=0.00953 and kidney=0.0088, while in 
the combination treated group GR was (liver=0.00482+0.00849 
kidney=0.00692+0.00116), showing a better recovery of enzyme activity tliereby 
bringing it close to the control group ,(GR; liver=0.00506+0.()0113, 
kidney=0.00723+0.00341) as compared to Vit.A or Vit.D alone. 
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4 Estimation of liver function markers (LFT) in serum 
4.1 Glutamate pyruvate transaminase (GPT) or alanine transaminase (ALT) 
The enzyme levels in diabetic and control groups were found to be 171.40± 0.42 U/L 
and 67± 0.34 U/L respectively and the group given vitamin A supplementation 
showed the en2yme level of 68.53±0.37 U/L whereas the group with supplementation 
of both Vit.A+Vit.D was found to have enzyme level 124.38±0.29 U/L while vitamin 
D supplemented group has (80.3±0.254 U/L),(fig 4.11) 
4.2 Glutamate oxaloacetate transaminase (GOT) or aspartate transaminase (AST) 
Serum aspartate transaminase is a disease marker enzyme of liver. Its level was found 
to be increased in case of diabetic group (167.39± 0.45 U/L) as compared to control 
group (86.521±0.39 U/L) while vitamin A supplemented group was found to have 
(109.67±0.44 U/L) enzyme level. However, in group given combination therapy 
Vit.A+ Vit.D the level was estimated to be (110±0.35 U/L) while in case of vitamin D 
treatment, the level was found to be (95.64±0.28 U/L). 
4.3 Alkaline phosphatase (ALP) 
In diabetic group the level of ALP was found to be (12.124±0.25 KA units) whereas 
in control group the enzyme level was (10.694 ±0.37 KA units). In case of vitamin A 
supplemented group, the level was found to be (11.392±0.47 KA units). The group 
with Vit.A+Vit.D supplementation was found to have (11.959±0.39 KA imits). The 
most significant recovery was seen with vitamin D with the level of enzyme being 
(11.12±0.28 KA units). All the results of LFT point towards Vit.D as best supplement 
for diabetes (fig 4.11) 
5 Estimation of renal function markers (RFT) in serum 
5.1 Creatinine 
The serum creatinine levels in control group was found to be (0.0361± 0.034 
mg/lOOml) which was increased in case of diabetic group to (0.0411±0.022 
mg/lOOml), however on vitamin D supplementation the creatinine level was reduced 
to (0.038±0.033 mg/lOOmI) compared to groups given vitamin A (0.0391±0.046 
mg/lOOmI) and Vit.A+Vit.D (0.0371±0.021 mg/100mI).The combination thus is most 
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effect in bringing down serum creatinine levels became closer to the control group 
(fig 4.12). 
5.2 Blood urea and BUN (Blood urea nitrogen) 
The levels of blood urea and BUN (fig 4.13) in control group were estimated to be 
16.71± 0.41 mg/dl, 35.759±0.29 mg/dl whereas in case of diabetic group it was 
21.8±0.17 mg/dl, 46.652±0.36 mg/dl both these parameters depicted a significant 
increase, however on supplementation with vitamin D the levels were almost 
normalised to 17.54±0.32 mg/dl and 37.53±0.44 mg/dl as compared to group 
supplemented with vitamin A (18.32±0.38 mg/dl, 39.222±0.25 mg/dl) and 
Vit.A+Vit.D (19±0.44 mg/dl,36.38±0.37 mg/dl).Increase in urea is indicative of 
negative nitrogen balance which is an index of chronic illness and muscle wasting. 
6 DNA damage 
Diabetes is known to cause major DNA damage in pancreatic cells. The results of 
comet assay, given in fig 4.14 and 4.15, are indicative of the same. The diabetic group 
is showing an increase in the DNA tail length; in case of pancreas 32.45+2.87 i^m, 
liver 29.6±1.2 ^m as compared to control; pancreas 6.66+1.20|im, liver 7.1+0.9 |am. 
A marked decrease in the tail length was observed in the treatment group 
supplemented with vitamin A alone with pancreas 19.25+1.9[xm, liver 25.4+1.33 i^ m, 
however, the combination treated group (Vit.A+Vit.D) demonstrated a recovery.lt 
was 26+1.5 |xm in pancreas, 22.36+2.8 |xm in liver. However, in vitamin D 
supplemented group the tail lengths were found as; pancreas 21.80+2.40 |im and 
liver 19.25+1.90 urn and thus the recovery was most significant. 
7 Histopathological analysis 
Fig 4.16, 4.17 and 4.18 show the histopathological results of control, diabetes and 
various treatment groups. In diabetic group there was an increased accumulation of 
lipid droplets, characteristic of non-alcoholic fatty liver disease in hepatocytes 
together with the destruction of bile duct, a marker of cirrhosis, a significant increase 
in fibrous content (fibrosis) and centrilobular hepatocytic degeneration (suggestive of 
parenchymal tissue cell death) whereas in group supplemented with vitamin A all the 
markers of NASH, cirrhosis and fibrosis were improved, showing similarity with the 
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control group (Table 4.1). In case of kidney, we observed a significant thickening of 
glomerular basement membrane in diabetic group along with edema of distal 
convoluted tubule and tubule-interstitial inflammation, all markers of kidney damage, 
which were found to be reduced in kidney tissues of group given vitamin A 
supplementation, however the extent of recovery was more in the combination group 
supplemented with both Vit.A +Vit.D. 
8 GHJT-4 expression study 
The GLUT-4 expression levels were assayed by sandwich ELISA in adipocytes and 
skeletal muscles. It was 5.65±0.02 ng/ml in adipocytes; 5.122±0.033 ng/ml in skeletal 
muscles in diabetic group as compared to 7.643±0.036 ng/ml in adipocytes; 
9.02±0.039 ng/ml in skeletal muscles, in control group. However, the GLUT-4 levels 
were significantly improved in Vit.D supplemented group; 6.9±0.021 ng/ml in 
adipocytes; 9.0±0.034 ng/ml in skeletal muscles. This was found to be 5.73±0.035 
ng/ml in adipocytes, 7.03±0.024 ng/ml in skeletal muscles in Vit.A supplemented 
group and in combination group treated with (Vit.A+Vit.D), the levels were; 
6.07±0.044 ng/ml in adipocytes, 6.92±0.029 ng/ml in skeletal muscles, thus 
suggesting the role of vitamin D in normalizing the GLUT-4 expression on the cells 
(fig 4.22). 
6 Spectroscopic study 
The absorption spectrum was recorder to show if there was any interaction between 
vitamin A and vitamin D. Vitamin D shows an absorption maxima at 300 nm which 
upon immediate addition of vitamin A does not change so as to demonstrate no 
interaction between the two vitamins i.e. vitamin D and vitamin A. 
The FTIR analysis depicted that fi-ee vitamin A and D exhibit bands around 1618-
1642 cm"' arising from C-C stretching vibrations (coupled with the neighboring 
vibrations along the conjugated system). Furthurmore, various vibrational bands 
observed in the region 1200-1500 cm'' which are connected with the CH2 scissoring 
(bending in the plane), twisting or wagging (bending out-of-plan) and the CH 
deformation modes. Also, the bands in the region 2940-2956cm'' corresponded to u 
(C-H) stretching vibrations of methyl groups. However, the IR spectra revealed a 
characteristic broad and strong band in the 3400-3100 cm"' assigned to the (0-H) 
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stretching vibration of OH group present in vitamins which is responsible for 
hydrogen bonding interaction with other molecules. However, the spectral changes 
are not strong and significant enough to suggest any interaction between vitamin A 
and vitamin D. 
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Fasting blood glucose levels 
Control Diabetic Vit.A alone Vit.A+Vit.D Vit.D alone 
Fig 4. shows the fasting blood glucose levels in control, diabetic and treatment 
groups. 
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Serum calcium levels 
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Fig 4.1 shows the serum calcium levels in control, diabetic and treatment groups. 
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Hexokinase 
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Fig 4.2 shows the hexokinase activity levels in control, diabetic and treatment groups. 
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Fructose 1,6 bisphospatase 
Fig 4.3 shows the Fructose 1,6 bisphosphatase levels in control, diabetic and treatment 
groups. 
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Glucose-6-phosphatase 
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Fig 4.4 shows the Glucose 6 phosphatase levels in control, diabetic and treatment 
groups. 
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Fig 4.5 shows the catalase activity levels in control, diabetic and treatment groups. 
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Superoxide dismutase 
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Fig 4.6 Depicts the superoxide dismutase activity levels in control, diabetic and 
treatment groups. 
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Glutathiones-transferase 
140 
120 
100 
E 80 
3 60 
40 
20 
Liver 
Kidney 
Control Diabetic Vit.Aalone Vit.A+Vit.O 
Fig 4.7 Demonstrates the Glutathione-s-transferase activity levels in control, diabetic 
and treatment groups. 
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Glutathione reductase 
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Fig 4.8 shows the Glutathione reductase activity levels in control, diabetic and 
treatment groups. 
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Glutathione reduced(GSH) and sulphydryl group 
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Fig 4,9 shows the GSH and -SH levels in control, diabetic and treatment groups. 
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Lipid peroxidation 
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Fig 4.10 shows the MDA levels in control, diabetic and treatment groups. 
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Fig 4.11 shows the SGOT,SGPT and alkaline phosphatase activity levels in control, 
diabetic and treatment groups. 
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Fig 4.12 shows serum creatinine levels in control, diabetic and treatment groups. 
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Fig 4.13 shows the blood urea and BUN levels in control, diabetic and treatment 
groups. 
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COMET assay 
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Fig 4.14 Shows the extent of DNA damage and recovery in pancreatic cells of 
different groups. 
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COMET assay 
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Fig 4.15 Shows the extent of DNA damage and recovery in hepatocytes of different 
groups. 
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Histopathological analysis 
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Fig 4.16 Shows the histopathological changes in the hepatocytes of control, diabetic 
and vitamin A supplemented groups. 
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Histopathological analysis 
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Fig 4.17 Shows the histopathological changes in the kidney tissues of control, diabetic 
and vitamin A supplemented group. 
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Histopathological analysis 
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Fig 4.18 Shows the histopathological changes in the pancreas of control, diabetic, 
vitamin D alone, vitamin A alone and vitamin A+ vitamin D supplemented groups. 
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DNA tail lengths 
Same of group 
Control 
Diabetic 
Diabetic + vitamin D 
Diabetic + Vitamin A 
Diabetic + Vitamin A+ 
Vitamin D 
Treatment 
Saline 
Alloxan 
l,25(OH)2 vitamin D3 
Retinyl palmitate 
Retinyl palmitate +1,25 
dihydroxy vitamin Ds 
A verage tail length (pm) 
(Pancreas! 
6.66±].20 
32.45±2.87 
14.75±2.I 
19.25±1.9 
16±1.5 
i 
Table 4: DNA tail length of liver and pancreatic tissue observed by alkaline comet 
assay. 
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Histopathological changes in liver, kidney and pancreas of different treatment groups 
Accumulation of lipid 
droplets 
Increased fibrous content 
Destruction of bile duct 
Hepatocytic degeneration 
a.Centrilobular 
b.Perportal 
Thickening of glomerular 
basement membrane 
Edema in proximal 
convoluted tubule 
Tubulointerstitial 
inflammation 
Islet cell population 
Insulitis 
Control Diabetic Dihetic+ 
Group Group vitamin A 
Group 
Tissue Changes (Liver) 
_ +++ 
++ 
+++ 
+++ 
+ 
Tissue Changes (Kidney) 
+++ 
+++ 
++ 
Tissue Changes (Pancreas^ 
normal ++++ 
++++ 
++ 
+ + 
++ 
++ 
++ 
++ 
+ 
\ 
++ + 
+++ 
Dihetic+ vitamin 
A + vitamin D 
Group 
+ 
-• \ 
+ 1 
+ 
+ 
+ 
+ 
+ 
+ + 
++ 
Table 4.1: Shows the changes observed in liver, kidney and pancreas of diabetic and 
vitamins supplemented mice group with the number of (+) signs linearly indicating 
the extent of change. 
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UV Absorption Spectra 
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Fig 4.19 represents the UV-absorption spectra of vitamin A and vitamin D alone and 
in combintion at 0 hr. and Ihr. 
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FT-IR analysis 
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Fig 4.20 (a ) 1,25 dihydroxyvitamin D3 alone; (b) vitamin A alone; (c) 1,25 
dihydroxyvitamin D3 and vitamin A combination 50\iM each at 0 hr, where X axis 
denotes wave number (cm"') and y axis denotes % transmittance. 
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FT-IR analysis 
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Fig 4.21 (a ) 1,25 dihydroxyvitamin D3 alone; (b) vitamin C alone; (c) 1,25 
dihydroxyvitamin D3 and vitamin C combination 50nM each at 1 hr and 2 hr 
respectively, where X axis denotes wave number (cm'^ ) and y axis denotes % 
transmittance 
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GLUT-4 transporter expression 
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Fig 4.22 Shows GLUT-4 transporter expression determined by sandwich ELISA in 
different treatment groups including control, diabetic,vitamin A supplemented, 
vitamin A and vitamin D supplemented ones. 
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Diabetes, a multifaceted disease characterized by high blood glucose level {Antonio 
Ceriello 2005). It has taken the form of an epidemic in 2P' century. {Amos A, 
McCarty D, Zimmet P 2010) However, in recent decades there have been significant 
improvements in patient care but substantial numbers of patients are still not 
achieving the glycemic control levels specified in current guidelines of World Health 
Organization (1999). Drugs that are presently being used to avert the onset of diabetes 
are not good enough, on the contrary, providing drugs is pricey and the side effects 
require cautious monitoring, therefore vitamins offer a promising potential to help in 
combating diabetes and its complications without showing any side effects. 
In type 2 diabetes mellitus (T2DM), insulin is present at normal levels but the tissues 
do not respond to the hormone. This is caused by decreased sensitivity of target 
tissues to the metabolic effect of insulin (Brajendra KT, Arvind KS 2006). In type 2 or 
non-insulin-dependent diabetes mellitus, muscle and fat cells become 'resistant' to the 
actions of insulin and compensatory mechanisms that are activated in the (3-cell to 
secrete more insulin are not sufficient to maintain blood glucose levels within a 
normal physiological range and the major players of T2DM are pancreatic P-cell and 
insulin. (C. B. Wollheim and G.W. Sharp 1981) Since vitamin D plays a role in 
maintaining calcium homeostasis, it is expected to have a role in T2DM. Therefore, 
we have tried to see the role of vitamin D in treatment of diabetes. 
Vitamin D has been associated with numerous non-skeletal diseases including T2DM 
for over a decade (Jessica A. Alvarez and Ambika Ashraf 2010).Compaied to healthy 
controls subjects wdth T2DM have been observed to have significantly lower 
circulating 25(OH)D concentrations (R. Scragg et al 1995) .However, from a 
pathophysiological standpoint ,both vitamin D deficiency and T2DM share the same 
risk factors including increased adiposity, age and physical inactivity (which may 
translate to decreased time spent outdoors or reduced sun exposure) {A. W.Norman et 
al 1980). It has also been found that there occurs a seasonal variation in glucose and 
insulin concentration (C J. de Souza and A. H. Meier 1987) which may correlate to 
the seasonal variation of vitamin D exposure. In spite of all these findings the 
mechanism which relates vitamin D deficiency and T2DM remains elusive {Chertow 
B.S. et al 1983). Our present work is an attempt to shed some light on mechanism of 
action of vitamin D in T2DM systems. 
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In the present work we demonstrated the effect of 1, 25(OH)2D3 on glucose 
metabolism, calcium homeostasis and oxidative stress in type 2 diabetic mice in 
addition to its influence on histopathology and GLUT4 transporter expression. In 
addition to its involvement in alteration of glucose metabolic pathway, here, we report 
that the treatment of l,25(OH)2D produced significant changes in blood glucose and 
calcium concentration as well as in the activities of enzymes of glucose metabolic 
pathway as compared to diabetic group without supplementation. These changes are 
in accordance with the studies showing the lowering of serum glucose and an increase 
in serum calcium upon vitamin D supplementation (A. G. Pittas et al 2007) .Vitamin 
D deficiency causes an increase in PTH {K. C. R. Baynes et al 1997) leading to an 
increase in intracellular calcium {De BolandAR, Norman AW 1990) thus lowering its 
level in plasma whereas vitamin D supplementation re-establishes calcium 
homeostasis. 
The explanation for reduced levels of FBG and increased serum calcium in vitamin D 
treated diabetic groups as compared to untreated diabetic group can be given on the 
basis of its molecular action as well as its role in maintaining calcium homeostasis. 
Since, calcium is essential for proper insulin secretion and sensitivity {Bjorklund, A. 
Lansner, and V. E. Grill 2000), sustained elevations of intracellular calcium may 
inhibit insulin secretion, and also the ability of insulin-target cells to sense the brisk 
intracellular calcium fluxes necessary for insulin action, such as glucose transport {D. 
S. Worrall and J. M. Olefsky 2002).This resuUs in peripheral insulin resistance and 
thus increased plasma blood glucose levels. The mode of action of vitamin D is such 
that, it binds to its receptor (VDR) on the surface of pancreatic P-cells (Vidal M, 
Ramana CV, Dusso AS 2002). The ligand bound receptor then enters the cell and 
forms a heterodimer with retinoid X receptor (RXR) {Roberto Lin and John H. White 
2005) .This complex may then bind to the vitamin D response elements (VDRE) 
present in insulin gene promoter (Christakos S, Barletta F, Huening M et al 2003, 
Maestro B, Davila N, Carranza MC, Calle C. 2003) thereby increasing its 
transcription and finally increasing the levels of insulin in plasma. This increased 
insulin secretion can further be a cause of decreased FBG levels in vitamin D treated 
group. 
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Another mechanism by which 1,25 (OH)2D3 might lower FBG is suggested by its role 
in maintaining intracellular calciimi concentration. Adequate insulin secretion and 
sensitivity both are influenced by intracellular calcium concentration (Zemel MB 
1998). Therefore, the increase in serum calcium levels in vitamin D3 supplemented 
group is suggestive of the indirect effects of Vitamin D3 on insulin secretion and 
sensitivity {Bourlon PM, Faure-Dussert A, Billaudel B 1997), which may be mediated 
via its well-recognized role in regulating extracellular calcium and calcium flux 
through the p-cell or by its genomic actions. 
Our estimations of the enzyme activities of hexokinase, G6Pase and FBPase showed a 
distinct pattern. The decreased hexokinase activity in the group with diabetes, is an 
evidence of the fact that there is insufficient amount of glucose reaching the liver even 
in the state of hyperglycemia (Glinsman, W. H., E. P. Hem, and A. Lynch 1969), 
whereas increased activities of G6Pase and FBPase relates to almost twofold increase 
in gluconeogenic pathway which contribute to increased hepatic glucose production 
and thus hyperglycemia {Magnusson, I. et at 1992). However, the activities of these 
enzymes were found to have a reverse pattern in vitamin D3 treated group showing an 
increase in hexokinase and a decrease in G6Pase and FBPase activities, thereby 
providing an insight on the effect of vitamin D3 on glucose metabolism which 
eventually leads to maintenance of glucose homeostasis (Consoli, A. et al 1989). 
These results confirm the anti-hyperglycemic properties of l,25(OH)2D3. However it 
showed no direct effect on the activity of enzymes related to oxidative stress like 
SOD, catalase, GST. 
In the present study we report that the supplementation of vitamin D3 caused 
significant recovery from the diabetes induced tissue damage (liver and pancreas) 
when compared to group with no supplementation. We demonstrated it b} comet 
assay and histopathological analysis of the tissues (pancreas, liver and kidney). We 
observed the shortening of nuclear DNA tail length in the treated group. The most 
valued explanation of vitamin D3 induced recovery shown by the supplemented group 
can be on the basis of immune-modulatory and anti-apoptotic actions of vitiimin D3 
{Rita Riachy et al 2002, Rita Riachy , D'Herbomez M, Lefebvre J, Pattou F 2001). 
Recent studies have provided conclusive evidence that pancreatic P cell mass is 
reduced in T2DM and a probable reason for this reduction can be increased (3 cell 
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apoptosis, (Sempoux C, Guiot Y, Dubois D, Moulin P, Rahier 2001) ,the mechanism 
of this P-cell death being mediated by hyperglycemia. 
Glucose, the key physiological regulator of insulin, induces P-cell proliferation in a 
concentration dependent manner, {Maedler K, Spinas GA, 2001) however the 
proliferative capacity is suppressed after prolonged exposure to high glucose 
concentration. This complication is generally initiated by hyperglycaemic excursions 
which cause P-cell to produce IL-lp {Maedler K, Sergeev P, 2002) followed by FAS 
upregulation. Under normal conditions, FAS upregulation leads to cell proliferation in 
the presence of FLIP but in presence of hyperglycaemic excursions, the level of FLIP 
decreases finally switching the pathway to deleterious signals, causing cell death and 
eventually diabetes. 
This is the site where vitamin D3 might exert its effect and thereby stop apoptosis. 
Previous studies have shown that the inhibition of P cell fimction (insulin synthesis 
and insulin secretion) induced by IL-ip or IFN-y in vitro is prevented by 
\,25(On)2Di{Sandler S, Buschard K, Bendtzen K,1994).ThQreforQ, our results of 
comet assay are in accordance with the studies showing anti-apoptotic effect of 
vitamin D3 on pancreatic p cells. 
Hyperglycemia ^ • » Insulin secretion Kjlucose disposal 
Vitamin D3 
Differentiation \ 
Function T 
Proliferation J 
Decreased p-cell mass 
Fig.5 Hypothetical model illustrating the consequence of hyperglycemia on P-cell production 
of IL-Ifi in parallel with insulin secretion. The paracrine effect of IL-lfi induces Fas 
engagement, which in the presence of FLIP leads to fi-cell proliferation, differentiation, and 
increased function. 
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The explanation for shortening of nuclear DNA tail length in hepatocytes of the 
vitamin D3 treated group, is based on the fact that patients with type 2 diabetes have 
increased circulating levels of free fatty acids, leptin and TNF-a, (Van Steenbergen W 
& Lanckmans S1995) which are also found to be involved in the pathogenesis of non-
alcoholic steatohepatitis (NASH) (Shimabukuro M, Zhou YT, Levi M, linger RH 
1998, Hotamisligil GH & Spiegelman BM 1994), further leading to cirrhosis diver 
damage) via fibrosis. However, vitamin D supplementation decreases the cytokine 
levels through decrease in expression of TNF-a, involved in the development of 
NASH (Cantorna, M. T. iPP5).This may also help in reducing FFA and leptin by 
improving glucose homeostasis thereby reducing liver cirrhosis as shown b) the 
shortening of nuclear DNA tail length in liver cells in vitamin D supplemented group 
as compared to diabetic group receiving no vitamin D. 
In case of histopathology, the tissues showed significant recovery from damage in 
vitamin D supplemented group. In diabetic group, the liver showed accumulation of 
lipid droplets, increased fibrous content, destruction of bile duct and hepatocytic 
degeneration together with significant thickening of the glomerular basement 
membrane, oedema of proximal convulated tubule, hyaline deposition, degeneration 
of distal convulated tubule and tubule-interstitial inflammation. However, the 
pancreatic tissues demonstrated a decrease in islet cell population and presence of 
insulitis. 
To sum up the effect of 1,25 dihydroxyvitamin D3 on type 2 diabetic mice, it can be 
said that 1,25 dihydroxyvitamin D3 maintains intercellular calcium concentration both 
in pancreas and peripheral insulin sensitive tissues, thus increasing the calcium 
mediated GLUT4 transporter expression on the surface of skeletal muscles and 
adipocytes. This helps in increasing the glucose uptake by the cell and simultaneously 
removing it from circulation, thus bringing down hyperglycemia. ,25 
dihydroxyvitamin D3 also enhances the calcium mediated release of insulin from 
insulin granules in pancreas thereby increasing the concentration of insulin in blood, 
and making it available to control the increased blood glucose. 
Since hyperglycemia is the main player in the development of diabetic complications 
and also causes oxidative stress and related problems. By bringing down 
hyperglycemia and establishing normoglycemia, 1,25 dihydroxyvitamin D3 plays a 
128 
major role in controlling type 2 diabetes and related complications. Therefore, we 
suggest with caution that 1,25 dihydroxyvitamin D3 is could be used as an add-on 
therapy for diabetic treatment, this will help in delaying the diabetes related 
complications. 
In addition to the effect of 1,25 dihydroxyvitamin D3 in the treatment of diabetes, we 
also analysed the role of this vitamin (1,25 dihydroxyvitamin D3) in combination with 
other vitamins i.e. vitamin C (ascorbic acid ) and vitamin A (retinyl palmitate). 
Inability of 1,25 dihydroxyvitamin D3 to directly improve the anti-oxidant enzyme 
parameters led us to study the combinations, as it is not only hyperglycemia alone that 
needs to be normalised but other contributing factors like oxidative stress, that should 
also be treated and kept imder surveillance for effective management of type 2 
diabetes mellitus. 
Although the mode of action, the targets acted upon and the mechanism of action of 
both these vitamins (1,25 dihydroxyvitamin D3 and vitamin C) is totally different 
from each other but given together, they have the potential to act upon the two biggest 
most basic abnormalities of type 2 diabetes mellitus i.e. hyperglycemia and oxidative 
stress (Anabela Rolo P, Carlos Palmeiro M. 2006). In addition to their dual action, 
they are less costly, easily available, and free from side effects and pose no threat of 
further complications. Our work compares the effect of vitamin C alone and in 
combination with vitamin D on glucose metabolic enzymes, anti-oxidant enzymes, 
DNA damage, histopathological changes and levels of GLUT4 expression in type 2 
diabetic mice. 
It was found that the group given combination therapy (Vit.C+Vit.D) showed a 
significant decrease in FBG levels as compared to the group given vitamin C alone. A 
probable explanation for this finding can be given by looking at the individual actions 
of these vitamins. Vitamin C, a known anti-oxidant, plays its anti-diabetic role by 
scavenging the reactive oxygen species (ROS) generated due to hyperglycemia 
(Misato Kashiba 2002), thus protecting p-cells from free radical mediated damage 
thereby helping in increased cell survival and near normal insulin secretion eventually 
bringing down fasting blood glucose levels (Mohammad Afkhami-Ardekani & Ahmad 
Shoj'aoddiny-Ardekani 2007). Vitamin D, however adopts a different mode of action. 
129 
mediated via calcivun homeostasis. Intracellular calcium concentration is very 
important for insulin secretion and sensitivity as sustained elevations of intracellular 
calcium may inhibit insulin secretion and the ability of insulin-target cells from 
sensing the brisk intracellular calcium fliixes necessary for insulin action (Worrail DS 
and Olefsky JM. 2002).Thus, resulting in peripheral insulin resistance and increased 
plasma blood glucose levels. Vitamin D supplementation therefore maintains the 
required calcium concentration and help in increased insulin secretion and senshivity 
(Bjorklund, Lansner A and Grill VE. 2000) thereby removing excess glucose from 
circulation. When both these vitamins are given together as (Vit.C+Vit.D) 
combination they are expected to give a near two-fold effect as evident by results of 
combination group when compared to vitamin C alone group. This effect is also 
supported by the observation that serum calcium level is also increased in 
(Vit.C+Vit.D) combination group, suggesting that calcium mediated anti-
hyperglycaemic effect is because of vitamin D alone as in vitamin C treated group, no 
changes were observed in serum calcium levels. 
The enzyme activities of hexokinase, G6Pase and FBPase also showed a distinct 
pattern. The decreased hexokinase activity in the group with diabetes, depicts 
insufficient supply of glucose to the liver (Glinsman WH, Hem EP and Lynch A. 
1959) however, the increased activities of G6Pase and FBPase are indicative of 
enhanced hepatic glucose production and finally hyperglycemia (Magnusson I. 1992). 
However, in the group given combination therapy, the enzymes display improvement 
in activities compared to the group given vitamin C alone. The combined action of 
vitamin C+ vitamin D, helps in decreasing p-cell death via scavenging ROS by 
vitamin C and increase in insulin secretion and sensitivity mediated by vitamin D. 
Once the required amoimt of insulin enters circulation, it facilitates glucose to enter 
into the peripheral tissues, leading to normalization by upregulating hexokinase tl and 
downregulating G6Pase, FBPase 4. The probable reason for a marked changed in the 
activities in the combination therapy group is that vitamin D not only works on insulin 
secretion but also on insulin sensitivity (Bourlon PM et al. 1997). This increase in 
insulin sensitivity may be due to the increased expression of glucose transporter (as 
expression on the cell surface also depends on intracellular calcium concentration) 
mainly GLUT-4 in peripheral tissues namely liver and adipocytes. This led to increase 
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in extracellular glucose uptake that accounts for increase in hexokinase activity with a 
simultaneous decrease in G6Pase and FBPase activities. The dual action of vitamin 
C+ vitamin D in (D + Vit.C + Vit. D) group, is therefore, responsible for the 
improvement in the activities of glucose metabolic enzymes as compared to vitamin C 
alone group. 
We also analysed the anti-oxidant enzyme activities in both the treatment groups and 
found that the presence of vitamin C alone as well as with vitamin D, imparts anti-
oxidant effect to the therapy {Reusch JEB et al. 1991). Since it is already known that 
vitamin D does not possess any anti-oxidant properties, the enzyme activities of SOD, 
catalase and GST show a better result in group given vitamin C alone as compared to 
vitamin C+ vitamin D group. These results can be further understood by observing the 
levels of cellular reductants (GSH and SH) in groups given vitamin C alone 
(D+Vh.C) and along with vitamin D (D+Vit.C+Vit.D) (Daniel Tessier M. 2009). 
In order to further clarify the direct effect of the vitamin C supplementation alone and 
in combination with vitamin D we analysed MDA levels to assess the extent of lipid 
peroxidation. It was observed that though lipid peroxidation was decreased in vitamin 
C supplemented group (D+Vit.C) (Mehmet Qay et al. 2001, Laranjinha J et al. 1999) 
but in the combination treated group (D+Vit.C+Vit.D), the reduction in MDA levels 
was more pronounced, supporting the beneficial effect of the combination in targeting 
two major players of type 2 diabetes that is hyperglycemia and oxidative stress. 
Similar results were obtained in case of DNA damage. It was found that the 
combination therapy (D+Vit. C+Vit.D) lead to a greater decrease in DNA tail length 
as compared to vitamin C alone group (D+Vit.C). These resuhs also support the very 
idea of using both these vitamins (Vit.C+ Vit.D) to target hyperglycemia (Paolisso G 
et al. 1995) and oxidative stress (Meerza D et al. 2012, Sebastian Padayatty et al. 
2003). The histopathological analysis of the liver demonstrated an accumulation of 
lipid droplets, increased fibrous content, destruction of bile ducts and hepatocytic 
degeneration in diabetic group while groups treated with vitamin C alone (D+Vit.C) 
and combination (D+Vit.C+Vit.D) depicted a decrease in these pathological 
conditions with the extent being same in both the groups. In case of type 2 diabetes, 
there occurs a cardinal abnormality of insulin resistance in peripheral tissues 
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including muscles and adipocytes. This defect in insulin sensitivity leads to increased 
lipolysis and thus higher levels of circulating non-esterified free fatty acids 
(NEFA's).Once in circulations these NEFA's compete with glucose for oxidation in 
liver, causing a sequential inhibition of pyruvate dehydrogenase, 
phosphofrucktokinase and hexokinase 11 activity and causing accumulation of 
diacylglycerol, ceramides and lipids in the liver. These metabolites after accumulation 
activate phosphorylation of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) via 
ser/threo kinase cascade finally bringing down the downstream events of insulin 
signalling pathway and contributing to fiirther insulin resistance (Steven Kahn E. 
2006). Another mechanism by which type 2 diabetes leads to liver damage is 
mediated by increased oxidative stress. There occurs an increase in mitochondrial 
oxidative stress due to excess intracellular fatty acid deposition leading to increased 
free radical production which ultimately induces inflammation; cellular necrosis and 
also fibrosis, all contributing to liver damage (Diego Garcia-Compean 2009). 
Interestingly, vitamin C supplementation alone and along with vitamin D acts by 
normalising these complications via two probably distinct pathways. Vitamin C, a 
potent antioxidant, scavenges the fi-ee radicals generated by fatty acids and its 
metabolites and thus stops the vicious circle of inflammation, cirrhosis and fibrosis, 
protecting the liver from fi"ee radical induced damage. However, in case of vitamin D 
the site of actions seems to be slightly different. Vitamin D has been found to 
maintain the calcium homeostasis within the cells which is very important for insulin 
action, therefore, by maintaining required calcium concentration in adipocytes, 
vitamin D can increase the insulin sensitivity via increasing GLUT-4 expression and 
GLUT-4 mediated glucose uptake thereby decreasing lipolysis and NEFA's levels in 
circulation, finally stopping NEFA's induced liver damage. 
Therefore, fi-om the analysis of the results, we can conclude that the combination 
therapy consisting of both vitamin C and vitamin D is likely be more beneficial in 
correcting the underlying abnormalities compared to any one of these vitamins alone. 
This combination approach brings together the anti-hyperglycemic effect of vitamin D 
and the anti-oxidant effect of vitamin C, thus targeting both, the cause and the effect 
leading to type 2 diabetes and related complications. This, combination therefore, in 
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all probability will be very effective if given as supplementation to people suffering 
from type 2 diabetes mellitus. 
The next combination of vitamins that we used in this study was vitamin A+ vitamin 
D.1,25 dihydroxy vitamin D3 and vitamin A both belong to the class of steroids, 
mediate their actions both at the cellular as well as at genetic level. The molecular 
signalling pathway of both of these hormones is however rather complex and 
discrepancies have been found in the results observed. According to the common 
notion, the reason for this could be because both of these vitamins mediate their 
molecular actions via interacting with retinoid x receptor (RXR) present inside the 
cell. Studies have suggested the antagonistic relationship of vitamin A with vitamin 
D. However, it is of due importance to note that vitamin D can mediate its actions not 
only by making vitamin D receptor VDR: RXR heterodimers but also as homodimers 
(VDR:VDR) {(Cheskis B, Freedman LP) or heterodimers VDRrRAR (retinoic acid 
receptor) and VDR:TR (thyroid receptor), depending upon the type of vitamin D 
response element (VDRE'S) present in the gene to be upregulated or downregulated 
(Thompson PD, Jurutka PWJ.The preferred heterodimers for VDRE's is: RXR: RXR 
for (D receptor) DRl type, VDR: RXR for DR3 type, VDR: TR for DR4 type, VDR: 
RAR for DR5 type (Cheskis B, Freedman LP). DR1-DR6, are the vitamin D response 
elements, having direct repeats with 1,2,3,4,5 and 6 flanking nucleotides. 
e.g. DR5 - GGGTCACCGAAAGGTCACT 
DR6 -GGGTGACCGCAAAGGTGACT 
Therefore, at the molecular level, no specific rule can define the relationship between 
vitamin A and vitamin D as antagonistic or synergistic as it varies from gene to gene. 
Also, the type of VDRE'S (DRl, DR3, DR4, DR5 or DR6) will determine whether a 
highly specific or rather flexible binding of VD in combination with other ligands like 
9 cis retinoic acid and all trans retinoic acid can be expected. However, many m vitro 
studies suggest that 9 cis retinoic acid positively co-ordinates the action of nuclear 
signalling of vitamin D and both 9 cis retinoic acid and 1,25 dihydroxyvitamin D3 
enhanced reporter gene expression from a vitamin D responsive promoter. (Cheskis 
B, Freedman LP) 
133 
At the cellular level, the mode of action of these vitamins is rather simple to 
understand. Retinaldehyde, the first intermediate formed from vitamin A, and all 
trans retinoic acid, mediates most of the actions, whereas 1, 25 dihydroxy vitamin D3, 
the final metabolite of vitamin D performs all the fimctions. Retinaldehyde inhibits 
PPARy activation thus (a) decreasing the triglyceride content in white adipose tissues, 
skeletal muscles and liver, (b) increasing the effect of leptin and (c) enhancing fatty 
acid combustion and energy dissipation. The other metabolite, all trans retinoic acid 
acts as a specific ligand for PPARp/8, a key regulator of fatty acid oxidation in mascle 
and fat. Therefore, both these metabolites act together, ameliorating induced obesity 
and insulin resistance. 1, 25 dihydroxy vitamin D3, the fimctional form of vitamin D, 
maintains the required calcium levels inside the cells possessing vitamin D receptors 
(VDR's) (like pancreas, skeletal muscles and adipocytes), finally increasing the 
insulin secretion by pancreas and insulin sensitivity in target tissues, as both these 
processes are calcium dependent. 
In the present study the vitamin A supplemented group demonstrated a decrease in 
FBG levels and FBPase activity along with an increase in the activity of hexokmase 
as compared to the diabetic group, suggesting towards the increased amount of 
glucose reaching liver which may be due to increased expression of GLlJT-2 
transporter on the surface of the liver cells. Vitamin A supplementation has already 
been found to induce the expression of GLUT-2 in insulinoma cell line INS-1 All 
trans-retinoic acid induced GLUT-2 m-RNA expression was observed after 48 hrs of 
incubation. Another mechanism by which vitamin A leads to increased glucose uptake 
may involve PKC and thus effecting insulin sensitivity positively. It has been found 
that all trans retinoic acid modulates the activity of PKC by directly binding to its 
isozymes (Ferna 'ndez-Meji 'a C, Davison MB). These PKC isoforms might play a role 
in ser/thr phosphorylation of insulin receptor substrate (IRS-1, IRS-2) and also 
inactivate NADH oxidase. This may inactivate and block the downstream signalling 
pathway of insulin action and free radical production. This effect of all trans-retinoic 
acid may prove helpfiil in insulin signalling pathway ultimately improving insulin 
sensitivity and reducing oxidative stress. However, the changes were not that 
significant in the group given the combination treatment i.e. vitamin A+ vitamin D, 
this could be due to the presence of vitamin D and since both vitamin D and vitamin 
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A involve RAR for their cellular action, the presence of both these vitamms together 
can lead to the decrease in the available RAR in the cell. Once the amount of RAR 
decreases, neither of the vitamins (vitamin D or vitamin A) are able to carryout their 
molecular functions, thereby leading to poor results. 
Vitamin A 
Cellular action 
PKC inhibition 
hihibition of 
Oxidative stress 
Molecular action 
Vit.D 
Via RAR IS) 
Expression of 
enzymes 
Fig 5.1 Suggestive mechanism of action vitamin A involved in bringing down 
oxidative stress parameters and affecting expression of enzymes. 
This is the reason that combination of vitamin D and vitamin A showed mixed results 
depending upon the parameter analysed and the pathway used by the vitamins. The 
oxidative stress parameters showed better results in case of combination group when 
compared to vitamin A alone because to lower down the free radical production 
vitamin A probably uses the PKC pathway, inhibiting NADH oxidase and thus 
lowering oxidative stress parameters however in case of glucose metabolic enzymes 
both vitamin A and vitamin D probably mediate their effects via molecular 
mechanism causing RAR insufficiency in the cell and eventually effecting the results 
negatively than in case of either of the vitamins alone. 
The oxidative stress parameters observed in our study, with the only exception of 
SOD showed a marked decrease (catalase, GST and GR) in vitamin A supplemented 
group whereas there was no significant difference between vitamin A treatment group 
and the group given vitamin A+ vitamin D. This could be due to the fact that vitamin 
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D alone did not directly influence oxidative stress parameters while vitamin A has 
demonstrated anti-oxidant action in our treated groups. The decrease in the activity of 
SOD in the diabetic condition can be explained on the basis of excessive production 
of superoxide and hydroxyl radicals, which might have utilized all cellular SOD as the 
first line of defence against the fi-ee radicals. This resuh could also be attributed to the 
increase in glycation in case of diabetic group, which inactivate the enzyme. 
However, vitamin A or retinoic acid causes an increase in the SOD activity by acting 
as a lipoperoxy scavenger thereby controlling the free radical mediated glycation of 
SOD, resulting in an increase in SOD activity. 
The increase in the MDA levels in vitamin A supplemented group can be explained 
considering its role in adipocyte metabolism. Vitamin A has an inhibitory effect on 
adipogenesis together with stimulating fat thermogenesis. The regulatory cascade 
controlling adipogenesis involves C/EBP followed by increased expression of PPARy, 
once induced PFARy activates the transcription of adipocyte marker genes through 
interaction of PPARy: RXR heterodimer (Aria K, Lizuka S, Tada Y, Oikavia K 
/Vitamin A or retinoic acid inhibits adipogenesis by interfering with the 
transcriptional activity of C/EBP proteins, blocking the C/EBP mediated induction of 
downstream genes especially V'?AK'^.( Chawla A. and Lazar MA) In addition to this, 
retinoic acid (RA) upregulates RARy expression and decrease the expression level of 
RARa thus favouring RAR: RXR heterodimer formation, over PPARy: RXR 
heterodimer formation eventually bringing adipogenesis to a halt.(S'c^warz EJ, 
Reginato MJ, Shao D, Krakow SL). However, the pro-thermogenic effect of R^ is 
mediated through increase in the activity of uncoupling protein-l(UCP-l), which is an 
inner mitochondrial membrane protein, capable of short circuiting the proton gradient 
generated by respiratory chain. This uncouples fuel oxidation fi-om ATP synthesis and 
generates heat (Kawada T, Kamei Y. and Sugimoto E). Therefore, both iinti-
adipogenic and pro-thermogenic effects together reduce adipogenesis/lipogenesis and 
enhance lipolysis leading to an increase in circulating levels of lipids and free latty 
acids (FFA's). These metabolites then reach liver and are subjected to mitochondrial 
oxidation, producing high levels of oxidation products including MDA ihus 
accounting for an increase in MDA levels in vitamin A supplemented group. 
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On the other hand, the group given combination treatment with vitamin A and vitamin 
D exhibited lower level. This may be due to the effect of vitamin D in bringing down 
ROS through controlling hyperglycemia, which is partly responsible for high MDA 
levels. 
It is also known that beta cells contain low level of antioxidant enzymes when 
compared to other cells and therefore succumb more easily to the oxidative damage 
thus adversely effecting pancreatic DNA (Nedergaard J, Golozoubova V). In the 
current study we report that the supplementation of vitamin A has a protective role on 
the pancreatic tissue damage inflicted by type 2 diabetes. The explanations for this 
effect is based on the antioxidant activity of retinol on beta cell function and integrity 
thus leading to a reduction in pancreatic DNA tail length, in vitamin A supplemented 
group as compared to the diabetic group. Our data suggests cytoprotective effect of 
vitamin A supplementation and in the treatment of diabetes but further experiments 
are required to affirm the same and pave the way for a new and effective treatment 
schedule. The histopathological changes in the liver of diabetic group while a 
decrease in these pathological conditions was observed when supplemented with 
Vit.A. The defect in insulin sensitivity leads to increases lipolysis and thus higher 
levels of circulating non-esterified free fatty acids (NEFA's).Once in circulation these 
NEFA's compete with glucose for oxidation in liver, causing a sequential inhibition 
of glycolytic enzymes dovmstream and accumulation of diacylglycerol, ceramides and 
lipids. These metabolites then activate phosphorylation of insulin receptor substrate 1 
and 2 (IRS-1 and IRS-2) finally bringing down the downstream events of insulin 
signalling pathway and contributing to further insulin resistance (Lenzen S, Drinkgern 
J, 1996). Another mechanism, by which type 2 diabetes leads to liver damage, is 
mediated by increased oxidative stress due to mitochondrial dysfunction which 
ultimately induces inflammation, cellular necrosis and also fibrosis, all contributing to 
liver damage (Steven Kahn E).\n case of kidney, a marked thickening of glomerular 
basement membrane was observed which is a characteristic feature of 
glomerulosclerosis. This is formed due to the deposition of glycated proteins along 
with the presence of edema in distal convoluted tubule and interstitial inflammation, 
all markers of glomerular-nephritis. However, in vitamin A supplemented group, all 
these pathological changes were found to be reduced, most probably due to the free 
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radical scavenging action of vitamin A. Locally generated ROS increase tissue 
damage by causing lipid peroxidation, thus destroying the membrane integritx and 
causing tissue damage. However, the dual action of the two vitamins i.e. vhamin 
A+vitamin D in the group given combination treatment resulted in better and more 
significant changes in the tissues hinting towards the beneficial effect of these two 
vitamins. In order to understand the nature of relationship shared by these vitamms 
i.e. vitamin A and vitamin D, we carried out FTIR analyses which depicted no 
interaction between two vitamins at molecular level thus, there is no clear evioence 
that the presence of one vitamin will either be inhibitory to other vitamin or activating 
the action of another. What we suspect is that vitamin A and vitamin D share the 
receptor VDR-RXRA^DR-RAR, the combination in all probability effect the 
downstream signalling pathway. As the distributions of these receptors vary in 
different tissues, the effect may be synergistic or antagonistic. Further studies into 
gene expression and signalling pathways are however needed to fiiUy elucidate this 
effect. 
In the end, the study shows that if given in combination, vitamin A and vitamin D can 
act together to normalise and bring down type 2 diabetes related oxidative stress and 
related complications. 
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Abstract 
Diabetes has become the next most widespread epidemic after cancer and extensive research is being 
carried out to develop drugs for its therapeutics Recent studies have found that deficiency of Vitamin D 
results in reduction in insulin secretion and thus in hyperglycemia. Both insulin seaetion and sensitivity 
depends upon intracellular calcium concentration also and Vitamin D is one of the honnone wfiich has been 
found to regulate calcium flux within the cells In both observational and case-control studies, an inverse 
relationship has been reported with level of 25{OH)Vit D and degree of glycemic control Therefore, in the 
present review, an attempt is being made to present scientific evidence of linkage of Type 2 diabetes with 
Vitamin D levels in order to explore the possibility of Vit D as an add-on therapy to the existing treatment to 
strive near nonmo-glycemia. 
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Abstract 
The role of vitamin D is not nnerely limited to maintaining skeletal health but also extends to maintaining 
glucose homeostasis by preserving Insulin secretion and sensitivity and thus deficiency of vitamin D plays 
an important role in aetiopatnogenesis of 72 diabetes In addition to Its many other roles, vitamin O has 
recently been found to have growth inhibiting affects on pancreatic cancer cells Ecological studies have 
shovvn that there exists an inverse correlation between sun exposure and death rates for panaeatic cancer 
Since vitamin 0 has promising role in both type 2 diabetes mellitus and pancreatic cancer, its deficiency may 
be associated to any or both of these chronic diseases The present review thus aims to find conetation 
between diabetes and pancreatic cancer and if vitamin D is a comnwn link between the two 
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* Hyperglycemia or hyperinsulinemia can be a cause of both diabetes and pancreatic cancer »• Vitamin D 
can have a role in treating diabetes, by maintaining required intracellular calcium concentration and thus 
proper insulin secretion/sensitivity • It can also influence growth factors that promote tunrwr growth in 
pancreatic cancer »• Vitamin D can inhibit pancreatic cancer cell growth by activation of p21 and p27, whicti 
influence cell cycle progression and arrest cells in 60/G1 
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A B S T R A C T 
Aims; The purpose of the study was to examine the effect of 1,25(OH)2 VitaminDs supplementation on type 2 
diabetic (T2DM) mice. 
Materials and Methods: A total of 24 mice were taken and divided into three groups of control; diabetic and 
diabetic + vitamin D supplemented ones. Serum calcium leveL fasting blood glucose level (FBG). hexokinase 
activity, glucose-S-phosphatse and fructose 1.6 bisphosphatase activity were measured to establish a 
relevant correlation between vitamin D supplementation and hyperglycemia in T2DM. 
Results: There occurred an increase in FBG levels (250 ±0.41 mg/dl) and a significant decrease in serum 
calcium levels in the diabetic group (8.63 ± 0.40 mg/ml) both of which reached near control levels on vitamin 
D3 supplementation. The artivity of the glucose metabolic enzymes was also assayed in diabetic group and 
was found to be deviated from control group; hexokinase (0.0241 ±0.014 pg/mg/ml I FBPase (0.433 ± 
0.002 Mg/mg/ml) and G6Pase (0.918 ± 0.02 ng/mg/ml). However, the activity of these enzymes returned to 
near control values with hexokinase activity reaching 0.717 ± 0.003 Hg/mg/ml on vitamin D3 supplemen-
tation. The FBPase and G6Pase activities were decreased to 0.2733 ± 0.008 ng/mg/ml and GSPase 0.71 ± 
0.01 (ig/mg/ml respectively. In addition to enzymatic analysis, the organs of all three groups of mice were 
subjected to comet assay. The diabetic group receiving vitamin D supplementation showed a marked 
recovery exhibiting shorter tail length both in liver (21.80 ±2.40 pm) and pancreatic cells (19.25 ± 1.90 (in) 
as compared to the diabetic group exhibiting a uil length of 30.41 ± 2.50 pm and 32.45 ± 2.87 ^ tn in liver and 
pancreatic cells respectively. 
Conclusion: The present study shows that vitamin D3 supplementation is positively correlated with decrease 
in blood glucose level and serum calcium level in fasting condition. This suggests a positive influence of 
vitamin D on glucose homeostasis. Besides, the activity of various glucose metabolic enzymes (hexokinase, 
FBPase and G6Pase) as shown by our results and the remarkable shortening of DNA tail length in viumin D 
supplemented diabetic group as compared to diabetic group without supplementation further support the 
idea that vitamin D supplementation might be an add-on therapy for patients with T2DM. 
© 2012 Elsevier Inc All rights reserved. 
1. Introduction 
Globally, the number of people with diabetes is expected to rise 
from the current estimate of 150 million to 220 million in 2010 and 
300 million in 2025.Type 2 diabetes is the predominant form of 
diabetes worldwide, accounting for 90% of cases globally. Evidence 
has accumulated from observational studies and randomized con-
trolled trials, on the beneficial effects of good blood glucose control in 
the prevention of micro-vascular and macro-vascular damage in 
people with diabetes. The pathogenesis of T2DM is complex, therefore 
* Conflict of interest: The authors have no conflict of interests. 
* Corresponding author. Tel.: +91 571 2700741, + 91 9719069125: fax: +91 571 
2706002. 
E-mail address: imrananaseem2009@gmail.com (I. Naseem). 
1056-8727/S - see front nutter C 2012 Elsevier Inc All rights reserved. 
doi:10,1016/j.jdiacomp.2012.05.013 
from a pathophysiological standpoint; persons with T2DM consis-
tently demonstrate three cardinal abnormalities: resistance to the 
artion of insulin in peripheral tissues, defective insulin secretion 
particularly in response to glucose and increased glucose production 
by liver. 
Vitamin D's importance to the human body has been recognized 
for almost two centuries, although our understanding of its influence 
on the overall human health is relatively recent and still expanding. 
The discovery of the receptors for l a , 25-dihydroxyvitamin 
D3(l,25(OH)2D3), the activated form of viUmin D, in tissues with 
no direct role in calcium and bone metabolism (e.g. pancreatic beta 
cells) has broadened our view of the physiological role of this 
molecule (Holick. 2003; Haussler, Whitfield, & Haussler, 1998). 
Biologically active viUmin D in addition to its classical actions also 
acts as a "gene switch" to regulate the transcription of specific target 
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genes within the human genome including the insulin gene where the 
presence of vitamin D response elements has recently been 
elucidated. This finding suggests that the functions of vitamin D 
might extend to prevent impaired insulin secretion and sensitivity 
(Boucher, Mannan, Noonan, Hales, & Evans, 1995). A significant 
decrease has been reported in the levels of 1, 25(OH)2 vitamin D3 in 
type 2 diabetics both in human (Bouillon, Verstuyf, Verlinden, Eelen, 
& Mathieu, 2003) and animal models. Studies from different parts of 
India have shown widespread vitamin D deficiency in all age groups 
(Isaia, Giorgino, & Adami, 2001) and that Women who consumed 
800 lU or more of total vitamin D per day had a 23% lower risk for 
development of incident diabetes compared with women who 
consumed <200IU/day and those who consumed <400 lU/day 
vitamin D from supplements compared with women who consumed 
<100 lU/day had a 13% lower risk of diabetes (Scragg, Sowers, & Bell, 
2004). Therefore, these studies suggest that vitamin D might pfay a 
role in hyperglycemia. Vitamin D deficiency may, therefore, be 
involved in the pathogenesis of T2DM, (Kadowaki & Norman, 1984), 
and a better understanding of the mechanisms involved could lead to 
the development of preventive strategies. 
In this study we have estimated the changes in the fasting blood 
glucose and calcium levels in diabetic groups given vitamin D3 
supplementation and those not given the supplementation. In order 
to be more precise, we also assayed the activity of hepatic glucose 
metabolic enzymes like hexokinase, G6Pase and FBPase. Since 
diabetes affects and damages almost all major organs of the body, 
we also observed the extent of nuclear DNA damage in hepatic and 
pancreatic tissues of diabetic group and its recovery in the organs of 
vitamin D3 supplemented group. 
2. Materials and methods 
2./. Study population 
The present study was conducted on female albino mice at the 
Department of Biochemistry, Aligarh Muslim University. The mice 
were divided in three groups of 8 mice each. The first group was kept 
as control (C) and no treatment was given to it. To the second group 
an intra-peritoneal injection of alloxan (200 mg/kg body weight) was 
given and their fasting blood glucose (FBG) was monitored till they 
became diabetic (D). The third group was subjected to the same 
alloxan dosage and after it was confirmed that mice had become 
diabetic, another dosage of purified 1, 25(OH)2 vitamin D3 was given 
intra-peritoneally for a regular period of 15 days (D + Vit D). To rule 
out the effect of propylene glycol, a group of control mice was given 
the solvent propylene glycol but no changes were observed in the 
parameters analysed (data not shown). 
All mice were given free access to food and water and were housed 
in dark rooms with no exposure to sunlight in order to make them 
vitamin D deficient. Therefore, the intra-peritoneal injection of 
vitamin D3 was the only source of vitamin D to the treated group. 
2.2. In vivo /, 25(0H)2 vitamin D3 administration 
One group of vitamin D deficient mice was made diabetic by 
administration of alloxan (Sigma-aldrich, US.). The diabetic state was 
induced by giving an intra-peritoneal injection of 300 \ii containing 
200 mg/kg of alloxan. The establishment of diabetic state was further 
confirmed by estimating fasting blood glucose level using a 
glucometer. This group was termed as diabetic group (D). 
Another group of vitamin D deficient diabetic mice received 
l,25(OH)2D3 intra-peritoneally (Sigma-aldrich, U.S.) for 15 days after 
they had become diabetic. This treatment consisted of 7 ng/gm/day of 
1, 25(OH)2D3 dissolved in propylene glycol given intra-peritoneally 
for 15 days. This group was termed as treated group or (D -I- Vit D). 
2.3. Sample collection 
Overnight fasting mice were sacrificed by cervical dislocation at 
the end of 15 day period and their blood and tissue samples were 
collected for analysis. 2-3 ml blood was collected in heparinised 
centrifuge tubes which were immediately centrifuged at lOOOxg for 
15min. Furthermore, the serum parameters were analyzed on the 
same day while the tissues (liver and pancreas) were kept in Hepes 
buffer at - 20 °C for further enzyme analysis. 
2.4. Biochemical analysis 
Fasting blood glucose and serum calcium levels were analyzed in 
the treated animals. Activity of glucose metabolic enzymes like 
Hexokinase, G6Pase and FBPase was also analyzed from the liver 
tissues collected. 
2.5. Fasting blood glucose estimation 
Glucose levels were estimated in collected serum samples by 
glucose oxidase-peroxidase method ofTrinder (1969) using Ranbaxy 
Diagnostic kit. Briefly 10 |.il of the fasting blood samples was mixed 
with 1 ml of working solution (containing 6.7 U/ml of glucose 
oxidase, 6.2 U/ml of horseradish peroxidase, 0.2 Mm of 4-aminoanti-
pyrene, 8 M of phosphate buffer and 86 mM of phenol). The blank and 
standard solutions were also prepared simultaneously by adding 10 pi 
of distilled water and 10 (J of standard glucose (100 mg/dl) to 1 ml of 
working solution. All the tubes were mixed well and incubated at 
room temperature for 30 min. Blank solution was used to set the 
spectrophotometer and absorbance was read at 505 nm. 
2.6. Serum calcium estimation 
Serum calcium levels were estimated by using alkaline murexide 
reagent (Spare, 1964). To 1.5 ml of color reagent (containing 50 ml of 
stock color reagent and 1.5 ml of 3.75 N KOH) 2.5 ml of distilled water 
and 0.05 ml of serum sample were added. The stock color reagent was 
prepared by dissolving 40 mg of ammonium purpurate in 5 ml of 
distilled water and then diluting it with 500 ml of propylene glycol. 
The blank and the standard solutions were also prepared simulta-
neously by adding 2.55 ml and 2.5 ml of distilled water respectively to 
1.5 ml of color reagent. To make up the volume 0.05 ml of standard 
calcium (0.1 mg/ml) was added to standard solution. The tubes were 
capped with Parafilm and mixed thoroughly. The tubes were then 
allowed to stand for next 5 min and were finally read at 490 pm. 
2.7. Hexokinase activity 
The hexokinase activity was measured by the method of Crane and 
Sols (1953). The liver tissues were collected and homogenized in 
sodium phosphate buffer using table top homogenizer (REMI, U.S.A). 
The reaction was carried out at 37 °C by adding 1 ml reaction mixture 
containing Tris Hcl (50pm), Mgcl2 (10pm), ATP (5pmol), glucose 
(2 pm) is added to 1-1.5 mg of sample protein. The reaction was 
stopped after 1 h using 10% barium hydroxide and 10% zinc sulphate 
solutions. The samples were centrifuged at 2000 xg for 10 min and 
glucose was estimated in supernatant (free from phosphorylated 
derivatives).The glucose estimation was then done by the method of 
Nelson (1994), with standard glucose solution ranging between 5 and 
45 pg. 
2.S. FBPase activity 
The liver FBPase activity was measured by the method of 
Freedland and Harper (1959). The reaction was carried out by adding 
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1.5 ml of reaction mixture containing Tris HCl(50nm), Mgcl2(10|,un), 
Cysteine Hcl (12 nm), Fructose 1,6 diphosphate (lOf-im) to sample 
containing 0.6-0.8 mg. The reaction mixture was stopped by adding 
1 ml of 10% TCA after 60 min and the samples are centrifuged at 
2000xg for 10 min. The phosphate released was estimated by the 
method of Tausky and Shorr (1953). 
2.9. C6Pase activity 
It was assayed according to the method of Shull, Ashmore, and 
Mayer (1956). The reaction mixture in a total volume of 1.5 ml 
contained Tris-Hcl buffer (50urn); Mgcb (10.um): Glucose-6-
Phosphate(10|im) and 2-3 mg sample protein. The reaction was 
carried out at 37 °C and stopped with 1 ml of 10% TCA after 60 min. 
The samples were centrifuged at 2000 xg and phosphorous was 
estimated in the protein free supernatant by the method of Tausky 
and Shorr (1953). 
2.10. Comet assay 
The assay was performed in alkaline condition in accordance with 
protocol of Singh, McCoy, Tice, and Schneider (1988) with few 
modifications. First of all, fully frosted slides pre-coated with 1% NMA 
(as base layer) at 60 °C were prepared a day before sacrificing the 
animals. About 10,000 cells isolated from each organ cell suspension 
were mixed with 80 nl 1% of LMPA to form the working cell 
suspension separately for each organ. This suspension was pipetted 
over the base layer at 37 °C followed by covering with cover slips 
immediately. After solidification of second layer on ice packs, the 
cover slips were removed and a third layer of 0.5% LMPA (80 .ul) was 
pipetted over followed by placing of cover slips on it. This layer was 
also kept on ice packs for solidification. Then, the cover slips were 
removed and the slides were immerged in cold lysing solution (2.5 M 
NaCl + 100 mM EDTA -I-10 mM tris-base + 1% triton X-100) at pH 10. 
The process of lysis was allowed to continue for 3 h followed by 
unwinding for 30 min in alkaline electrophoretic running buffer 
(300 mM NaOH + 1 mM EDTA) at pH 13 in electrophoretic tank. After 
this, electrophoresis was performed for 35 min at 4 °C with constant 
field strength of 0.74 V/cm and current strength of 300 mA. The slides 
were washed with cold saline and were subjected to neutralization by 
neutralizing buffer (0.4 M tris-base) having pH 7.5 followed by 
washing with cold saline. The process of neutralization was repeated 
twice. They were then stained with 75 (JJ ethidium bromide (20 ).ig/ml) 
for 5 min. Finally, the slides were washed with chilled saline again and 
cover slips were placed on and they were kept in humidified slide box 
in refrigerator followed by their analysis on the next day. The slides 
were scored with the help of CX41 fluorescent microscope (Olympus, 
Japan) coupled with an image analysis system (Komet 5.5, Kinetic 
imaging, Liverpool, U.K.) attached with integrated CC camera COHU 
4910 (equipped with 510-560 nm excitation and 590 nm barrier 
filters). The comets were scored at the magnification of lOOx and 
images from 50 cells (25 from each replicate slide) were scored. 
Comet tail-length (migration of DNA from its nucleus in pim) was 
chosen as the parameter to assess the cellular DNA damage that was 
automatically generated by Komet 5.5 image analyzing system. 
2.11. Statistical analysis 
Results are expressed in meaniSEM for all continuous variables. 
Differences between the control, diabetic and diabetic + vitamin D 
supplemented groups are assessed using ANOVA followed by 
Student's t-test. For all the tests the p-value <0.05 was considered 
to be statistically significant. All the analysis was performed using 
SPSS and Origin 6.1. 
3. Results 
3.1. l.25(0H)2vitamin D3 treatment causes a decrease in FBC andsenim 
calcium levels in diabetic mice 
Figs. 1 and 2 show the fasting blood glucose levels and serum 
calcium levels in all the three groups (C, D, D -I- VitD). The FBC is seen 
to be increased in the diabetic group (250 ±0.41 mg/dl) marking the 
proper establishment of diabetic state as compared to the control 
group (160.97±0.21 mg/dl). The diabetic group given vitamin D 
supplementation shows a significant decrease in the FBC levels (190 ± 
0.37 mg/dl) thus suggesting its role in pathogenesis of hyperglycemia. 
Fig. 2 depicts the difference in the serum calcium levels of the three 
groups of mice. The increase in the serum calcium level in the vitamin 
D treated group (9.5 ±0.40 mg/ml) in comparison to the decreased 
levels in diabetic group (7 ± 0.43 mg/ml) is symptomatic of function of 
vitamin D in maintaining calcium homeostasis. 
32. Changes in the enzyme activities of glucose metabolic enzymes by 
h25(0H)2vitamin D3 supplementation 
Figs. 3,4A and 4B represent the variation in the activity of glucose 
metabolic enzymes i.e. hexokinase, G6Pase and FBPase respecfively. 
The activity of hexokinase was found to decrease in the diabetic group 
(0.241 ±0.014|.ig/mg/ml) and further increased (0.717 ±0.003 i^g/ 
mg/ml) on vitamin D supplementation. Further the activities of 
C6Pase and FBPase were analyzed in control group and were found to 
be 0.533 ±0.02 |.ig/mg/ml and 0.10707 ±0.002 (.ig/mg/ml respective-
ly. However, there was a significant increase in their activities in 
diabetic group, the FBPase activity was estimated to be 0.433 ± 
0.004 (.ig/mg/ml and GSPase activity was found to be 0.918 ± 
0.008 ng/mg/ml in diabetic group showing a rapid enhancement of 
glycogenolysis. Their activities again decreased FBPase (0.2733 ± 
0.008 Lig/mg/ml) and G6Pase (0.71 ±0.01 l^g/mg/ml) respectively on 
vitamin D supplementation. 
3.3. 1,25(0H)2 Vitamin D3 treatment caused decrement in the DNA tail 
length in liver and pancreatic samples 
Diabetes caused major DNA damage in liver and pancreas as 
evidenced by elongated tail length in diabetic group as compared to 
control group. Diabetic group showed an increase in the DNA tail 
length in liver and pancreatic cells with 30.41 ± 2.50 |.UTI and 32.45 ± 
2.87 (.im respectively (Figs. 5B and 6B) as compared to control group 
with tail length 7.65 ± 2.20 ).un and 6.66 ± 1.20 pm in liver and 
pancreatic cells respectively (Figs. 5A, 6A). However, vitamin D 
300 Fasting Blood Glucose level 
^ 250 I. 
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Fig. 1. Shows the increase in fasting blood glucose level in diabetic group which 
decreases on vitamin D supplementation. 
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Fig, 2. Depicts the decrease in the serum calcium concentration in the diabetic mice 
with no supplementation, however it became close to the control value in the diabetic 
group given vitamin D. 
supplemented group showed a significant decrease in liver and 
pancreatic DNA tail length with values of 21.80 ± 2.40 urn and 19.25 ± 
1.90 )jm respectively (Figs. 5C, 6C) (Table 1). 
4. Discussion 
Diabetes, a multifaceted disease characterized by high blood 
glucose level (Ceriello, 2005) has taken the form of an epidemic in 
21st century (Amos, McCarty, & Zimmet, 2010). However, in recent 
decades there have been significant improvements in patient care but 
substantial numbers of patients are still not achieving the glycemic 
control levels specified in current guidelines (World Health Organi-
zation (WHO), 1999). Drugs that are presently being used to avert or 
diminish the onset of diabetes are not good enough, on the contrary, 
providing drugs is pricey and the side effects require cautious 
monitoring therefore vitamins offer a promising potential to help 
in combating diabetes and its complications without showing any 
side effects. 
The major players of T2DM are pancreatic (^ >-cell and insulin but 
the pathogenic mechanisms by which hyperglycemia arises differ 
significantly. The characteristic features of T2DM are insulin resis-
tance and decreased insulin secretion (Bell & Polonsky, 2001) which 
together are dependent on intracellular calcium concentration 
(Wollhejm & Sharp, 1981). Since vitamin D plays a role in maintaining 
calcium homeostasis it may also be involved in T2DM. Therefore, we 
have tried to see the role of vitamin D in treatment of diabetes. 
Vitamin D has been associated with numerous non-skeletal 
diseases including T2DM for over a decade (Alvarez & Ashraf, 2010). 
Compared to healthy controls subjects with T2DM have been observed 
to have significantly lower circulating 25(OH) concentrations (Scragg 
et al., 1995). However, from a pathophysiological standpoint, both 
vitamin D deficiency and T2DM share the same risk factors including 
increased adiposity, age and physical inactivity (which may translate 
to decreased time spent outdoors or reduced sun exposure) (Norman, 
Frankel, Heldt, & Grodsky, 1980). It has also been found that there 
occurs a seasonal variation in glucose and insulin concentration 
(De Souza & Meier, 1987) which may correlate to the seasonal 
variation of vitamin D exposure. In spite of all these findings the 
mechanism which relates vitamin D deficiency and T2DM remains 
elusive (Chertow et al., 1983). Our present work is an attempt to shed 
some light on mechanism of action of vitamin D in T2DM systems. 
]n the present work we demonsfrare the effect 1, 25(OH)2D on 
glucose metabolism and calcium homeostasis in addition to its 
involvement in alteration of glucose metabolic pathway. Here, we 
report that the treatment of 1,25(OH)2D produced significant changes 
in blood glucose and calcium concentration as well as in the activities 
of enzymes of glucose metabolic pathway as compared to diabetic 
group without supplementation. These changes are in accordance 
with the studies showing the lowering of serum glucose and an 
increase in serum calcium on vitamin D supplementation (Pittas, Lau, 
Hu, 8i Dawson-Hughes, 2007), Vitamin D deficiency causes an 
increase in PTH (Baynes, Boucher, Feskens, & Kromhout, 1997) 
thereby leading to an increase in intracellular calcium (De Boland & 
Norman, 1990) thus lowering its level in plasma, however vitamin D 
supplementation re-establishes calcium homeostasis. 
The explanation for reduced levels of FBG and increased serum 
calcium in vitamin D treated groups as compared to diabetic can be 
given on the basis of its molecular action as well as its role in 
maintaining calcium homeostasis. Since, calcium is essential for 
proper insulin secretion and sensitivity (Bjorklund, Lansner, & Grill, 
2000), sustained elevations of intracellular calcium may inhibit 
insulin secretion and the ability of insulin-target cells from sensing 
the brisk intracellular calcium fiuxes necessary for insulin action, such 
as glucose transport (Worrall 8i Olefsky, 2002) resulting in peripheral 
insulin resistance and thus increased plasma blood glucose levels. 
Vitamin D binds to its receptor (VDR) on the surface of pancreatic |i-
cells (Vidal. Ramana, & Dusso, 2002). The ligand bound receptor then 
enters the cell and forms a heterodimer with retinoid X receptor 
(RXR) (Lin 8; White, 2003). This complex may then bind to the 
vitamin D response elements (VDRE) present in insulin gene 
promoter (Christakos, Barletta, & Huening, 2003; Maestro, Davila, 
Carranza, & Calle, 2003) thereby increasing iis transcription and 
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A (Control) B (Diabetic) C (Diabetic + vitamin D) 
Fig. 5. Liver hepatocytes showing DNA damage in diabetic state and recovery after treatment of Vitamin D. A. (Control) B. (Diabetic) C. (DialDetic + vitamin D). 
finally increasing the levels of insulin in plasma. This increased insulin 
secretion can further be a cause of decreased FBG levels in vitamin D 
treated group. 
Another mechanism by w/hich 1,25 (0H)2D3 might act in lowering 
FBG is suggested by its role in maintaining intracellular calcium 
concentration for adequate insulin secretion and sensitivity both of 
which are influenced by intracellular calcium concentration (Zemel, 
1998). Therefore, the increase in serum calcium levels in vitamin D3 
supplemented group is suggestive of the indirect effects of Vitamin D3 
on insulin secretion and sensitivity (Bourlon, Faure-Dussert, & 
Billaudel, 1997), which may be mediated via its important and well-
recognized role in regulating extracellular calcium and calcium flux 
through the fVcell or by its genomic actions. 
Our estimations of the enzyme activities of hexokinase, G6Pase 
and FBPase showed a distinct pattern. The decreased hexokinase 
activity in diabetic group is an evidence of the fact that there is 
insufficient amount of glucose reaching the liver even in the state of 
hyperglycemia (Glinsman, Hem, & Lynch, 1959), whereas increased 
activities of G6Pase and FBPase showed an almost twofold increase in 
gluconeogenic pathway which contributes to increased hepatic 
glucose production and thus hyperglycemia (Magnusson, Rothman, 
Katz, Shulman, & Shulman, 1992). However, the activities of these 
enzymes were found to be different in vitamin D3 treated group 
showing an increase in hexokinase and a decrease in G6Pase and 
FBPase activities, thereby providing an insight on the effect of vitamin 
D3 on glucose metabolism which eventually leads to maintenance of 
glucose homeostasis (Consoli, Nurjhan. Capani, & Gerich, 1989). These 
results confirm the anti-hyperglycemic properties of l,25(OH)2D3. 
In the present study we report that the supplementation of 
vitamin D3 caused significant recovei-y from the diabetes induced 
tissue damage (liver and pancreas) as shown by vitamin D3 treated 
diabetic group when compared to diabetic group with no supple-
mentation. We demonstrated it by comet assay of the tissues 
(pancreas and liver) from the vitamin D treated diabetic animals 
which exhibited the shortening of nuclear DNA tail length as 
compared to diabetic group without supplementation. The most 
valued explanation of vitamin D3 induced recovery shown by the 
supplemented group can be given on the basis of immune-
modulatory and thus anti-apoptotic actions of vitamin D3 (Riachy, 
Vandewalle, Conte, & Merman, 2002; D'Herbomez, Lefebvre, & 
Patrou, 2001). 
Recent studies have provided conclusive evidence that pancreatic 
\'> cells mass is reduced in T2DM and a probable reason for this 
reduction can be \\ cell apoptosis (Sempoux, Guiot, Dubois, Moulin, 
& Rahier, 2001). The mechanism of this P-cell apoptosis is mediated 
via hyperglycemia. In diabetes, hyperglycemic excursion can elicit {'•• 
cell production of IL-1(^  (Maedler et al., 2002), followed by Fas 
upregulation. In the presence of the caspase-8 inhibitor FUCE 
inhibitory protein (FLIP), Fas engagement is directed to proliferation. 
However, excessive glucose stimulation (hyperglycemia) will de-
crease FLIP, switching this adaptive pathway toward deleterious 
signals and eventually to diabetes (Maedler et al., 2002). This is the 
site where vitamin D3 might exert its effect and thereby stop 
apoptosis. Previous studies have shown that the inhibition of beta 
cell function (insulin synthesis and insulin secretion) induced by IL-
\[\ or IFN-7 in vitro is prevented by 1,25(OH)2D3(50). Therefore, our 
results of comet assay are in accordance with the studies showing 
ani-apoptotic effect of vitamin D3 on pancreatic ('. cells (Sandler, 
Buschard, & Bendtzen, 1994). 
The explanation for shortening of nuclear DNA tail length in 
hepatocytes of the vitamin D treated group can be given by the fact 
that patients with type 2 diabetes have increased circulating levels of 
A (Control) B (Diabetic) C (Diabetic + vitamin D) 
Fig. 6. Pancreatic cells showing DNA damage in diabetic state and recovery after treatment with vitamin D. 
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Table 1 
Tail length of DNA using alkaline comet assay. 
Name of the group 
Control 
Diabetic 
Diabetic H 
Treatment 
saline 
alloxan 
1.25{OH)2 
Average tail length 
of liver cells 
(in iim) 
7.6512.20 
30.41^2.50 
21.80x2.40 
Average tail length 
in pancreatic cells 
(in wm) 
6.66 ±1.20 
32.45 ± 2.87 
19.25x1.90 
free fatty acids, leptin and TNF-a, (Van Steenbergen & Lanckmans, 
1995) which are also found to be involved in the pathogenesis of non-
alcoholic steatohepatitis (NASH), (Shimabukuro, Zhou. Levi, & Unger, 
1998; Hotamisligil &and Spiegelman, 1994), further leading to 
cirrhosis (liver damage) via fibrosis. However, vitamin D supplemen-
tation causes a decrease in the cytokine majorly involved in NASH. 
Vitamin D causes a decrease in the expression of TNF-« (Cantorna, 
Woodward. Hayes. & De Luca. 1998). and may also help in reducing 
FFA and leptin by improving glucose homeostasis thereby reducing 
liver cirrhosis as shown by the shortening of nuclear DNA tail length 
in liver cells taken from vitamin D supplemented group as compared 
to diabetic group receiving no vitamin D. 
Hence, from the studies carried out. we conclude that the 
supplementation of 1.25(OH)2 vitamin D to patients with type 2 
diabetes will in all probability help to restore glucose homeostasis 
(normogiycemia) and will thereby reduce the pancreatic and 
liver damage. 
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1. Introduction 
In Type 2 diabetes mellitus, insulin is present at normal levels 
but the tissues do not respond to the hormone. This is caused by 
decreased sensitivity of target tissues to the metabolic effect of 
insulin [1]. In type 2 or non-insulin-dependent diabetes mellitus, 
muscle and fat cells become 'resistant' to the actions of insulin and 
compensatory mechanisms that are activated in the p-cell to 
secrete more insulin are not sufficient to maintain blood glucose 
levels within a normal physiological range [2]. Patients with T2DM 
consistently demonstrate three cardinal abnormalitiesidefective 
insulin secretion, particularly in response to a glucose stimulus 
(b-cell dysfunction); resistance to action of insulin in the 
Corresponding author at: Aligarh Muslim University, Aligarh, India. 
E-mail address: jamalahmadl l@redifrmail.com Q. Ahmed). 
peripheral tissues, particularly muscle and fat but also liver 
(insulin resistance); and increased glucose production by the liver 
(hyperglycemia). The precise way these factors interact, finally 
lead to the onset of T2DM [3| . 
From a pathophysiological standpoint, it is actually the inability 
of the pancreatic beta cell to adapt to the reductions in insulin 
sensitivity that occurs over the lifetime of human subjects that 
precipitates the onset of T2DM [4]. The most common factors that 
place an increased secretory burden on the beta cell are puberty, 
pregnancy, a sedentary lifestyle, and an over-eating leading to 
weight gain. 
2. P-Cell dysfunction 3': 
The endocrine pancreas contains b cells that secrete insulin in 3 ' 
response to elevated glucose levels. Once secreted, insulin 35 
performs the function of maintaining normal glucose levels in 3( 
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the body by interacting with the plasmalemmal receptors of a 
number of different cell types, it is the inability of the p cells to 
secrete required amounts of insulin in response to circulating 
levels of glucose, that paves the way for T2DM.The exact 
mechanism by which glucose stimulates insulin production by 
3 cells is mediated by facilitated diffusion of glucose inside 
pancreatic p cells via glucose transporter GLUT2 present on the 
cells surface of pancreatic P cells. The numbers of these 
transporters are however found to be reduced on the cells of T2 
diabetic patients. Glucose after entering p cells is converted to 
glucose-6-phosphate, by the one of the glycolytic rate determining 
enzyme, glucokinase [5,6]. Glucokinase acts as a glucose sensor of 
the p cells and leads to increased insulin secretion. The entry of 
glucose to P cells and insulin releases follows a cause and effect 
pathway. This dose-response relationship leads to more insulin 
secretion as more and more glucose enters the pancreatic P-cell. 
The pathway by which glycolysis mediates insulin secretion 
depends upon the opening and closing of ATP dependent K+ 
channel present inside the cell. The step involving the oxidation of 
glyceraldehyde-3-phosphate generates NADH which eventually 
generates ATP. Increase in ATP concentration in p cells leads to 
blockade of ATP-dependent K* channel causing membrane 
depolarization followed by increased cytosolic Ca^ * concentration 
which leads to fusion of preformed insulin granules with the 
plasma membrane and thus insulin secretion [7]. 
On the other hand, in case of obesity (an underlying cause of 
T2DM) there occurs p cell compensation such that there is 
increased insulin secretion even in response to normal glucose 
levels. This abnormality can only be possible if there is increased p-
cell sensitivity in response to glucose. The root cause of this defect 
can be: (a) an increase in p cell mass and thus presence of more 
GLUT2 receptors as found in obese individuals (8] or (b) increased 
expression of hexokinase as compared to glucokinase leading to 
increased insulin secretion in response to wide range of glucose 
concentrations, thus resulting in hyperinsulinemia [9]. 
3. Insulin resistance 
Insulin resistance indicates the presence of an impaired biologic 
response to either exogenously administered or endogenously 
secreted insulin. It is manifested by decreased insulin stimulated 
glucose transport and metabolism in adipocytes and skeletal 
muscles and by impaired suppression of hepatic glucose output 
[10]. 
Understanding of the mechanism and signaling of insulin 
allows the division of the mechanism of insulin resistance into 
three groups: prereceptor, receptor and postreceptor insulin 
resistance. Type A insulin resistance is due to a decrease in the 
number of insulin receptors, whereas patients with type B insulin 
resistance have circulating auto-antibodies against some portion 
of their insulin receptors, and this results in impaired binding of 
insulin to target cells (11 J. The majority of insulin resistance is of 
the postreceptor type due to the extraordinary complexity of the 
intracellular pathways of insulin action. 
A large number of epidemiologic studies showed that insulin 
resistance rises as the body fat content increases from the very lean 
to very obese; implying that the absolute amount of body fat has an 
effect on insulin sensitivity [12]. 
4. From obesity to insulin resistance 
The signaling pathway by which adiposity is linked to insulin 
resistance is however rather complex. Adipocytes release non-
esterified fatty acids (NEFA), tumor necrosis factor a(TNF-a) and 
hormones like leptin and adiponectin which modulate insulin 
action in the peripheral tissues thus becoming a major player of 
insulin resistance [13,14]. Studies have found out certain agents 
that may be helpful in nullifying the diseased conditions caused 
due to imbalance of these factors (TNF, leptin, adiponectin). Vaspin 
(visceral adipose tissue derived serpin) is an adipocyte serine 
protease inhibitor that improved insulin sensitivity and glucose 
homeostasis when administered to obese, insulin-resistant 
rodents [15]. An acute effect was seen within 1-2 h, and chronic 
administration was accompanied by normalized gene expression 
for leptin, resistin, TNF-a and adiponectin. 
5. Peripheral insulin resistance 
5./. Skeletal muscle insulin resistance 
5.1.1. Non esterified fatty acids 
NEFA's being the most critical of aII;compete with glucose for 
substrate oxidation in isolated muscle [16].The increase in fatty 
acid metabolism leads to an increase in intramitochondrial acetyl 
coenzyme A (COA)/COA and reduced adenine dinucleotide 
(NADH)/NAD+ ratios, with subsequent inhibition of pyruvate 
dehydrogenase. The resulting increased intracellular mitrochon-
drial and cytosolic citrate concentrations result in allosteric 
inhibition of phosphofrucktokinase, the key regulating enzyme 
of glycolysis. Subsequent accumulation of glucose 6 phosphate 
would then inhibit hexokinase 11 activity, resulting in an increased 
intracellular glucose concentration and decreased glucose uptake 
thus resulting in insulin resistance [17J. Increased NEFA concen-
tration inside the cells can also trigger a serine/threonine signaling 
cascade via fatty acid metabolites like diacylglycerol (DAG) and 
fatty acyI coenzyme A(fatty acyl COA].This pathway once activated 
causes phosphorylation of insulin receptor substrate l(IRSl) and 
insulin receptor substrate 2(IRS2) thereby decreasing their ability 
to bind phosphatidylinositol-3-OH kinase (Pl(3)l<), this interaction 
is however necessary for glucose transporter 4(GLUT4) transloca-
tion and thus insulin mediated glucose uptake [18]. 
5.1.2. Triglyceride content 
Glucose uptake and intramuscular triglyceride content has 
been found to follow an inverse relationship. The increase in the 
triglyceride content occurs due to imbalance of free fatty acid 
uptake and oxidation, as in case of obese individuals. The major 
reason for this can be the presence abdominal adiposity as 
abdominal fat is lipolytically more active thus leading to increased 
circulating levels of NEFA's, followed by muscular uptake of free 
fatty acids than more than it can oxidize. The mechanism involved 
in this mismatch of uptake and oxidation is mediated by malonyl 
CoA [19]. The increased insulin levels in circulation due to P cell 
dysfunctions mediate initial increase in glucose uptake by skeletal 
muscles. This glucose entering the glycolytic pathway causes an 
increase in citrate levels by activating tricarboxylicacid(TCA) cycle 
and providing an alternate substrate for acetyl CoA carboxylase 
(ACC).ACC after activation generates malonyl CoA thus inhibiting 
carnitine palmitoyltransferase-1 (CPT-1) thus blocking the transfer 
of fatty acyl CoA into mitochondria for oxidation [20-22]. This 
accumulation of triglycerides like long chain fatty acyl CoA and 
diacyglycerol after activation sets several protein kinases into 
action, leading to serine/threonine phosphorylation of insulin 
receptor and resulting in decreased IR kinase activity finally 
causing insulin resistance [23]. 
5.2. Adipocyte insulin resistance 
Adipocyte insulin resistance is actually adipocyte mediated 
insulin resistance. Adipocytes secrete hormones which regulate 
and mediate processes like lipid metabolism, lipolysis. and insulin 
mediated glucose uptake aiid utilization. The abnormal decrease in 
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the levels of these hormones adds to the already existing 
conditions forT2DM. In obesity, the levels of adipocyte hormones 
like leptin and adiponectin are decreased while the levels of TNF-a 
and resistin are found to be increased thus making obesity a cause 
for T2DM. 
5.2.1. Tumor necrosis factor a 
TNF, synthesized by adipocytes is a 26 kD prohormone which 
undergoes cleavage to give 17 kD soluble form [24-27]. It binds to 
its receptor p60 and p80 present in most cell surfaces and mediates 
its actions. Several studies have demonstrated that TNF causes 
insulin resistance in 3T3-L1 adipocytes and L6 myoblasts in cell 
cultures [28-31]. This resistance can be mediated by several 
pathways, like downregulation of GLLrr4, inhibition of insulin 
mediated IRS-1 phosphoi'ylation, inhibition of tyrosine kinase 
activation or by inactivating insulin receptor. Studies suggest that 
one of the mechanism by which TNF plays its role is by 
downregulating GLUT4 in adipocytes both by destabilizing GLUT4 
mRNA and by decreasing GLUT4 transcription [32-361. Isoferulic 
acid, another potential anti-diabetic drug, has been found to 
increase muscle glucose transport with increased expression of 
GLUT4 in insulinopenic rats; it also inhibits gluconeogenesis by 
reducing phosphoenolpyruvatecarboxykinase (PEPCK) [37]. How-
ever, it has been found that the mechanism whereby TNF 
stimulates serine phosphorylation of lRS-1 plays a central role 
in conferring insulin resistance. 
5.2.2. Leptin 
Leptin is also known as an anti-obesity hormone due to its 
primary physiological function of preventing obesity by regulating 
food intake and energy balance. Leptin plays a pivotal role in 
energy homeostasis by decreasing food intake and increasing 
energy expenditure via hypothalamic centers, affecting feeding 
behavior and activating the sympathetic nervous system [38]. 
Leptin is also a signal for adaptation to fasting [39]. Leptin mediates 
energy homeostasis, body weight, appetite, fat stores or glucose 
metabolism and the action of insulin [40,411. However, the 
presence of central abdominal fat in case of obese individuals 
causes a decrease in leptin levels and thus paves the way for insulin 
resistance. 
Insulin can inhibit both glycogenolysis and gluconeogenesis by 
activating and de-activating enzymes involved in these pathways. 
Insulin suppresses glycogenolysis by increasing phosphodiester-
ase activating and by changing the assembly of protein phospha-
tase complexes [49,50]. Gluconeogenesis however is controlled by 
insulin mediated inhibition of phosphoenolpyruvate carboxyki-
nase transcriptional activation via phosphorylation of foxhead 
transcription factor (Foxol and FoxoA2) [51-54]. 
An alternate pathway of insulin mediated hepatic glucose 
production inhibition is mediated via glucagon and free fatty acids. 
Insulin causes a decrease in glucagon secretion from pancreatic a 
cells thereby inactivating and downregulating both glycogenolysis 
andgluconeogenesis [55]. Insulin also shows its anti-lipolytic effect 
by decreasing the activity of triacylglycerol lipase and other 
enzymes in adipocytes. This leads to decreased amount of fatty 
acids in circulation and thus uptake by liver eventually resulting in 
reduction in gluconeogenesis and hence glucose production. 
In case of obese individuals, insulin mediated inhibition of 
glucose production is impaired due to the presence of abdominal 
fat deposits. These deposits are resistant to the anti-lipolytic 
actions of insulin and thus insulin in unable to inhibit lipoprotein 
lipase activity resulting in increased levels of free fatty acids in 
circulation, making them fully available to act as precursors for 
glucose synthesis in hepatocytes [56,57]. 
7. Role of central nervous system in t2dni 
Central nervous system plays an important role in insulin 
secretion and glucose homeostasis. Insulin has its receptors not 
only on peripheral tissues but also on the surface of brain cells 
where it maintains energy balance [58] and deletion of these 
receptors from neurons have been found to induce obesity [59] 
thereby highlighting their probable importance In pathogenesis of 
T2DM.Any alteration in the number of brain insulin receptors 
causes an imbalance in the glucose homeostasis, not leaving 
behind the liver glucose production [60]. These findings thus, 
clearly suggest that T2DIVI can also result due to underlying defects 
in central nervous system 161-64]. 
8. Insulin signaling abnormalities in insulin resistance 
5.2.3. Adiponectin 
Adiponectin. another hormone secreted from adipocytes, has 
insulin sensitizing effects, as it enhances inhibition of hepatic 
glucose output as well as increase glucose uptake and utilization in 
fat and muscle. The expression of adiponectin is decreased in obese 
humans and mice [42]. In humans, adiponectin levels relate with 
insulin sensitivity and thus their decrease in obesity increases the 
probability of insulin resistance [43,44]. Drugs like rimonabantare 
being used to reduce adiposity and improve insulin sensitivity in 
overweight and obese individuals with and without diabetes by 
increasing adiponectin production [45]. 
5.2.4. Resistin 
Resistin is another adipocyte hormone which has inverse 
relationship with insulin sensitivity. In obese individuals resistin 
levels are found to be increased thus accounting for decreased 
insulin sensitivity and high insulin resistance [46]. 
6. Hepatic glucose production: it's role in insulin resistance 
Liver is the main site for glucose synthesis and storage in the 
form of glycogen which can later be utilized to give energy to carry 
out various cellular processes. This process of conversion of 
glycogen into glucose and glucose synthesis by other precursors is 
strictly controlled by the pancreatic hormone, insulin [47,48]. 
8.1. Insulin signaling 
Insulin signaling is initiated through the binding to and 
activation of its cell surface receptor and initiates a cascade of 
phosphorylation events, second messenger generation, and 
protein-protein Interactions that result In the diverse metabolic 
events in nearly every tissue. The insulin receptor consists of two 
insulin binding a. subunits and two catalytically p subunits that are 
disulfide linked into an a2(i2 heterotetrameric complex [65]. 
Insulin binds to the extracellular a subunits, activating the 
Intracellular tyrosine kinase domain of p subunit. Once receptor 
3 subunit phosphorylates its partner on specific tyrosine residues 
that may have distinct functions such as stimulation of Intramo-
lecular association of signaling molecules such as She and Grb. 
members of the insulin receptor substrate famlly(IRSl,2,3,4), She 
adaptor protein isoforms, and SlRP(signal regulatory protein) 
family members, stimulation of mitogenesis and receptor inter-
nalization [66]. 
The insulin receptor (i subunit has also been shown to undergo 
serine/threonine phosphorylation, which might decrease the 
ability of receptor to autophosphorylate. Obesity however reduces 
the activation of insulin receptor. The NEFA's which enter the 
peripheral tissues change into lipid metabolites like fatty acyl 
CoA's and diacylglycerol(DAG), DAG once formed activates novel 
PKC isoforms that catalyze the serine/threonine phosphorylation 
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of the 3 subunit and thus attenuates insuiin signaling, making way 
for insulin resistance. The activities of a number of protein kinase C 
(PKC) isoforms that catalyze the serine or threonine phosphory-
lation of the insulin receptor are found to be elevated in animal 
models of insulin resistance and in insulin resistant humans [67|. 
9. Downstream events following insulin receptor 
phosphorylation 
The insulin receptor substrates (IRS's) act as multifactorial 
docking proteins activated by tyrosine phosphorylation. The IRS 
proteins have multiple functional domains including Pleckstrin 
homology (PH) and phosphotyrosine binding (PTB) and She 
domains that interact with other proteins to mediate insulin 
signaling events. Serine phosphorylation of JRS proteins can reduce 
the ability of these proteins to attract P13-kinase, thereby 
minimizing its activation [68], and also can lead to an accelerated 
degradation of lRS-1 protein. Based on in vitro studies serine 
phosphorylation may lead to dissociation between insulin 
receptors/IRS-1 and/or PI3-kinase activation [69] and thus 
impaired insulin action. The causes of lRS-1 serine phosphorylation 
are given in the table below (Table 1) It has also been found that 
disruption of IRSl in mice resulted in mild insulin resistance and 
growth retardation, whereas disruption of 1RS2 resulted in (5 cell 
failure and secondary insulin resistance Table 2. 
10. PI3-kinase activation 
The next step in the insulin signaling cascade after IRS 
phosphorylation requires the involvement of P13-kinase.Binding 
of IRS's to the regulatory subunit of this enzyme at Src homology 2 
domain results in the activation of P13-kinase which is necessary 
for insulin action on glucose transport [70], glycogen syntha-
se(GS)|71], protein synthesis 172), antilipolysis, and gene expres-
sion and inhibition of the enzyme by fungal inhibitor wortmanin. 
Table 1 
Type of Insulin Resistance in T2DM. 
Insulin resistance 
Pre-receptor resistance 
Antibodies against insulin. 
Mutant insulin structures. 
Defect in primary structure of insulin P chain at one or more positions. 
Familial hyperproinsulinemia. 
B-C proinsulin: mutation at the cleavage site between the B chain 
and the connecting (C) peptide. 
A-C proinsulin: mutation at the cleavage site between the A chain 
and connecting (C) peptide. 
Receptor resistance 
Type A. Decrease in insulin receptor number and/or affinity for 
the hormone. 
Impaired expression of receptor tyrosine kinase activity 
Point mutation blocks insertion of mature receptor into plasma 
membrane. 
Type B. Receptor blocked by circulatory antibodies to the receptor 
Leprechaunism: An autosomal recessively inherited disorder of insulin 
function that leads to severe intrauterine growth retardation. 
characteristic 
dismorphic features and a disturbed glucose homeostasis. The 
defect underlying this disease is a structural defect in insulin receptor 
Post- receptor resistance 
Decreased capacity of pancreatic (3 cells to compensate for the 
underlying insulin resistance by increased insulin secretion 
Possible underexpression (down regulation) of p-cells glucose 
transporters (therefore failure to recognize and respond to 
hyperglycemia) 
Autoantibodies to CLlJr-2 transporter of (3 cells 
Mutation of the glucokinase gene may prevent uptake and 
metabolism of glucose necessai'y for the mechanism of insulin 
secretion. May be responsible for type 2 diabetes mellitus. 
Table 2 
Causes of lRS-1 serine phosphorylation. 
1.Obesity 
2.Diacylglycerol 
B.Hyperlipidemia 
4.Hyperglycemia 
S.Hyperinsulinemia 
inhibited all these functions [73-76]. PI3kinase activation is also 
necessary for the stimulation of the glucose transporter GLUT-4 
mediated increase in glucose uptake in insulin sensitive tissues 
however in case of obesity and similar underlying conditions IRS's 
fail to bind and activate this second player of the cascade thereby 
causing insulin resistance and sustained increase in circulating 
glucose levels in spite of increased insulin secretion from pancreas 
[77-79]. Not only this, PI3 kinase also activates phosphatidylino-
sitol 3,4,5 triphosphate(PIP3) dependent serine/threonine kinases 
such as PI dependent protein kinases 1 and 2(PDKland PDK2) 
which activates the next participant of the pathway Akt and 
protein kinase c (PKC), therefore an alternative for this important 
participant of the insulin signaling pathway may be provided by 
using vanadium salts. These vanadium salts may prolong the TKA 
of insulin receptors and possibly some post-receptor kinases 
byinhibition of protein tyrosine phosphatases, especially PTP-IB 
[80]. They can also enhance glucose transport in skeletal muscle 
when P13K signaling is blocked, suggesting an additional, more 
distal, and effect along the insulin signaling pathway. 
11. Akt/PKB as a mediator of insulin action 
The phosphoinositides generated by P13 kinase causes the 
activation of Akt. These phosphoinositides bind directly to the PH 
domains of Akt/PKB and through a combination of events uncover 
the phosphorylation sites coupled with activation of PI dependent 
serine/threonine kinases(PDKl,PDK2) which then phosphorylate 
Akt thereby activating it. Phosphorylation on two regulatory 
residues, S473 and T308 for Aktl, is critical for complete Akt/PKB 
activation. PDKl is not regulated by PI3-kinase directly, but rather 
is thought to phosphorylate Akt/PKB after polyphosphoinositide 
binding increases T308 accessibility. Insulin activates Akt/PKB via 
PI3-kinase dependent phosphorylation in skeletal muscle, [81] 
adipose tissue, [82] and numerous tissue culture systems. Once 
activated Akt phosphorylates and activates proteins involved in 
glucose uptake, GLUT4 translocation, lipogenesis, and protein 
synthesis, [83] as well as providing protection from apoptosis. 
Disruption of Akt resulted in insulin resistance and diabetes in 
mice [84]. Studies have also shown a decrease in IRS-associated 
P13-kinase and Akt activity in insulin resistant skeletal muscle [85]. 
However, omentin: another peptide from adipocytes has the 
ability to increase insulin-stimulated glucose in adipocytes and Akt 
phosphorylation in the absence and presence of insulin [86]. 
12. Signaling events downstream of Akt 
Akt phosphorylates and inactivates glycogen synthase kinase 
3(GSK3) [87| thereby activating glycogen synthase leading to 
insulin mediated glycogen synthesis thus lowering the circulating 
glucose levels and maintaining normoglycemia. In addition to this, 
Akt also phosphorylates several proteins resident in GLUT4 
containing vesicles [88[ which may act as a mechanism of Akt 
mediated CLUT4 translocation to the cell surface and increased 
insulin mediated glucose uptake by the peripheral tissues [89,90]. 
The primai^ y effect of insulin is to stimulate translocation of the 
glucose transporter GLUT4 from an intracellular pool to the 
surface of the cells, primarily in skeletal muscles and adipose 
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tissues. The normal signaling pathway results in this translocation 
via Akt but in obese individuals this pathway may be blocked at 
different steps by different biomolecules like NEFA's, TNF-a, and 
adipokines. However, all the blockages converge to result in insulin 
resistance. 
13. Incretins 
The incretin effect is the process of increasing oral glucose 
stimulatory effect on insulin secretion as compared to intravenous 
glucose. These incretins also inhibit hypergiucagonemia and are 
found to have b-cell anti-apoptotic effects. These functions are 
however mediated by GLP-1 and GIP in case of humans. Nowadays 
many biomolecules are being synthesized which have incretin like 
Ci2 effect (91 ]. 
Exenatide, a synthetic incretin is similar to naturally occurnng 
incretin (exendin-4) found in the saliva of the Gila monster, is now 
being used for the treatment of T2DIV1. Once inside the system 
exenatide produces GLP-1 like affects and is also resistant to 
degradation by enzyme dipeptidyl peptidase iV (DPP-IV) thus 
having an increased half-life 2h to carry out the required 
functions. 
Vildagliptin and Sitagliptin are the two DPP-IV inhibitors, 
administration of which increases the half-life of incretin like 
molecules and are also found to moderately increase GLP-1 and GIP 
levels along with reductions in HbAu levels. 
Liragiutide, another incretin-like molecule, is a DPP-fV resistant 
analog of GLP-1 and is shown to cause better lowering of fasting 
glucose as compared to other incretins. In addition to its beneficial 
actions another advantage of using liragiutide is the less number of 
side-effects this biomolecules has, like nausea etc. [91 ]. 
14. Conclusion 
Insulin resistance, which is a major cause of T2DM can be used 
as a potential target for developing drugs to possibly treat this 
metabolic disorder. However, the only problem is the complexity 
of the insulin signaling pathway which limits the approach to this 
aspect of treatment. The pharmacology of T2DM has until now 
depended only on the use of drugs like metformin and 
thiazolidinediones, but now new areas should be explored using 
drugs that effect the phosphorylation/dephosphosphorylation of 
insulin receptors, insulin receptor substrates and the factors 
involved in downward signaling pathway of insulin. Molecules 
improve the glucose/insulin dose-response relationship (incretins) 
should be made use of, taking into consideration their side-effects 
Q3 as well. Development of such drugs will not only provide multiple 
targeted treatments but also might help in faster recovery of Type 2 
diabetics. 
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